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Abstract
Proteolipid protein (PLP) and DM-20 account for more than 50% of total myelin protein in 
the central nervous system (CNS) and are produced by alternative splicing of the primary 
pip transcript. While PLP is thought to contribute to the stability of the intraperiod line in 
CNS myelin, little is known about the function of DM-20. It has been suggested that DM- 
20 may be involved in oligodendrocyte differentiation and survival. The present work 
confirmed that the marked upregulation of the pip gene, and change in transcript ratio from 
dm-20 to pip predominance, occurs around the time of onset of myelination. In separate 
areas where myelination commenced at different times, these changes were correlated with 
the “age” of myelination in that area, rather than the chronological age of the developing 
CNS as a whole.
Using a combination of semi-quantitative reverse transcription-polymerase chain reaction 
(RT-PCR) and immunocytochemistry, both transcripts and product were shown to be 
present in the embryonic mouse spinal cord as early as embryonic day 12 (E l2). This 
expression was linked to the oligodendrocyte progenitor lineage. The presence of DM-20 
isoprotein in these oligodendrocyte progenitors challenges previous perceptions that pip 
gene expression occurs only in mature post-mitotic oligodendrocytes. These studies also 
support the hypothesis that oligodendrocytes originate in a discrete region of the ventral 
spinal cord.
Pip and dm-20 transcripts were demonstrated in the sciatic nerve, cranial sympathetic trunk 
and cranial cervical ganglion in the peripheral nervous system (PNS) with dm-20 being the 
predominant message present. No developmental change in plp/dm-20 transcript ratio 
similar to that seen in the CNS was seen. Nerve transection studies in both sciatic nerves 
(PNS) and optic nerves (CNS) demonstrated selective downregulation of the pip isoform 
suggesting different regulatory mechanisms for the two isomers, with axonal factors being 
more important for pip.
Pip gene expression was present in the olfactory nerve layer (ONL) of the olfactory bulb 
during both embryogenesis and postnatal life. Transcripts and protein were found to be 
exclusively dm-20 and were shown to be present in the olfactory nerve ensheathing cells of 
the ONL.
The combination of these studies has added further evidence to support the theory of 
separate functions for the PLP and DM-20 isoproteins. Expression of the dm-20 isoform 
appears to be the default pathway in “non-myelin” environments with dramatic 
upregulation of the pip isoform during active myelination.
To my parents and Katey
Tell a student that the only people who are going to read this great document are the 
supervisor, two examiners and one or two close friends, and you will be regarded with
rank disbelief
Steven Rose
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CHAPTER 1. INTRODUCTION
l.l.DEVELOPMENT OF THE NERVOUS SYSTEM
Development of the vertebrate nervous system begins with the induction of the neural plate 
from uncommitted ectoderm. The neural plate then invaginates longitudinally until the 
lateral extremities of the original plate, the neural folds, meet centrally and fuse over the 
neural groove to form a neural tube and canal (Schoenwolf and Smith 1990) (Figure 1). 
The margins of the non-neural ectoderm fuse dorsal to the neural tube and the two layers of 
ectoderm separate. A longitudinal column of cells arises from the junction of the neural 
and non-neural ectoderm and lies dorsolaterally on either side of the neural tube throughout 
its length. These are the neural crest cells which will give rise to the spinal, autonomic and 
cranial nerve sensory ganglia, melanoblasts of the epidermis and cells of the adrenal 
medulla. Regional differentiation of the neural epithelium along the cranio-caudal axis is 
present at the neural plate stage (Roach 1945) and gives rise rostrally to the forebrain and 
midbrain and caudally to the hindbrain and spinal cord.
The neural tube is divided into three concentric layers (Figure 1). Adjacent to the neural 
canal is the germinal layer of proliferating neuroepithelial cells. The proliferative function 
of this layer is ultimately exhausted, and the resulting single layer of cells forms the 
ependymal lining of the ventricular system. Peripheral to the germinal layer is the mantle 
layer which will become the grey matter of the definitive spinal cord, nuclei of the brain 
stem and, after migration to the external surface of the neural tube, the cerebral cortex of 
the telencephalon. The external layer of the neural tube is the marginal layer which gives 
rise to the white matter of the brain and spinal cord and contains relatively few cells. The 
spinal cord is also divided into dorsal and ventral portions at the level of the sulcus 
limitans, a longitudinal groove present in the lateral wall of the neural canal. The dorsal or 
alar plate is concerned predominantly with sensory systems, and the ventral or basal plate 
with motor systems.
Two important structures present during development of the neural tube are the floor plate 
and the notochord. The floor plate arises from cells at the ventral midline of the neural 
plate (Schoenwolf and Smith 1990), whilst the notochord is of mesodermal origin and lies 
ventral to the neural plate (Figure 1). Differentiation of the floor plate appears to be 
induced by the notochord (Placzek et al. 1990), and both structures appear to act as sources 
of polarising signal in the embryonic tissues. It is likely that these two cell groups are 
involved in controlling the pattern of cell differentiation along the dorso-ventral axis of the 
developing nervous system. Moreover, the fate of neuroepithelial precursor cells appears 
to be dependent on the position that they occupy with respect to the notochord and floor 
plate (Yamada et al. 1991).
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Figure 1. Development of the neural tube. Temporal development of the neural tube is 
demonstrated from the upper to the lower diagram. The embryonic spinal cord can be seen 
to consist of three concentric layers (lower diagram).
1.2.MYELINATION AND THE PROTEOLIPID PROTEIN
(plp) GENE
1.2.1.The myelin sheath
Myelin is a highly specialised extension of the plasma membrane elaborated by specific 
glial cells in both the central nervous system (CNS) and peripheral nervous system (PNS). 
In the CNS the myelinating cell is the oligodendrocyte (Bunge et al 1961; Bunge et al. 
1962), with one oligodendrocyte capable of myelinating many segments of different axons, 
possibly as many as 60, simultaneously (Bunge 1968; Matthews and Duncan 1971). In the 
PNS, the Schwann cell fulfils the same function but maintains a 1:1 ratio with the myelin 
intemode (Peters and Muir 1959). The tightly compacted multilamellar sheath surrounds 
axons and facilitates rapid, saltatory conduction of nerve impulses (Huxley and Staempfli 
1949) necessary for integrated function of the vertebrate nervous system. Disruption of the 
myelin sheath, whether due to developmental abnormalities (dysmyelination) as seen in 
myelin gene mutations, or due to loss (demyelination) during disease processes, invariably 
leads to devastating neurological symptoms.
1.2.2.CNS/PNS myelin
Although CNS and PNS myelin have general similarities in composition and structure, 
several differences exist. The manner of formation of the myelin lamellae is identical, 
however periodicity varies (CNS 10.5-11.5nm/PNS 11.5-12.7nm in specimens for electron 
microscopy), and CNS sheaths never attain the same thickness as those around axons of 
similar diameter in the PNS (Fraher 1992). The Schwann cell is surrounded by a basal 
lamina and the myelin sheath is formed directly from the soma of the Schwann cell whilst 
the oligodendrocyte lacks a basal lamina and myelination may occur at a distance from the 
soma by spiral wrapping of numerous extensions of the plasma membrane. Some Schwann 
cell-like oligodendrocytes have been demonstrated in the developing spinal cord where 
they are found in close association with the myelin sheath of a single axon (Remahl and 
Hildebrand 1990). Proteolipid protein (PLP) and myelin basic protein (MBP) are the 
major proteins present in compact CNS myelin accounting for 50% and 30% total myelin 
protein respectively (Lees and Brostoff 1984). In the PNS, MBP, although present in 
compact myelin, comprises only 5-15% total myelin protein and PLP is found in 
considerably smaller amounts and never in compact myelin. Protein zero (P0) is the major 
myelin protein in the PNS accounting for over 50% total protein (Greenfield et al. 1973). 
(see 1.3.5.PLP in the peripheral nervous system).
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1.2.3.Myelin composition (CNS)
Lipids
Lipid accounts for approximately 70% of the dry weight of myelin (Norton and Cammer
1984). There are no lipids specific to myelin, however the high content of 
galactosphingolipids, cerebroside (galactosylceramide) and sulphatide is a distinguishing 
feature of myelin lipid. These three comprise about 65% of total lipid and 45-50% total 
dry weight of myelin (Norton and Cammer 1984). Myelin lipid is also enriched in 
cholesterol and ethanolamine phosphoglycerides relative to other membranes. Cerebroside 
is the most “myelin typical” lipid and within the CNS is a specific marker for 
oligodendrocytes (Raff et al. 1978).
Proteins
The protein composition of myelin is relatively simple with the major proteins being 
myelin specific.
a) Myelin proteolipid protein (PLP):
(See 1.3.MYELIN PROTEOLIPID PROTEIN)
b) Myelin basic protein (MBP):
MBP represents ~ 30% total myelin protein and consists of a family of proteins produced 
by differential gene splicing (de Ferra et al. 1985). Four major isoforms exist in rodents 
with apparent molecular weights up to 20kD. MBP is thought to be important in 
maintaining the fusion of the major dense line in the compact myelin sheath. Different 
isoforms have also been reported which predominate during embryogenesis and may have 
a function unrelated to myelinogenesis (Nakajima et al. 1993).
c) Myelin-associated oligodendrocyte basic protein (MOBP):
MOBP is the most recently characterised myelin protein (Yamamoto et al. 1994) and is the 
most abundant after PLP and MBP. Two peptides have been described with apparent 
molecular weights of 12kD and 25kD. MOBP shares several characteristics with MBP 
(small, hydrophilic, basic and distributed throughout compact myelin), and may perform a 
similar function.
e) 2 3 ’-cyclic nucleotide 3 ’-phosphodiesterase (CNP):
CNP represents ~ 5% total myelin protein (Sprinkle et al. 1978) and consists of two 
peptides with apparent molecular weights of 46kD and 48kD. CNP is part of the 
Wolfgram fraction of proteins (45-65kD/insoluble in chloroform/methanol). CNP may be
5
involved in oligodendrocyte differentiation (Scherer et a l 1994) or maintenance of the 
myelin membrane (Trapp 1990).
d) Myelin associated glycoprotein (MAG):
MAG is a minor constituent of CNS myelin protein (~1%) (Quarles et al. 1973). It has an 
apparent molecular weight of lOOkD of which 30% is carbohydrate. It localises to 
periaxonal regions and is thought to be involved in contact between the myelin forming 
cell and the axon.
f) Minor proteins:
Several other CNS myelin proteins have been documented such as: Myelin 
oligodendrocyte glycoprotein (MOG) (Linington et a l 1984); Myelin oligodendrocyte- 
specific protein (MOSP) (Dyer et al 1991); Oligodendrocyte-myelin glycoprotein (OMgp) 
(Mikol et a l 1993) and P2 (Trapp et a l 1983). Although the amounts of these proteins are 
relatively small this may not reflect their functional significance. Inspection of SDS- 
PAGE gels from myelin preparations suggests that there are further, as yet uncharacterised 
proteins.
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1.3.MYELIN PROTEOLIPID PROTEIN
Proteolipids are a class of lipoproteins characterised by their solubility in organic solvents, 
particularly chloroform/methanol mixtures (Folch and Lees 1951) and are found as 
membrane components in many animal, plant and bacterial cells. Myelin proteolipid 
protein (PLP/proteolipid apoprotein/Folch-protein lipophilin/P7) , which has been shown 
to have no cross reactivity with other proteolipids (Macklin et al. 1982), is the major 
myelin protein of the CNS and accounts for approximately 50% of total myelin protein 
(Lees and Brostoff 1984).
PLP is an extremely hydrophobic membrane protein consisting of a 276-residue long 
polypeptide chain with four strongly hydrophobic sequences linked by highly charged 
hydrophilic sequences (Stoffel et al. 1984). The protein can be isolated by separation from 
lipids using either acid solvents or detergents. The lipid-free protein (apoprotein) can be 
converted to a water soluble form by gradual replacement of the organic solvent with water 
(Lees and Sakura 1978). Protein from mature animals can be resolved on sodium dodecyl 
sulphate (SDS) polyacrylamide gels into two protein bands, the major PLP component and 
a minor band corresponding to the isoprotein DM-20, so named due to its apparent 
molecular mass on SDS gels (DM-20 ~ 20kDa/PLP ~ 24kDa). The actual molecular 
masses of the two isoproteins are higher than these values (DM-20 ~ 26.5kDa (Nave et al. 
1987b)/PLP ~ 30kDa (Stoffel et al. 1983)). Lower molecular weight myelin proteolipids 
have been described in the cow (Chan and Lees 1974; Lepage et al. 1986; Vacher-Lepretre 
et al. 1976), mouse (Nussbaum and Mandel 1973) and rat (Campagnoni et al. 1976). Two 
related proteolipid proteins of similar apparent molecular mass to PLP (PIip (Helynck et 
al. 1983) in bovine adult CNS) and DM-20 (PIIp’ (Schindler et al. 1990) in bovine foetal 
CNS) have also been reported.
1.3.1.The plp gene
The plp gene (Figure 2) is located on the X-chromosome (Mattei et al. 1986; Willard and 
Riordan 1985) (Xq21.33-22 in man) and is approximately 17kb in size. The gene is 
composed of seven exons, although an eighth exon has been proposed based on the 
isolation of a cDNA with a novel ?> region (Kamholz et al. 1992). Two major transcription 
initiation sites have been described in the rat and mouse around nucleotides -130 and -160 
(Macklin et al. 1987; Milner et al. 1985). However, even at these two sites, there is a 
degree of heterogeneity with respect to the exact point of initiation. The two major sites 
appear to be used in a selective manner with the more distal site being utilised in the CNS 
and the proximal in the PNS (Kamholz et al. 1992). Plp mRNA is also heterogeneous in 
terms of the length of the 37 untranslated region (3 UTR) due to utilisation of alternative 
polyadenylation sites (Figure 2). Three major transcript sizes are seen; 1.5-1.6kb, 2.4- 
2.6kb and 3.0-3.4kb, with relative amounts varying between species. By northern analysis 
the rat has a major band of 3.2kb and a minor band of 1.6kb (Milner et al. 1985); the
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mouse has major bands of 2.4-2.6kb and 3.0-3.4kb with a minor band of 1.6kb (Gardinier 
et a l 1986; Sorg et al. 1987), and the human has a major band of 3.2kb and a minor band 
of 2.2kb with very little 1.6kb transcript (Kronquist et al. 1987). The significance of these 
multiple transcript sizes is unknown although availability of multiple polyadenylation 
sequences may confer greater evolutionary tolerance to mutational loss of these important 
post-transcriptional processing sites. All transcripts are translated to give the same 277 
amino acid protein, the amino-terminal methionine being removed post-translationally.
A second isoform, DM-20, is generated by the use of an alternate 57 splice site in exon 3 
(Nave et al 1987b). Exon 3B is deleted from the processed transcript giving a protein 
identical to PLP apart from the deletion of 35 residues (amino acids 116-150). With the 
exception of anurans (frogs), in which the plp gene is duplicated (Nave et a l 1993), these 
proteins are the products of a single gene.
Expression 
Tissue expression
Although it was initially thought that plp gene expression was restricted to the 
oligodendrocyte in the CNS it has become apparent that expression occurs in several other 
cell types. Transcripts can be demonstrated in embryonic and adult peripheral nerve and 
cranial and spinal ganglia (see 1.3.5.PLP in the peripheral nervous system), the olfactory 
nerve layer of the olfactory bulb (OB) (see 1.4.THE OLFACTORY BULB) and in 
unidentified cells in the mouse and rat embryonic brain and spinal cord. Partial transcripts 
have been found in astrocytes (Macklin 1988) and full length transcripts in some 
astrocytoma cell lines (Kashima et al 1993). Plp and dm-20 transcripts are found in the 
C6 glioblastoma cell line (Ikenaka et al 1992; Nave and Lemke 1991) (which has some O- 
2A-like characteristics) and surprisingly in several “neuronal” cell lines derived from 
phaeochromocytoma, neuroblastoma or melanoma cells (PC-12, NG108-15, N18-TG, 
Neuro-2A) (Ikenaka et a l 1992). Gene expression in immortalised cell lines is generally 
under less strict regulatory control than expression in “wild-type” cell cultures resulting in 
a more complex mRNA profile. The possibility of tumour-derived cell lines expressing 
“uncharacteristic” genes must therefore not be overlooked. Dm-20 transcripts have also 
been identified in heart and localised by in situ hybridisation (ISH) to the cardiac myocytes 
(Campagnoni et a l 1992). Protein has been demonstrated in the PNS and OB (Griffiths et 
al 1995a; Wight et a l 1993). Based on the generation of transgenic mice it has been 
suggested that elements involved in directing tissue specific expression may reside within 
intron 1 of the gene (Wight et a l 1993).
ISH using plp/dm-20 riboprobes and tissue sections from adult animals demonstrates 
multiple foci of signal corresponding to the cell bodies of individual oligodendrocytes,
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concentrated in the white matter and more sporadically in grey matter. Immunostaining 
shows a similar pattern with localisation to the compact myelin sheath.
Postnatal developmental expression
Interpretation of studies on developmental expression of the pip gene can be difficult to 
correlate due to differences in species studied, whether transcript or product were detected, 
sensitivity of the assay employed and the area of the CNS involved. However general 
patterns can be seen. The ratio of PLP/DM-20 protein changes during early myelination. 
Studies on postnatal rat (LeVine et al. 1990), mouse (Gardinier and Macklin 1988), foetal 
cow (Van Dorsselaer et al. 1987) and human (Kronquist et a l 1987) have shown that DM- 
20 predominates during early myelination, whereas PLP is either equivalent or the major 
isoform in the adult. Production of plp/dm-20 transcripts and protein (Macklin et a l 1983; 
Naismith et a l 1985) appear to parallel myelination and increase dramatically with 
increasing numbers of myelinating oligodendrocytes in the CNS, with peak levels seen 
around post-natal day 20 (P20) in the mouse (Campagnoni and Hunkeler 1980; Gardinier 
et a l 1986; Sorg et al 1987) and around P25 in the rat (Milner et a l 1985; Naismith et a l
1985). Levels of transcript in the adult mouse are approximately 25-30% of those at peak 
myelination (Gardinier et al 1986; Naismith et a l 1985) indicating a high turnover of the 
protein. The ratio of plp/dm-20 transcripts in the post-natal rat CNS is always >1 and a 
ratio of at least 2:1 is present in the adult (LeVine et a l 1990; Nave et a l 1987b). At the 
cellular level pip transcripts have been demonstrated by ISH as early as PI in the mouse 
hind brain (Verity and Campagnoni 1988) and at P0 in the rat lumbosacral cord (Baron et 
al 1993). Protein is detectable by western blots at PI in the rat (LeVine et al. 1990) and 
P3 in the mouse (Gardinier and Macklin 1988). DM-20 predominates at this time with 
predominance of PLP occurring several days later.
Embryonic expression
Plp/dm-20 transcripts have been documented in embryonic brain (Ikenaka et a l 1992; 
Timsit e/a/. 1992a; Timsit et a l 1995), spinal cord (Timsit et a l 1995; Yu et a l 1994) and 
PNS (Timsit et a l 1992a; Timsit et a l 1995; Wight et a l 1993; Yu et a l 1994). 
Expression of the pip gene during embryogenesis is of particular interest for two reasons. 
Firstly, the expression of a major myelin gene at a time when no myelin sheaths are present 
(sheaths are seen only after E l8 in the mouse) is intriguing and would indicate a non- 
structural role for the gene. Secondly, the dm-20 isoform appears to be the sole or 
predominant transcript present at this time (Ikenaka et a l 1992; Timsit et a l 1992a) which 
would potentially implicate it in an alternative function. This is comparable to the 
peripheral nervous system where PLP/DM-20 is not present in the compact myelin sheath 
(Griffiths et a l 1989; Griffiths et a l 1995a; Puckett et a l 1987) (see 1.3.5.PLP in the 
peripheral nervous system); DM-20 is the major isoprotein present (Griffiths et a l 1995a;
Ikenaka et a l 1992; Pham-Dinh et al. 1991) and a non-structural role for DM-20 has also 
been postulated. Both of these situations contrast with the mature myelinated CNS where 
PLP is the dominant isoform (see 1.3.1.The pip gene), probably acting as a structural 
protein. DM-20 protein has been isolated from foetal bovine cerebral hemispheres prior to 
the appearance of white matter (Schindler et al 1990) and plp/dm-20 transcripts have been 
localised to the area of the diencephalic basal plate in the mouse as early as E9.5 (Timsit et 
al 1992a; Timsit et a l 1995), the positive cells being thought to represent oligodendrocyte 
precursors (0-2As). Embryonic expression of other major CNS myelin genes (CNP and 
MBP), and the major PNS myelin gene P0 in non-myelinating cells has been described 
(Nakajima et al. 1993; Scherer et al. 1994; Yu et al. 1994; Zhang et al. 1995).
There is still some controversy regarding the location and lineage of the cells responsible 
for embryonic plp/dm-20 expression in the spinal cord. ISH studies have localised 
transcripts in the rat to a column of cells either side of the mid-line, just above the floor 
plate at E l2 (Yu et a l 1994). This signal was subsequently only detectable at E l8 when it 
was located in the ventral white matter and at later ages throughout the whole of the spinal 
cord white matter. In contrast, in the mouse, positive cells were found in a slightly more 
dorsal position at E14.5 (Timsit et a l 1995) and such cells progressively colonised the 
spinal cord between E l4.5 and PI, first ventrally and then dorsally, predominantly in the 
white matter tracts.
Pip gene expression in the rat was suggested to be of neuronal origin (Yu et a l 1994) 
based indirectly on the differing temporal and spatial position of the dm-20+ cells at E l2 
relative to CNP or platelet derived growth factor a  receptor (PDGFaR)+ cells. It has been 
suggested that CNP and PDGFaR may be early markers of oligodendrocyte precursors in 
the spinal cord (Pringle et a l 1992; Pringle and Richardson 1993; Yu et a l 1994). Timsit 
et a l (1995), however were unable to demonstrate co-localisation of neuronal markers 
TuJl (neurone specific tubulin), neurofilament or F4/80 (macrophage/microglial marker) 
with dm-20+ cells in either the brain or spinal cord. There is the possibility that dm-20 
may be labelling pluripotent stem cells which may give rise to either neurones or 
oligodendrocytes (De Vitry et a l 1980; Price and Thurlow 1988; Williams et a l 1991) and 
that dm-20 may be expressed transiently by neuronal precursors (Timsit et a l 1995; Yu et 
al 1994).
Alternatively, pip gene expression in the mouse was suggested to be present in 
oligodendrocyte precursors (Timsit et a l 1995). Spatial and temporal position of plp/dm- 
20+ cells is in agreement with previous studies using other presumptive oligodendrocyte 
progenitor markers (PDGFaR and CNP) at E14 (Pringle and Richardson 1993; Yu et a l 
1994), however a more diffuse labelling of grey and white matter is seen with both of these 
markers at older ages. In addition, the ventral ventricular zone, adjacent to the central 
canal has been identified as the probable site of origin of the 0-2A lineage. Fok-Seang and 
Miller (1994), using A2B5 as an 0-2A marker, and Warf et al (1991) showed that at E14
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in the rat, only cells cultured from the ventral cord were capable of giving rise to 
oligodendrocytes. Noll and Miller (1993) used a combination of BrdU (a thymidine 
analogue) incorporation and 0-2A specific markers (see 1,5.THE 0-2A LINEAGE) to 
locate 0-2A cells originating in this area. Ono et a l (1995) demonstrated a similar 
situation in the E6 chick spinal cord with 04+ 0-2A progenitors arising close to the dorsal 
aspect of the floor plate in a similar position to that seen with plp/dm-20+ cells in the El 2 
rat. It is possible that the various presumptive markers may be labelling additional cell 
types or possibly subsets of the oligodendrocyte lineage. An alternative theory for the 
origin of oligodendrocytes in the spinal cord is that they originate from radial glial cells in 
the peripheral white matter (Choi et a l 1983; Hirano and Goldman 1988). This is based on 
the demonstration of radially oriented glial cells exhibiting markers of the 0-2A  lineage 
and radial glial cells which appeared to have a combination of oligodendrocyte and 
astrocytic characteristics. As it is highly likely that at least some of the astrocytes of the 
spinal cord are derived directly from radial glial cells it was suggested that this could be a 
common site of origin for both astrocytes and oligodendrocytes. The present body of 
evidence however, suggests that the ventricular zone is the most likely origin of 
oligodendrocyte precursors in the spinal cord.
Conflicting evidence is available regarding expression of pip  in 0-2A cultures from 
neonatal rat brain, with either positive (Lubetzki et a l 1991) or negative (Yu et a l 1994) 
northern blots using a plp/dm-20 probe. This may reflect differences in purity of culture or 
sensitivity of hybridisation.
Regulation
The pip gene is transcribed by RNA polymerase II. It is a complex transcriptional unit 
generating several message isoforms. As such, a variety of mechanisms may be involved 
in determining both total transcript levels and also the relative amounts of the pip  and dm- 
20 isoforms. Gene regulation may occur at three general levels; 1) transcriptional control, 
usually at the level of rate of transcript initiation; 2) post-transcriptional processing 
involving factors such as polyadenylation, primary transcript splicing and transcript 
stability and 3) translational or post-translational control (Darnell Jr. 1982). Regulation of 
the pip gene has been demonstrated at transcriptional, post-transcriptional and translational 
levels and it has become evident that pip gene expression is dependent on a highly complex 
and integrated system involving numerous regulatory factors, associated intermediate 
genes and feedback mechanisms working at several levels of regulation. Interpretation of 
published data regarding pip gene transcriptional regulation is difficult due to the diverse 
experimental approaches employed. Studies involving in vivo and in vitro systems, or 
using “wild type” oligodendrocytes or glial cell lines have all been documented. Glial cell 
lines appear to be partially deregulated and, as a result, exhibit a higher degree of message 
complexity. Evidence from several studies looking at individual factors influencing pip
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gene expression and potential regulatory regions of the pip gene contains inconsistencies, 
probably due to the reasons outlined above, and it is presently only possible to give a 
generalised picture of the regulatory factors influencing pip gene expression.
As is the case with most pol II genes, transcriptional regulation appears to be the major 
controlling step in pip gene expression. It is this increased rate of synthesis of pre-mRNA 
which is primarily responsible- for the production of the large amounts of PLP/DM-20 
protein required during myelination (Cook et a l 1992; Gardinier and Macklin 1990). 
Several factors have been shown to induce transcription of the pip  gene including 
corticosteroids (Zhu et a l 1994), cAMP (Nave and Lemke 1991; Ye et a l 1992), PDGF 
(Grinspan et al 1993), high cell density and serum deprivation (Nave and Lemke 1991) 
and presence of neurones (Giulian et a l 1991; Kidd et a l 1990; Macklin et a l 1986; 
McPhilemy et a l 1990; Scherer et a l 1992). Corticosteroids have also, conversely, been 
demonstrated as down-regulators of pip gene expression (Tsuneishi et a l 1991). Post- 
transcriptional control has been inferred based on differences between plp/dm-20 transcript 
and protein ratios (LeVine et a l 1990). Increased stability of mRNA could account for 
post-transcriptional rises in message levels, however evidence supporting this is 
conflicting. Increase in stability of mRNA would be reflected in measured half-life; one 
group has suggested half-life to be around 25 hours and found no extreme changes (Cook 
et a l 1992). However evidence supporting increased stability both in vivo (Gardinier and 
Macklin 1990), and in vitro under the influence of retinoic acid (Lopez-Barahona et a l 
1993; Zhu et a l 1992) has also been presented. Protein kinase C (Asotra and Macklin 
1993) may also act at this level as may corticosteroids (Kumar et a l 1989). Factors 
controlling the alternative splicing of pre-mRNA are unknown and involve complex 
protein/RNA interactions during splice site selection. Thyroid hormone has been shown to 
effect pip gene expression at the transcriptional and translational level (Campagnoni and 
Macklin 1988), and PLP synthesis is increased at the translational level by hydrocortisone 
(Verdi et a l 1989).
Sequence analysis of 1.5kb of the 57 flanking region of the human, rat, and mouse pip 
genes revealed that the proximal region from -250 to +100 (+l=the most upstream 
transcription start site) is highly conserved in the three species (~ 95% identity) (Janz and 
Stoffel 1993). Regions further upstream are only about 50% identical. This indicates that 
the evolutionary conserved proximal region may contain c/s-regulatory sequences essential 
for the functional expression of the pip gene. C/s-elements act as recognition targets for 
trans-acting factors, the protein products of regulatory genes. Both physical analysis 
(using footprinting and gel shifts) and functional analysis (using reporter genes) of cis- 
regulatory elements have been performed in cultured cells and transgenic mice. These 
studies demonstrated that both positive and negative cfr-regulatory sites involved in 
regulation of the pip gene are located in the 57 non-coding region (Bemdt et a l 1992; 
Cambi and Kamholz 1994; Nave and Lemke 1991) and possibly in intron 1 (Wight et a l
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1993) (Figure 2.) Although there is interspecies variation, some of these sites are highly 
conserved and are also present in other myelin specific genes such as MBP, MAG and P0 
suggesting common trans acting factors giving co-ordinated regulation of myelin gene 
expression (Bemdt et a l 1992; Nave and Lemke 1991). It is not clear which c/s-regulatory 
area(s) confer glial specific expression, however glial specific expression of a plp/lac Z 
transgenic fusion-gene containing 2.4kb upstream sequence extending to the 51 end of exon 
2 has been demonstrated (Wight et al. 1993). This may indicate the presence of cis- 
elements within intron 1.
Several regulatory genes which appear to be involved in regulation of the pip  gene have 
been documented and include MyTl, a member of the zinc finger superfamily of 
transcription factors (Kim and Hudson 1992; Armstrong et al. 1995), Spl transcription 
factor and a brain enriched 66kD protein (Janz and Stoffel 1993) and the POU-domain 
transcription factor, SCIP (Collarini et al 1992). Factors regulating embryonic expression 
of the pip gene are unknown although it has been suggested that early expression of 
“pattern forming” genes such as the Pax family or the hedgehog gene may induce 
expression of the pip gene in the ventral ventricular area of the spinal cord (Yu et a l 1994).
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1.3.2.Phylogeny
Compact myelin is formed in all vertebrates except Agnatha (lamprey, hagfish) (Waehneldt 
1990). CNS myelin of bony (Actinopterygii) and cartilaginous (Chondrichthyes) fish carry 
several glycosylated components recognised by antibodies against the major mammalian 
PNS protein P0. In contrast, unglycosylated PLP is the major CNS protein of all tetrapods 
(Mammalia, Aves, Reptilia and Amphibia) (Waehneldt et al 1985). It is likely that the 
integral myelin proteins in the CNS of fish were replaced in amphibia and higher animals 
by proteolipid protein (Schliess and Stoffel 1991). Studies on cross-immunoreactivity with 
mammalian PLP antibodies indicated the spontaneous appearance of PLP-like protein 
approximately 400 million years ago, before the appearance of the tetrapods, in CNS 
myelin of Sarcopterygii fish (Lungfish (glycosylated) and Coelacanth (non-glycosylated)) 
(Waehneldt et a l 1986; Waehneldt and Malotka 1989). DM-20 is not detectable by SDS 
gel electrophoresis and immunoblotting in amphibia (Schliess and Stoffel 1991; Waehneldt 
et a l 1985) and neither cDNAs nor PCR product could be demonstrated in Xenopus brain 
(Nave et al 1993). It has been suggested from peptide studies that DM-20 arose following 
a point mutation which generated the alternate DM-20 splice site in post amphibian 
tetrapods (Karthigasan et al 1991; Schliess and Stoffel 1991); alternatively the DM-20 
splice site may have been lost in amphibians and is just not immunodetectable in the lower 
vertebrates, although present.
The spontaneous appearance of PLP/DM-20 is now under question after the discovery of 
DM-20-like cDNA sequences in the Elasmobranch cartilaginous fishes Squalus acanthias 
(shark) and Torpedo californica (electric ray) (Kitagawa et a l 1993). DM proteins were 
similar but not identical between the two species, and three proteins termed DMa, DMp 
and DMy were described with DMa having the greatest similarity to mammalian DM-20 
(62.7% identity, 80.5% similarity). DMa and DMy are expressed in shark myelinated 
CNS tracts. Two DM-20-like proteins, termed M6a and M6b, have also been isolated from 
mouse (Yan et al 1993); M6a is mainly neuronal in localisation but is also present on the 
apical surfaces of choroid plexus, renal tubules and olfactory epithelium and is similar to 
DMp. M6b is found in both grey and white matter and has the greatest similarity to DMy. 
M6 protein is glycosylated, and the DM-like proteins have the consensus sequence 
(NXS/T) for N-linked glycosylation. Neither the DM-like or M6 proteins contain the PLP 
specific insert and in contrast to the splice site mutation theory above, it has been suggested 
that DM-20 initially arose by a gene duplication of one of the DM-like genes (probably 
DMa) and that this was coincident with, or preceded the acquisition of, the PLP specific 
segment (Kitagawa et a l 1993).
Within the tetrapods, the PLP gene is conserved to an extraordinarily high degree. The 
cDNA sequence is known for rat (Milner et a l 1985), mouse (Macklin et a l 1987), human 
(Hudson et a l 1989b; Kronquist et a l 1987), rabbit (Tosic et a l 1994), dog (Nadon et al 
1990), frog and chicken (Nave et al. 1993; Schliess and Stoffel 1991). In addition, the
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bovine protein sequence is known (Stoffel et al 1983). Remarkably, the protein sequences 
are nearly identical (100% between rodents and human, and >98% including cow and dog), 
a phenomenon unprecedented for any other myelin protein. In non mammalians, such as 
the chicken and frog, conservation is still high at 95% and 70% respectively, with the 
majority of deviations present in the hydrophilic, non-transmembrane domains (Nave et al 
1993; Schliess and Stoffel 1991). Even at the nucleic acid level conservation is extremely 
high. In the 831 nucleotides of the protein coding regions only 11 differences between 
mouse and rat (Milner et al. 1985) and 25 between mouse and human (Diehl et al. 1986) 
have been demonstrated, and all of these are conservative. Upstream and downstream 
untranslated regions also show a high degree of conservation even extending into the 5/ 
flanking DNA sequences (Janz and Stoffel 1993; Kronquist et al. 1987; Nave and Lemke 
1991; Macklin et al. 1987). Selective pressure on regulatory, coding and non-coding 
sequences of the pip  gene is obviously extremely strong and pip  may be one of the most 
conserved genes so far described.
1.3.3.Protein structure, function and synthesis 
Structure
Several suggestions have been made regarding the exact orientation and integration of the 
PLP protein in cell membranes (Hudson et al. 1989a; Laursen et al. 1984; Popot et al. 
1991; Stoffel et a l 1984; Weimbs and Stoffel 1992) (Figure 3, Figure 4). The four highly 
hydrophobic domains are postulated to lie within the lipid bilayer as a  helices with the 
surrounding hydrophilic areas protruding into either the intra or extra-cellular space. 
Proposed models have been based on combinations of theoretical, immunological, 
biochemical and biophysical data and by comparison to known transmembrane proteins, 
however some evidence has been contradictory and the true molecular arrangement 
remains unresolved. The major differences relate to the positioning of the N and C- 
terminals and the hydrophilic, highly charged DM-20-deleted portion (residues 116-150) 
either at the intracellular or extracellular face.
Most recent studies (Popot et a l 1991; Weimbs and Stoffel 1992; Weimbs and Stoffel 
1994) suggest that both the N- and C-terminals lie on the cytoplasmic surface. 
Additionally, residues 103-116 have been localised at the major dense line (Sobel et al
1994), which would predict that the adjacent DM-20 deleted segment is also likely to be on 
the cytoplasmic surface.
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Figure 3. PLP/DM-20 membrane orientation models, a) Stoffel et a l b) Laursen et a l c) 
Hudson et al.
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Figure 4. PLP/DM-20 membrane orientation models (cont.). a) Popot et al., b) Weimbs 
and Stoffel ( O U T  = extracellular membrane face, IN  = intracellular membrane face). 
Hydrophobic domains predicted to form transmembrane a  helices are shown as shaded 
boxes. The residues deleted in DM-20 are shown as a thick red line. The latest models 
predict four trans-membrane domains with N and C termini, as well as the DM-20 deleted 
portion of the protein, positioned at the cytoplasmic face.
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Function
The high degree of conservation of the primary structure of PLP is suggestive of multiple 
critical protein-protein interactions. When looking at PLP/DM-20 in the more primitive 
tetrapods (Nave et a l 1993) or the DM family of proteins (Kitagawa et a l 1993; Yan et a l
1993) the hydrophobic transmembrane domains are the most highly conserved regions 
suggesting that the most important protein-protein interactions occur in the plane of the 
membrane, potentially in the formation of homo-oligomeric complexes (Nave et a l 1993). 
Many lines of evidence point to the two protein isomers of the pip  gene having different 
functions. The predominant localisation of PLP in the compact myelin sheath and 
observed abnormalities of the intraperiod line in a PLP “knockout” mouse and several 
PLP-deficient mutants (Boison and Stoffel 1994; Boison et a l  1995; Duncan et a l 1987), 
suggests a role in maintenance of the regular periodicity of the compact sheath, possibly as 
an adhesive strut. It has been suggested that PLP may also be involved in generation of the 
major dense line as well as the intraperiod line (Duncan et al 1987; Kitagawa et a l 1993). 
In contrast with pip, the dm-20 isoform is also expressed at times, and in tissues where no 
obvious role in myelination could be present. Dm-20 expression is present prior to pip  
during embryogenesis, well before myelination has begun (see 1.3.1.The pip  gene). Pip 
gene expression is also present in CNS and PNS glia and cardiac myocytes where again, 
little correlation with myelination is evident (see 1.3.5.PLP in the peripheral nervous 
system). The uncoupling of hypomyelination and glial cell death (the two major 
phenotypic characteristics of pip mutants), in the rumpshaker pip mutant mouse (Schneider 
et a l 1992) (see 1.3.4.Mutations of the pip gene) strongly suggested a role for the DM-20 
isomer in glial cell development. The jp rsh is the least severe of the pip  mutants and is 
associated with normal levels of DM-20 protein. Interestingly, the equivalent mutation in 
humans (Kobayashi et a l 1994), and another mutation predicted to have normal levels of 
DM-20 (Saugier-Veber et a l 1994), are also associated with a less severe phenotype than 
other pip mutations. All these facts point towards a non-structural role for DM-20. In 
addition to the high degree of similarity present between different members of the DM 
family of proteins, similarities are also present to segments of channel forming regions of 
the nicotinic acetylcholine receptor and the glutamate receptor macromolecular complexes 
(Kitagawa et a l 1993). The idea that DM-20 originated from an ancestral gene encoding 
an “adhesive pore” forming protein is enticing. Indeed several studies have indicated that 
PLP may form pores in the membrane and be involved in ion transport (Diaz et a l 1990; 
Helynck et a l 1983; Lin and Lees 1982).
Protein synthesis
Pip mRNA is translated on membrane bound ribosomes of the rough endoplasmic 
reticulum (RER) (Colman et a l 1982) and then packaged in the Golgi complex prior to its 
transport and incorporation into the myelin sheath (Nussbaum and Roussel 1983;
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Townsend and Benjamins 1983). Immunostaining of transfected cell lines; and cultured 
oligodendrocytes for PLP/DM-20 shows a punctate pattern corresponding to Golgi, 
cytoplasmic vesicles and endosomes (Dubois-Dalcq et a l 1986; Gow et a l 1994a; 
Sinoway et a l 1994; Timsit et a l 1992b). The protein is probably carried to the membrane 
by vesicles which use microtubule-dependent transport processes (Brown et a l  1993; 
Trapp 1990) and is probably co-transported with specific lipids (Pasquini et a l 1989). 
Transport from the RER to the membrane takes ~ 30min. (Colman et al 1982). Some cell 
transfection studies suggest that both PLP and DM-20 need to be present to enable 
incorporation into the membrane, and interestingly increased staining for PLP/DM-20 at 
cell-cell contact boundaries (as seen with other “adhesive” proteins such as P0) has been 
seen when PLP and DM-20 are present together (Sinoway et a l 1994) but not obvious 
when PLP or DM-20 alone are present (Gow et a l 1994a; Timsit et a l 1992b). The 
necessity for both PLP and DM-20 to achieve these cell-cell interactions is disputed by 
other studies (Montague et al. In press). PLP appears to form hexamers under certain 
conditions (Smith et a l 1984) and although direct evidence for PLP/PLP or PLP/DM-20 
interactions has been elusive, some cell transfection studies suggest that PLP/DM-20 
heteromeric interactions may occur (Sinoway et a l  1994).
Two modifications of the PLP/DM-20 protein occur post translationally; first the N- 
terminal methionine is removed leaving the final 276 residue protein (Milner et a l 1985), 
and secondly, the protein is covalently acylated, predominantly with palmitic, oleic and 
stearic acids. The acylation occurs non-enzymically (Ross and Braun 1988) and may occur 
within the myelin sheath. The lack of an amino terminal leader sequence (other than the 
single methionine which is removed) to target this transmembranous protein to the 
membrane would indicate that PLP is targeted using an internal signal. Studies using a 
PLP-LacZ fusion protein suggest that the first 13 amino acids may contain a myelin 
specific topogenic signal (Wight et a l 1993). The position of the acylated residues 
(thought to occur only on the cytoplasmic side of membranes) has been used to predict 
orientation of PLP in the membrane (Weimbs and Stoffel 1992) (see 1.3.3.Protein 
structure, function).
1.3.4.Mutations of the pip gene
The high evolutionary conservation of PLP is reflected in the severe phenotype of pip 
mutant animals. Mutations have been characterised in several species (Table 1) and 
several allelic forms are present in man and mice. The majority of detected mutations in all 
species are point mutations within the coding region causing single amino acid 
substitutions and most of these are present in the carboxy-terminal half of the protein (Gow 
et a l 1994b). The first and most extensively studied mutation was the jimpy (jp) mouse 
resulting from a point mutation within the 37 acceptor splice site of intron 4. The resultant 
deletion of exon 5 and alteration in reading frame generates a message coding for a
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truncated protein with an altered carboxy terminus (Nave et al. 1987a). The pip gene 
appears intolerant of almost any change, and even conservative amino acid substitutions, 
such as the jp msd mutation (Gencic and Hudson 1990; Macklin et al. 1991), result in gross 
phenotypic changes. Although there are differences in severity and age of onset between 
species and allelic forms the general phenotype is similar with hypomyelination, 
generalised tremors, seizures and early death, prior to adulthood, in hemizygous affected 
males. The degree of hypomyelination varies being very marked in the myelin deficient rat 
(md-rat) (Duncan et al. 1987) and jimpy mouse (jp) (Sidman et al. 1964) but less severe in 
the shaking pup (sh-pup) (Griffiths et al. 1981). Any myelin which is formed is usually 
disproportionately thin, poorly compacted and fails to immunostain for PLP protein. 
Abnormalities of the intraperiod line are common (Duncan et al. 1987; Duncan et al.
1989). A moderate to severe astrocytosis is seen and deficits in astrocyte cell cycle and 
metabolism have been reported (Knapp and Skoff 1993). In severely affected mutants, pip  
mRNA levels are < 5% of normal and protein is undetectable. There is also a profound 
effect on the other major myelin gene, MBP, where transcripts and protein levels are both 
decreased (Bourre et al. 1980) although compact myelin still immunostains strongly for 
MBP. Expression of other myelin protein genes such as MAG and CNP is also affected 
(Yanagisawa and Quarles 1986).
Interestingly, pip mutants such as jp , as well as being hypomyelinated, have reduced 
numbers of mature oligodendrocytes, probably due to their premature death (Knapp et al.
1986) prior to the stage at which they would be expected to produce PLP protein 
(Vermeesch et al. 1990). Increased mitotic rates of immature glia and distended RER have 
also been seen. This is not the case in other hypomyelinating, myelin protein mutants such 
as shiverer mice (MBP mutant) and quaking mouse (not determined) (Privat et al. 1979; 
Samorajski et al. 1970). An exception to this trend is seen in the jp rsh pip  mutant 
(Schneider et al. 1992) where normal or increased numbers of oligodendrocytes are seen. 
Although hypomyelinated, these mice “recover” and have a normal lifespan. PLP protein 
levels are severely decreased, but the amount of the DM-20 isoprotein is normal (Mitchell 
et al. 1992). This is intriguing in that it uncouples the two major phenotypic characteristics 
of pip mutants, that is, hypomyelination and glial cell death, and suggests a connection 
between DM-20 and glial cell survival and development. An interesting parallel is seen in 
man in some cases of X-linked spastic paraplegia type 2A (SPG2), a much less severe 
allelic disorder than Pelizaeus-Merzbacher disease (PMD), associated with point mutations 
in exons 3B and 4. The mutation in exon 3B (Saugier-Veber et al. 1994) predictably 
would result in altered PLP but normal DM-20 protein; the exon 4 mutation (Ilel86-Thr) 
(Kobayashi et al. 1994) is identical to the jp rsh mutation and again would presumably result 
in normal levels of DM-20 as in the mouse.
Female heterozygotes of the pip mutants are mosaics having oligodendrocytes expressing 
either the mutated or wild-type gene, due to X-inactivation. Phenotype varies considerably
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between different mutants and even within animals with the same mutation. Small patches 
of amyelination/hypomyelination may be present, particularly in the optic nerve (Duncan et 
al. 1986; Duncan et al. 1993). The myelin defects may show some resolution with time as 
seen in heterozygotes of the sh-pup which may show a slight tremor in early life which 
disappears with age. (Bartlett and Skoff 1986). Theoretically 50% of oligodendrocytes 
should be affected, however the extent of dysmyelination is always considerably less than 
this and in some instances may be minimal. This is presumably due to increased 
proliferation of normal immature glia to compensate for the loss of mutant cells.
The phenotypic effects of the natural mutations may be the result of one or more factors. 
The absence or critical reduction of functionally active PLP and/or DM-20 may be the 
major factor. Amounts of protein present are always subjectively far lower than would be 
expected, even allowing for the marked reduction in transcripts. This suggests that the 
oligodendrocytes may have translational or post-translational mechanisms for minimising 
the accumulation of myelin proteins whenever myelin assembly is blocked. It has been 
demonstrated in vivo (Roussel et al. 1987) and in vitro (Gow et al. 1994b) that mutant 
PLP/DM-20 protein is arrested in its passage through the ER, and congestion of the 
secretory pathways with abnormal protein has been put forward as a possible cause of 
oligodendrocyte death in pip mutant animals (Gow et al. 1994b). Studies of PLP- 
transgenic jp /Y  mice suggest that the jp  allele may act in a dominant negative manner, such 
that aberrantly folded protein complexes with normal protein triggering proteolytic 
degradation (Schneider et al. 1995). It is also possible that jp  PLP is, in a less specific 
way, toxic to oligodendrocytes, although the presence of a family with PMD due to 
complete deletion of the pip gene (Raskind et al. 1991) where no protein either toxic or 
otherwise could be present would argue against this. Details of glial cell numbers are 
however, not available in these cases, and the phenotype is much less severe than classical 
PMD.
An interesting comparison can be made between the pip gene and the peripheral myelin 
protein-22 (PMP-22) gene. PMP-22 is also a membrane spanning protein and has two 
isomers differing in their 51 untranslated region. One isoform is found in compact 
peripheral myelin and appears to be regulated like conventional myelin genes, while the 
other is present outside the nervous system, is not regulated like a myelin gene and arrests 
the growth of fibroblasts (Bosse et al. 1994). The PMP-22 gene, on chromosomes 17 and 
11 in man and mouse respectively, is the candidate gene for the hypertrophic neuropathies 
Charcot-Marie-Tooth disease type 1A (CMT-1A) and Dejerine-Sottas hypertrophic 
neuropathy (DS) in man and the trembler and trembler-J mutant mice. As with the pip 
gene, duplications, deletions and point mutations are all associated with varying clinical 
phenotypes; point mutations are found in trembler/trembler-J mice (Suter et al. 1992a; 
Suter et al. 1992b), CMT-1A (Patel and Lupski 1994) and DS (Roa et al. 1993). The 
majority of cases of CMT-1A are associated with a 1.5Mb duplication containing the PMP-
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22 gene (Patel and Lupski 1994) and a 1.4Mb deletion containing the PMP-22 gene is most 
frequently responsible for hereditary neuropathy with liability to pressure palsy 
(tomaculous neuropathy) (Chance et a l 1993). Although there is no significant sequence 
similarity between PLP and PMP-22, interesting similarities are apparent. Both have two 
isomers, one highly integrated in the myelination process, the other probably involved in 
growth and development, and both are intolerant of either point mutation or alteration in 
gene dosage.
Transgenic mice
The generation of PLP transgenic animals, initially to investigate the possibility of 
“rescuing” dysmyelinating mutants, has yielded some unexpected insights into the 
regulation of the pip gene. Lines of transgenic mice exhibiting increased pip  and dm-20 
transcript levels due to the presence of transgenes have been found to develop a phenotype 
similar to the jp  mutant (Kagawa et a l 1994; Readhead et a l 1994) In one line, 
hemizygous mice are clinically normal but have subtle hypomyelination, whilst 
homozygotes exhibit the classical tremoring phenotype and die at about 60 days. 
Oligodendrocyte numbers are normal and thin PLP+ sheaths are present. Cases of PMD 
due to duplication of the gene are also recognised (Cremers et a l 1987; Ellis and Malcolm
1994). Another transgenic model has been used to increase levels of dm-20 under the 
regulation of the pip promoter (Johnson et a l 1995; Mastronardi et a l 1993) creating a 
demyelinating phenotype, possibly due to excess DM-20 preventing stabilisation of the 
myelin sheath. Attempts to “rescue” jimpy mutant mice using pip and/or dm-20 transgenes 
have achieved partial success (Nadon et a l 1994; Schneider et a l 1995). However, normal 
levels of gene expression are not seen and the phenotype remains essentially unchanged, 
suggesting that the jimpy mutation exerts a dominant-negative effect. These “rescue” 
studies also suggest that presence of both PLP and DM-20 may be required for normal 
myelination.
Pip gene function is normally tightly regulated so that deregulation of expression, whether 
quantitative or qualitative results in major phenotypic effects. Decreased levels of 
functional PLP/DM-20 due to missense mutations, frameshifts and deletions or, 
alternatively, increased levels due to duplication or transgenic copies, result in 
dysmyelination in most instances and demyelination in the case of elevated levels of DM- 
20 .
Knockout mice
Whilst attempting to generate mice expressing only the dm-20 isoform by the use of 
homologous recombination, two strains of mice totally deficient of both isoforms were 
produced (Boison and Stoffel 1994; Boison et al. 1995). Absence of transcripts was due to
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the unexpected retention of a neo cassette, introduced for selection purposes in reverse 
orientation, within intron 3, in the mature message. Surprisingly, these mice did not 
develop the lethal phenotype associated with pip mutations and did not even show gross 
behavioural abnormalities. EM analysis identified abnormal, loosely wrapped myelin 
sheaths with a complete lack of an intraperiod line and lack of myelination of small 
diameter axons. Nerve conduction velocities were decreased and specialised tests 
identified neuromotor deficits. Another line of knockout mice have been produced 
(K.Nave unpublished) which also appear to have no gross phenotypic abnormalities and 
even fewer abnormalities on EM examination although intraperiod lines appear abnormal. 
These mice further confirm the function of PLP/DM-20 in maintaining the structural 
integrity of the myelin sheath, in particular the intraperiod line. Surprisingly, the total lack 
of these proteins, especially DM-20 does not seem to be necessary for survival of 
oligodendrocytes and it is possible that any such functions may be compensated by other 
proteins. These findings seem to add weight to the argument that loss of oligodendrocytes 
in the mutant animals may be due to abnormal conformations or toxic effects of mutant 
proteins, or deleterious effects on the integrated regulatory machinery of myelination. It 
does however seem somewhat surprising that the function of a gene as highly conserved as 
the pip  gene can be removed with so little gross phenotypic effect. It is also interesting that 
the case of deletion of the pip gene in a human patient did not result in a normal phenotype, 
but the severe neurological syndrome of Pelizaeus-Merzbacher disease. The final 
conclusion must be that the situation is still highly confusing and far from being resolved.
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Species Allele Mutation
Mouse JP
Rat
Dog
Rabbit
Pig
Human
msd
JP
. rsh
JP
md-rat
sh-pup
pt
Missense (splice site), frameshift 
causing truncated C-terminal
Missense, exon 6
Missense, exon 4
Missense, exon 2
Missense, exon 3A
Missense, exon 2
hypomyelinogenesis cong. ? Not determined
Pelizaeus-Merzbacher Missense, exons 2,3,4,5
Deletions; partial (ex. 3+4), total
Frameshifts, exons 4,7
Duplication 
Other (*)
Spastic paraplegia (SPG2) Missense, exon 3B
Missense, exon 4 (rsh)
Table 1. Summary of mutations affecting the pip gene. (*) Cases of PMD have been 
described with no mutations or alterations of the structural gene. These may represent 
mutations within regulatory regions.
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1.3.5.PLP in the peripheral nervous system
The specificity of PLP to the CNS was first questioned with the demonstration of 
transcripts and protein in Schwann cells in the PNS (Griffiths et a l 1989; Puckett et a l 
1987), although most studies have found that protein is not present in the compact myelin 
sheath (Ono et al 1990; Puckett et a l 1987). Early embryonic expression of the pip  gene, 
thought to be predominantly dm-20 has been demonstrated by several groups. Plp/lacZ 
transgene product has been demonstrated in spinal nerves, dorsal root ganglia and olfactory 
bulbs at El 5 in the mouse at a greater intensity than in the CNS (Wight et a l 1993). DM- 
20 protein has been demonstrated as early as E l3 in spinal ganglia and nerves (P Dickinson 
unpublished) and ISH studies have shown expression in cranial, spinal and autonomic 
ganglia and nerves and olfactory blastema as early as E10 (E l2.5 for the olfactory 
blastema) (Timsit et a l 1992a; Timsit et al 1995; Yu et a l 1994) (P Dickinson 
unpublished). DM-20 has been defined as the major transcript and protein in post-natal 
sciatic nerve and cranial sympathetic trunk (Agrawal and Agrawal 1991; Griffiths et a l 
1995a; Pham-Dinh et a l 1991) and its predominance in the embryonic PNS has been 
inferred by the use of differential immunostaining and ISH (Griffiths et al 1995a).
The pip gene is expressed in both myelin-forming and non-myelin-forming Schwann cells 
with the predominance of DM-20 being even greater in the latter (Griffiths et a l 1995a). 
Both isoproteins have a cytoplasmic distribution, however PLP seems to be predominantly 
located in the perinuclear region of myelinated intemodes whereas DM-20 is found in non­
myelin-forming Schwann cells, satellite cells, the olfactory nerve layer and paranodes 
(paranodal cytoplasm and lateral loops), Schmidt-Lantermann incisures and to a lesser 
degree the perinuclear area of intemodes (Griffiths et al 1995a).
The reason(s) for the differences between CNS and PNS localisation is unknown and could 
be due to several factors influencing pip gene expression in oligodendrocytes and Schwann 
cells. Use of the alternative initiation site (Kamholz et a l 1992), differences in the 
PLP/DM-20 ratio, differences in lipid composition or disputed differences with respect to 
lack of post-translational acylation of the protein (Agrawal and Agrawal 1991; Tetzloff and 
Bizzozero 1993) may affect the ability of the protein to be inserted into the compact myelin 
sheath. Interestingly, PLP/DM-20 protein appears to be present in the compact PNS 
myelin of transgenic mice carrying extra copies of the wild type pip gene (Griffiths et a l 
1995b; Readhead et al 1994) (Anderson and Griffiths unpublished). No information is 
available on the relative amounts of PLP and DM-20 in these animals which might explain 
this finding. PLP/DM-20 immunostaining has also been described in myelin-like figures 
in the PNS of P0 knockout mice (Giese et al. 1992).
The pattern of PLP/DM-20 localisation in the PNS is very unusual for a myelin protein. 
Major myelin proteins such as P0 and MBP are present in the myelin sheath and those such 
as MAG which are located in uncompacted regions of myelin-forming Schwann cells are 
not found in non-myelin forming Schwann cells or satellite cells (Trapp and Quarles 1982;
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Trapp and Quarles 1984), unlike PLP/DM-20. In myelinating Schwann cells, expression 
of the pip gene appears to be uncoupled from myelination (Gupta et al. 1991; Stahl et al.
1990), although modest increases in transcript levels have been reported during 
myelination (Kamholz et al. 1992). Presence of DM-20 in non-myelin-forming Schwann 
cells, satellite cells and the unmyelinated olfactory nerve layer is also presumably unrelated 
to myelin formation. As with the developing oligodendrocyte (see 1.5.THE 0-2A 
LINEAGE) in the CNS, the myelin-forming Schwann cell develops from a precursor cell 
and begins expressing various markers in a regulated progression beginning with NGF- 
receptor and then SI00 at about E l5 and later 04, GalC and finally myelin proteins such as 
MBP, MAG and P0 postnatally (Jessen and Mirsky 1991). Mature non-myelin-forming 
Schwann cells express a different set of protein markers such as GFAP and NGF-receptor 
and N-CAM. S-100 and 04  are common to both types of mature Schwann cell (Jessen and 
Mirsky 1991). Developing Schwann cell precursors are highly mitotic (Stewart et al. 
1993), as are the 0-2A oligodendrocyte progenitors, and expression of myelin protein 
genes is usually associated with the post mitotic mature glial cell. It is therefore interesting 
that the pip gene is very active before El 5 in these dividing Schwann cell precursors. 
Following axotomy, myelin genes such as P0 are profoundly down-regulated, however 
levels of pip gene transcripts remain relatively unchanged (Gupta et al. 1991). All these 
features suggest that the function and regulation of the pip gene in the PNS are different 
from the CNS and from other typical myelin proteins in the PNS. However, an interesting 
parallel can be drawn with early embryonic expression of dm-20 in the brain and spinal 
cord, (see 1.3.1.The pip gene) and the early expression in the PNS.). As DM-20 is the 
major PNS isoform it is probable that these anomalies may reflect functions of DM-20 
different from those of PLP.
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1.4.THE OLFACTORY BULB
The olfactory bulb is a highly specialised region of the CNS acting as a relay centre for 
olfactory nerve axons and has a defined laminar structure (Figure 5). The outer olfactory 
nerve layer (ONL) is composed of the olfactory nerves and their supporting glia (Doucette 
1984; Doucette 1989). Deep to the ONL lies the glomerular layer. The glomeruli 
represent anatomical and functional entities in which the central endings of the olfactory 
axons synapse with the dendrites of periglomerular, tufted and mitral cells (Pinching and 
Powell 1971a; Pinching and Powell 1971b; Valverde and Lopez-Mascaraque 1991). 
Whilst the periglomerular cells provide lateral communication between the glomeruli, the 
myelinated axons of the mitral and tufted cells form the olfactory tract and convey 
olfactory information to several regions of the brain. Tufted cells are found in the external 
plexiform layer and mitral cells in the deeper inner plexiform and mitral cell layers 
(Pinching and Powell 1971a). Another neuronal cell type, the anaxonic granule cell, is also 
found in these deeper layers, predominantly in the granule cell layer and is thought to be 
involved in lateral communication and summation of impulses. The olfactory system is an 
exceptional area of the CNS for several reasons. Neurones of the olfactory epithelium are 
produced throughout the entire life of the animal (Graziadei and Monti Graziadei 1979) 
and their axons are able to grow from the PNS to reach their target cells in the olfactory 
bulb (OB) of the CNS. The ability of the OB to support neuronal outgrowth is thought to 
be attributable, in part, to the glial cells that reside mainly in the ONL, which may provide 
signalling and guidance to the olfactory sensory neurones (Doucette 1984). Two types of 
glial cell have been described in the ONL, the astrocyte and a highly specialised glial cell 
which ensheathes the olfactory nerves, the olfactory nerve ensheathing cell (ONEC) 
(Doucette 1984; Doucette 1989). ONECs are also found in the outermost part of the 
adjacent glomerular layer, where they are situated at the interstices separating the glomeruli 
but never entering into them (Pinching and Powell 1971b; Valverde and Lopez- 
Mascaraque 1991). The ONECs appear to share properties of both Schwann cells and 
astrocytes (Barnett et al. 1993; Doucette 1984; Doucette 1990) (S. Barnett personal 
communication). Recent studies using clonal cell lines transformed with SV40 large T 
antigen and cell-sorted ONECs suggest that there may be two sub-divisions of the ONEC 
cells into astrocyte-like and Schwann cell-like cells which have a common origin (S. 
Barnett personal communication).
ONECs originate from the olfactory placode (future nasal epithelium), along with the 
olfactory neurones, and are not of neural tube or neural crest origin (Barnett et al. 1993; 
Valverde et al. 1992). The olfactory bulb primordium forms from an evagination of the 
telencephalon and the “migratory mass” of ONECs and axons forms a cap over the 
developing OB which will become the ONL (Doucette 1989; Doucette 1990; Valverde et 
al. 1992). The ONECs have an exclusive role of forming the glia limitans at the PNS-CNS 
transitional zone of the olfactory nerve (Doucette 1991). Myelinated fibres are never seen
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in the olfactory nerve (De Lorenzo 1957; Gasser 1956), although a small number of 
myelinated fibres may travel with the nerve and it has been suggested that ONECs may 
ensheathe some of these myelinated fibres (Doucette 1990). It has also been demonstrated 
that ONECs can myelinate peripheral axons in culture (Devon and Doucette 1992). 
Oligodendrocytes are present in the deeper layers of the olfactory bulb (Valverde and 
Lopez-Mascaraque 1991) and are responsible for myelination of dendritic segments and 
cell bodies of mitral and tufted cells, and also the mitral and tufted cell axons which run in 
the granule cell layer eventually forming the olfactory tract.
In vivo the ONL can be divided into areas using several antigenic markers (S. Barnett 
personal communication), however the whole of the ONL will immunostain for 04, 
vimentin and neural cell adhesion molecule (N-CAM) and all but the outermost layer stains 
with S-100. The ONL is negative for GalC staining. Expression of markers in cell sorted 
cultures (Barnett et al. 1993) shows variation with both media and time and does not seem 
to parallel in vivo development exactly (for example, 04  staining is lost in culture), 
however cells retain markers such as S-100, N-CAM and vimentin and remain GalC- (S. 
Barnett personal communication).
Expression of the pip gene in the OB has not been studied in detail. Pip expression was 
detected initially in the post-natal mouse at P9 by ISH (Shiota et al. 1989) although the 
location is not given and may correspond to expression in oligodendrocytes rather than 
ONECs, and at PI by northern analysis (Kanfer et al. 1989). A recent study (Griffiths et 
al. 1995a) demonstrated the presence of both protein and transcripts localised to the ONL 
at P5 and suggested that this was predominantly the dm-20 isoform. During 
embryogenesis PLP/LacZ fusion protein is present at E l4.5 in transgenic mice (Wight et 
al. 1993) and transcripts, presumed to be dm-20, are present in the olfactory blastema as 
early as El 2.5 (Timsit et al. 1995). Expression of the pip gene, predominantly in the form 
of the dm-20 isoform, in the non-myelinated ONL both during embryogenesis and during 
post-natal life may represent another example of the alternative, non-myelin-related 
function(s) of this protein.
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Figure 5. Diagramatic representation of the olfactory bulb (coronal section). Non­
myelinated olfactory nerve fibres enter the olfactory nerve layer and synapse with mitral and 
tufted cell dendrites in the glomeruli. Myelinated mitral and tufted cell axons travel in the 
granule cell layer and project centrally in the olfactory tract. The direction of these axons is 
perpendicular to the plane of section.
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1.5.THE 0 -2 A LINEAGE
Oligodendrocyte precursors are thought to originate as neuroectodermal cells of the 
subventricular zones which migrate and mature into post-mitotic myelin-producing 
oligodendrocytes. Much of the oligodendrocyte developmental lineage has been elucidated 
from studies of oligodendrocytes in culture and based on this work three major macroglial 
cell types were identified in culture; the type-1 astrocyte, the type-2 astrocyte and the 
oligodendrocyte (Miller et a l 1985; Raff et al. 1983; Raff 1989). These cells develop from 
two different precursors, the type-1 astrocyte from an undetermined precursor and the 
oligodendrocyte and type-2 astrocyte from a highly motile (Small et a l 1987) progenitor 
called the 0-2A progenitor (Raff et a l 1983). The 0-2A progenitor migrates, divides and 
differentiates into an oligodendrocyte or type-2 astrocyte depending on environmental 
signals (Raff et a l 1983; Raff 1989). In the absence of foetal calf serum (FCS) 0-2A 
progenitors give rise to oligodendrocytes and in the presence of 10% FCS to type-2 
astrocytes. Type-1 astrocytes secrete platelet derived growth factor (PDGF) which 
stimulates the proliferation of 0-2A progenitors and prevents them differentiating 
prematurely into oligodendrocytes (Noble et a l 1988; Richardson et a l 1988). Type 1 
astrocytes can be distinguished from type 2 astrocytes by the fact that they do not stain 
with A2B5 but do stain with rat neural antigen 2 (Ran-2). Type 2 astrocytes are 
A2B5+/Ran-2- (Raff et a l 1984a). There is some controversy regarding the ability of O- 
2A progenitors to generate type-2 astrocytes in vivo, and the current consensus would 
regard the 0-2A progenitor as essentially producing oligodendrocytes under normal 
conditions (Franklin and Blakemore 1995).
The developmental profile of the 0-2A progenitor can be characterised by the sequential 
appearance of developmental markers, identified by a panel of cell specific antibodies 
(Figure 6). The earliest precursor cell recognised (termed the preprogenitor) immunostains 
for the intermediate filament protein vimentin (vim) (Gonye et a l 1994; Hardy and 
Reynolds 1991) before developing into a bipolar 0-2A progenitor staining for one or more 
of the gangliosides recognised by the antibody A2B5 (Einsenbarth et a l 1979; Raff et al 
1983) or the single ganglioside GD3 (LB1) (Levi et a l 1987). (A2B5 will also stain 
neurones and astrocytes (Einsenbarth et a l 1979; Schnitzer and Schachner 1982) and GD3 
will also stain microglia and reactive astrocytes (Wolswijk 1994). These 
vim+/A2B5+/GD3+ cells represent the 0-2A progenitor and are bipotential, (in culture) 
developing into either glial fibrillary acidic protein (GFAP) + type 2 astrocytes or 
oligodendrocytes (vim, GD3 and A2B5 staining are lost as the 0-2A matures). The cell 
then progresses to the multipolar, post migratory proliferative proligodendroblast which 
may still be bipotential. These cells additionally stain with 04/A007 Ab (Sommer and 
Schachner 1981) which recognise proligodendroblast antigen (POA) (Bansal et a l 1992) 
(04/A007 also stains Schwann cells (Mirsky et al 1990)). The cell now starts to express
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galactolipids and stains with 04/A007 now recognising sulphatide and seminolipid 
followed by Ranscht monoclonal antibody (R-mAb) (Ranscht et a l 1982) which 
recognises sulphatide, seminolipid and galactocerebroside (GalC) (Pfeiffer et al. 1990) and 
then the 01 Ab (Sommer and Schachner 1981) which recognises GalC specifically and is 
taken as the indication of a cell committed to the oligodendrocyte lineage (Raff et al 
1978). Schwann cells also stain for GalC on their surface but this is lost in culture 
(Ranscht et a l 1982). This immature oligodendrocyte also stains for CNP at this time and 
goes on to become a mature oligodendrocyte with the regulated appearance of terminal 
markers (such as MBP, MAG, DM-20, 010, PLP and Oi l )  and the synthesis of myelin 
membrane (Dubois-Dalcq et al 1986; Fanarraga et a l 1993; Kuhlmann-Krieg et a l 1988). 
Appearance of DM-20 occurs before PLP with both isoforms having been previously 
reported late in oligodendrocyte development, after the appearance of 01, CNP and MBP 
(Fanarraga et a l 1993). Cultured 0-2A progenitors are capable of reversing the 
differentiation process, even 2 days after becoming GFAP+ type 2 astrocytes to become 
GalC+/GFAP- oligodendrocytes (Raff et a l 1984b).
There is evidence to suggest that the 0-2A progenitor may also give rise to a unipolar O- 
2Aadult progenitor (04+/GalC-) which may have stem cell-like properties in the adult 
CNS (Noble et a l 1989).
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Figure 6. Representation of the sequence of oligodendrocyte differentiation in the mouse. 
Progenitors (PROG) develop through an intermediate stage (INT) to the committed 
oligodendrocyte (OLIGO). Stages of differentiation are defined by specific antibodies 
against surface molecules or cytoplasmic antigens (underlined). Horizontal arrows
represent duration of expression and vertical arrows represent antigens recognised by the 
antibodies. CNP, 2 \3 ’-cyclic nucleotide 3’-phosphodiesterase; GC, galactocerebroside; 
MBP, myelin basic protein; PLP, proteolipid protein; POA, proligodendroblast antigen; 
SUL, sulphatide.
1.6.MYELINOGENESIS
Myelination within the CNS is a highly heterogeneous process. Not only do different 
regions myelinate at different times and rates, but different tracts within these areas also 
show considerable variation. Early studies showed that myelination occurs in an orderly 
sequence (Flechsig 1894; Langworthy 1929; Tilney and Casamajor 1924; Windle et a l 
1934) and numerous microscopic, biological, biochemical and molecular biological 
techniques have been used subsequently to expand this work.
According to Flechsig (1894) the first myelinated fibres are found in the spinal cord. 
Myelination then spreads into the medulla, pons, midbrain and finally into the 
telencephalon (within the cortex, projection areas myelinate before association areas). 
Light and EM microscopy in several species such as man (Langworthy 1933), possum 
(Langworthy 1928), rat (Banik and Smith 1977; Tilney 1933) and mouse (Uzman and 
Rumley 1958) and more recent ISH studies using myelin specific probes against pip  and 
mbp in the mouse (Shiota et al. 1989; Verity and Campagnoni 1988) have corroborated this 
general caudal to rostral sequence of brain myelination.
The pattern of myelination in the optic nerve is particularly interesting; In the rat, 0-2A 
progenitor cells first appear in the optic nerve at ~ E l6 and migrate along the nerve from 
the chiasmal end towards the retina with an equal dispersion of cells by P5-P9 (Small et al
1987). However myelination even within the optic nerve is itself heterogeneous beginning 
at several different sites along the nerve by P6 and progressing in a general rostral to 
caudal direction from retina to the chiasm (Black et a l 1982; Colello et al. 1995; 
Hildebrand and Waxman 1984; Skoff et a l 1980; Tennekoon et a l 1977). The situation is 
further complicated if different species, such as the rabbit, are also studied where 
myelination appears to be much more homogenous in nature (Skoff et a l 1980). 
Myelination is first seen in the cervical region of the spinal cord and has been shown to 
progress in a rostral to caudal direction in man (Langworthy 1933; Lucas Keene and Hewer 
1931), possum (Langworthy 1928), dog (Fox et al 1967), cat (Langworthy 1929), rat 
(Tilney 1933) by microscopic examination and by ISH in the rat (Schwab and Schnell 
1989). Within the spinal cord there is a set pattern of myelination of tracts at any one level, 
with the ventral columns being myelinated first followed by the cuneate, ventrolateral, 
gracile, and later by the rubrospinal and corticospinal tracts (Baron et a l 1993; Fox et a l 
1967; Langworthy 1928; Langworthy 1929; Lucas Keene and Hewer 1931; Matthews and 
Duncan 1971; Tilney 1933). Hildebrand and Skoglund (1971) although agreeing with a 
general rostral to caudal gradient states that hindlimb dorsal column afferent fibres (gracile 
tract) myelinate earlier in the lumbar region than the cervical; that is, fibres myelinate from 
their cell body distally, a theory supported by Langworthy (Langworthy 1933). However, 
an immunocytochemical study looking at the presence of oligodendrocyte markers MBP 
and 01 demonstrated a rostral to caudal gradient in both descending and ascending tracts 
(Schwab and Schnell 1989).
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Other general trends include the myelination of motor areas and motor nerve roots before 
sensory (Langworthy 1928; Langworthy 1929; Yakovlev and Lecours 1967) and PNS 
before CNS. Interesting parallels can be made between myelination, phylogeny and 
ontogeny. Generally speaking, the phylogenetically older tracts and areas such as the 
vestibulospinal, tectospinal, reticulospinal tracts (ventral columns) and brainstem 
myelinate earlier than the phylogenetically more advanced areas such as the cortex and fine 
motor tracts such as the corticospinal (pyramidal) and rubrospinal tracts. Ontogenetically, 
the fore limbs develop ahead of the hind limbs which is paralleled by the earlier 
myelination of the cervical cord relative to the lumbar and the cuneate tract (forelimb 
sensory) prior to the gracile (hindlimb sensory).
Onset and duration of myelination varies enormously between species; myelin sheaths can 
be demonstrated in rat ventral columns by electron microscopy just before birth at El 9 and 
only at P12 in the corpus callosum (Bjartmar et al. 1994) and most myelination is 
completed by 2 months. In the cat the same tracts begin myelinating 4 weeks before and 3 
weeks after birth respectively and are still doing so by 7 months (Remahl and Hildebrand 
1982). In humans myelin is initially present in the cord by the fourth or fifth month of 
foetal life and myelination continues until puberty (Langworthy 1933) and probably very 
much later than this in the neocortex.
Even within the framework of general observations stated above the process of myelination 
is remarkably complex. Myelin does not make its appearance in all parts of the CNS at the 
same time, nor simultaneously in all parts of an individual fibre and there appears to be 
pulses or waves of rapid myelination (Langworthy 1933) preceded by periods of 
oligodendrocyte proliferation (Bensted et al. 1957; Matthews and Duncan 1971; 
Samorajski and Friede 1968; Schonbach et al. 1968; Skoff et al. 1976a; Skoff et al. 
1976b). Even after myelination has commenced, rates of progression vary and one system 
may be surpassed by another in which the process commenced much later (Langworthy 
1933).
Following the work of Flechsig (1894) several authors have attempted to correlate 
myelination with the acquisition of specific reflexes indicating functionality of the tracts 
involved (Langworthy 1928; Langworthy 1929; Langworthy 1933; Tilney and Casamajor 
1924; Tilney 1933; Windle et al. 1934). In 1916 Kappers hypothesised that 
“...myelinisation of a nerve fibre occurs at a time when impulses first begin to travel along 
the fibre.” (Kappers 1916). Almost 80 years later following studies on transected optic 
nerves, Barres and Raff (1993) suggested that “...axonal electrical activity normally 
controls the production and/or the release of the growth factors that are responsible for 
proliferation of oligodendrocyte precursor cells...”, the cells responsible for myelination.
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1.7.AIM OF THESIS
Proteolipid protein is the major protein constituent of CNS myelin and abnormalities of pip 
gene expression are associated with severe dysmyelinating phenotypes in man and several 
animal species. The pip gene encodes two isoproteins, PLP and DM-20, the latter having a 
deletion of 35 amino acids. PLP is postulated to play a structural role in maintaining the 
double intraperiod line of the myelin sheath, whilst DM-20 may have a non-structural role 
which is not directly associated with the myelination. Many workers have studied 
expression of the pip gene in terms of transcriptional output or protein levels, often looking 
at relatively large, heterogeneous areas of myelinating CNS tissue. Less information is 
available regarding the relative expression of the two isoforms and how this is related to 
the local myelinating environment. It was therefore the aim of this thesis to address this 
area of study looking at more defined, homogeneous areas of the CNS during myelination 
with particular reference to the developmental patterns of expression of the pip  and dm-20 
isoforms. The ventral columns of the spinal cord and mid-optic nerve were chosen as well 
defined, easily accessible areas of the CNS known to have different ages of onset of 
myelination (~ PI and P7 respectively). Given the possible non-myelinating role of DM- 
20 it was also decided to study pip gene expression in tissues where plp/dm-20 message 
had been demonstrated but no obvious connection with myelination was present; such 
areas included the embryonic spinal cord and the PNS.
Experimental design required the use of a technique which was both highly sensitive, and 
capable of discriminating between the two pip isoforms. Reverse transcription-polymerase 
chain reaction (RT-PCR) technology provided both the means of quantifying the relative 
amounts of the pip and dm-20 isomers, and also the degree of sensitivity required when 
analysing low levels of transcripts. Limiting message was due to both the small amounts 
of tissue available when studying specific myelinating areas, and low levels of message 
present in tissues prior to myelination. Although the use of RT-PCR is an indirect method 
of measuring pip gene expression, direct methods such as northern blotting and even 
transcript mapping were not found to be sensitive enough to be appropriate alternatives. 
Use of this indirect method did however necessitate calibration of the RT-PCR protocol 
prior to collection of data, and the appropriate use of positive, negative and internal 
controls. It was envisaged, with the use of this extremely powerful molecular technique, 
together with routine immunocytochemical and histological techniques, to gain a more 
detailed appreciation of the developmental and spatial expression of the pip gene.
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CHAPTER 2. MATERIALS AND METHODS
2.1.TISSUE FIXATION AND PROCESSING
2.1.1.Fixation
Fixatives
Buffered neutral formaldehyde (BNF), (4%)
Tissues fixed in BNF were paraffin-embedded and sections taken for routine haematoxylin 
and eosin (H and E) staining, immunocytochemistry and in situ hybridisation.
1 litre of fixative:
40% Formaldehyde 100ml
Tap water 900ml
NaH2P 0 4 4g/l
K2H P04 8g/l
Strong fixative (paraformaldehyde/glutaraldehyde 2%/5%)
Tissues fixed in strong fix were resin-embedded and sections taken for methylene 
blue/azure II staining, immunocytochemistry and electron microscopy.
500ml of fixative:
8% Paraformaldehyde 250ml
(20gparaformaldehyde + 250ml distilled water (DW); heat to 65°C; 
add lM NaO H  till solution clears; cool to 4°C)
25% Glutaraldehyde 100ml
Make up to 500ml with 0.08M isotonic cacodylate buffer
(Sodium cacodylate 16.05g, NaCl 3.8g, CaCl2 0.055g, MgCl2 0.102g;
Add DW to 100ml: pH  to 7.2-73)
CaCl2 250mg
Filter in fume hood, adjust to pH 7.2 
Carnoy’s fixative
Camoy’s fixed tissue was collected for RNA extraction and subsequent RT-PCR.
100ml of fixative:
Absolute alcohol 60ml
Chloroform 30ml
Glacial acetic acid 10ml
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Techniques
Immersion
a) Tissue culture cover slips:
After routine surface immunostaining, coverslips were fixed in methanol at -20°C for 
lOmin., washed in distilled water and dried prior to mounting. Coverslips to be processed 
for in situ hybridisation (ISH) alone or for ISH after immunostaining for surface markers 
were immersion fixed in 4% paraformaldehyde for 20min., rinsed twice in PBS and stored 
at 4°C in 70% ethanol. Coverslips to be processed for immunostaining for cytoplasmic 
markers by the technique of Gow et a l (1994a) were immersion fixed in 2% 
paraformaldehyde in Dulbecco’s modified Eagle medium (DMEM) for 30min.
b) Cryosections:
Cryosections were immersion fixed in 2% paraformaldehyde in PBS for 20min. when 
immunostaining for cytoplasmic markers and in 2% paraformaldehyde in PBS for 5min. 
when immunostaining for the surface marker 04.
Intra-cardiac perfusion
All perfusions were carried out in a fume hood. Post-natal animals and embryos as young 
as E l4 were perfused transcardially with either BNF, strong fix or Camoy’s fix. Animals 
were killed by halothane or carbon dioxide inhalation and pinned in dorsal recumbency. 
After exposure of the heart via a thoracotomy, the right auricle was incised and perfusion 
initiated through the left ventricle using 23-27 gauge needles depending on the size of the 
animal. E14 and E l6 embryos were perfused through fine, pulled glass Pasteur pipettes. 
The animals were first exsanguinated by perfusion with 0.85% NaCl followed by between 
5-120ml fixative with fixation being assessed by rigidity. Animals were stored at 4°C in 
fixative moisturised containers for lhr. after which time the required tissue was dissected 
and stored at 4°C in the same fixative until processed. Embryos younger than E14 were 
decapitated and immersion fixed in the appropriate fixative.
2.1.2.Processing 
Paraffin processing
Tissue for paraffin wax embedding was processed using a Shandon Elliot automatic tissue 
processor (Histokinette) and was passed through the following dehydration solutions:
1) 70% methylated spirit 2hr.
2) 70% methylated spirit / 5% phenol 2hr.
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3) 90% methylated spirit / 5% phenol 2hr.
4) Methylated spirit 2hr.
5) Ethanol / 5% phenol lhr.
6) 1% celloidin in methyl benzoate 4hr.
7) Xylene lhr. (x3)
8) Paraffin wax 4-6hr.
Tissues were blocked out at 60°C in fresh paraffin wax.
Celloidin was obtained from Merk “Necoloidine”(R) as an 8% solution, treated as a 100% 
solution when made up with methyl benzoate.
Resin processing
Samples were processed for araldite resin embedding using a Lynx™ el microscopy tissue 
processor (Leica). Samples were passed through the following solutions:
1) Isotonic cacodylate buffer 4°C 50min.
2) 1% osmium tetroxide in cac. buffer room temp 2hr.
3) Isotonic cacodylate buffer 4°C 30min.
4) 50% alcohol 4°C 5min.
50% alcohol 4°C 1 Omin.
5) 70% alcohol 4°C 5min.
70% alcohol 4°C 1 Omin.
6) 80% alcohol 4°C 5min.
80% alcohol 4°C lOmin.
7) 90% alcohol 4°C 5min.
90% alcohol 4°C lOmin.
8) 100% alcohol 4°C 20min. (x2)
9) Propylene oxide room temp 15min. (x2)
10) 1:3, resin:propylene oxide room temp 13hr.
11) 1:2, resin:propylene oxide room temp 6hr.
12) 1:1, resin:propylene oxide room temp 18hr.
13) Resin 30°C 4hr.
Processed samples were embedded in resin filled rubber moulds and left to polymerise
overnight in a 60°C oven.
Resin composition:
30g Araldite CY212 (resin)
25.2g Dodecanyl succinic anhydride (DDSA) (hardener)
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1.2ml 2,4,6-tri-dimethylaminomethyl-phenol (DMP 30) (accelerator)
1.0ml Di-butyl phthalate (plasticiser)
Cryo-preservation
Tissue was cryo-preserved by snap freezing samples embedded in “Tissue-Tek” OCT 
compound (Miles inc.). Samples were suspended in OCT in small foil boats and held in 
isopentane cooled in liquid nitrogen. After freezing the foil was removed and the solid 
OCT embedded sample double wrapped in “Sealon film” (Fuji) and stored at -20°C.
Sections
Paraffin-embedded tissue
Paraffin embedded tissue sections were cut on a Biocut 2035 microtome (Leica) at 6pm for 
ISH and routine staining and left overnight in a 60°C oven.
Cryo-preserved tissue
OCT embedded cryosections were cut on an OTF cryostat (Bright instrument company) at 
15pm for ISH and immunocytochemistry and stored at -20°C until use.
Resin sections
Sections for light microscopy were cut at 1pm on a Reichert-Jung Ultracut E ultratome and 
placed on plain sulphuric acid treated slides (see 2.3.IN SITU HYBRIDISATION).
Ultra-thin sections
Sections for electron microscopy were cut at 70nm on the same ultratome and mounted on 
200 mesh-3.06mm diameter copper grids.
Staining techniques 
Light microscopy
a) Haematoxylin and eosin (paraffin sections):
Sections were passed through the following solutions:
1) Histoclear 2min.
2) Absolute alcohol 2min.
3) Methylated spirit 2min.
4) Water 2min.
5) Iodine 2min.
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6) Water lmin.
7) Sodium thiosulphate lmin.
8) Water lmin.
9) Mayer’s haematoxylin lOmin.
10) 1% acid alcohol 3 dips
11) Water 2min.
12) Scots tap water lmin.
13) Water lmin.
14) Methylated spirit lOsec.
15) Saturated alcoholic eosin 2min.
16) Methylated spirit lmin. (dehydration start)
17) Absolute alcohol 2min. (x2)
18) Histoclear 2min. (x2)
19) Xylene lmin.
The initial hydration steps (1-4) were omitted with unfixed material. Sections were 
mounted in DPX mountant (BDH).
Mayer’s haematoxylin was made up as follows: l.Og haematoxylin, 50.Og potassium alum 
and 0.2g sodium iodate in 1L water, brought to boiling point and left overnight before 
adding l.Og citric acid and 50.Og chloral hydrate.
Scots tap water was made up as follows: 3.5g sodium bicarbonate and 20.Og magnesium 
sulphate in 1L water.
b) Haematoxylin:
ISH sections were counterstained with haematoxylin after autoradiography as follows:
1) Water 2min.
2) Mayer’s haematoxylin 30sec.
3) Water 2min.
4) Scots water 15sec.
Sections were dehydrated and mounted as above,
d) Methylene blue/azure II (resin sections):
Slides were placed on a 60°C hot plate flooded with stain for 10-30sec. and rinsed in 
running tap water.
(Methylene blue/azure II: 1.0% methylene blue, 1.0% azure II, 1.0% borax in distilled 
water.)
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e) 4 ’,6-diamidino-2-phenylindole (DAPI):
Immunostained cryosections were counterstained with DAPI nuclear stain (6pg/ml) by 
flooding the section for lmin. and rinsing in distilled water.
Electron microscopy
Ultra thin sections were stained by covering grids with a saturated solution of uranyl 
acetate in 50% ethanol for 5-15min. at room temperature, before rinsing in 50% and 75% 
ethanol, distilled water (x2) and air drying. Grids were then stained with Reynold’s lead 
citrate for 5-1 Omin. inside aNaOH moisturised chamber and washed in 1M NaOH solution 
(x3) and distilled water (x5).
(Reynold’s lead citrate: 1.33g lead nitrate, 1.76g sodium citrate each dissolved in 15ml. 
water; mix together and shake vigorously for lmin. then occasionally for 3Omin. Clear 
with 8.0ml. 1M NaOH and make up to 50ml. with water; final pH 12.0).
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2.2.GENETIC MANIPULATION
2.2.1.Core techniques 
Ethanol precipitation
Nucleic acids were routinely precipitated in the presence of 0.3M sodium acetate (NaAc) 
pH 5.2 and 3 vol. ice cold ethanol. Amounts less than lpg were precipitated overnight at - 
70°C. Larger amounts were precipitated at -20°C or -70°C for not less than 2hr. and 1 hr. 
respectively. RNA riboprobes were also precipitated in the presence of 0.75M ammonium 
acetate (NH4Ac) or 0.4M lithium chloride (LiCl). Samples were centrifuged at 4°C for 15- 
3Omin. at 12,000g and the supernatant removed. RNA and DNA pellets were washed with 
75% ethanol/di-ethyl pyrocarbonate treated sterile distilled water (DEPC SDW) (see
2.2.2.Analysis of transcripts) and 70% ethanol/SDW respectively, either air dried for 10- 
20min. or vacuum dried for 2-3min. and reconstituted in the appropriate volume of either 
DEPC SDW or SDW respectively.
Chloroform extraction
Mineral oil was removed from PCR reactions by the addition of 2 vol. chloroform. The 
mixture was vortexed and centrifuged at 12,000g for 2min. before removal of the upper 
aqueous layer containing the nucleic acid.
Phenol:chloroform extraction
Deproteinisation of nucleic acids was performed using phenol:chloroform:isoamyl alcohol 
(25:24:1) extraction followed by ethanol precipitation. A phenol:chloroform mix was used 
since deproteinisation is more efficient when two different organic solvents are used. An 
equal volume of phenol :chloroform was added to the nucleic acid sample which was mixed 
to an emulsion and centrifuged at 12,000g for 2min. The aqueous phase was removed and 
nucleic acids precipitated as described above. Phenol:chloroform was prepared as follows:
1) Melt phenol at 68°C.
2) Add hydroxyquinoline to a final conc. of 0.1% (antioxidant, RNase 
inhibitor, chelates metal ions, colours organic phase yellow).
3) Saturate to raise pH >7.8 by repeated exposure to 0.5M Tris Cl (pH 8.0) using a 
separating funnel and agitation (DNA partitions into the organic phase at acid pH).
4) Add an equal volume of chloroform:isoamyl alcohol (24:1) and store under 0.1M 
Tris Cl (pH 8.0) in a light tight bottle at 4°C (Chloroform denatures protein and 
facilitates separation of the organic and aqueous phases. Isoamyl alcohol reduces 
foaming.).
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Enzymatic manipulations 
Restriction enzymes
Restriction enzymes were supplied by “Gibco BRL”, “Promega”, and “New England 
Biolabs” and used according to manufacturer’s instructions.
Modification enzymes
a) Klenow:
DNA polymerase I large (Klenow) fragment (Promega) was used to fill in 37 ends of DNA 
fragments. Up to ljig of DNA was treated in the presence of between 1-4U Klenow 
enzyme, 2mM dNTPs, 5mM Tris-HCl, pH 7.2, lOmM MgS04 and O.lmM dithiothrietol 
(DTT). The mixture was incubated for 3Omin. at room temperature followed by 
inactivation of the enzyme by heating at 65°C for lOmin. Product was purified using a 
Qiaex gel extraction kit (Qiagen) as described below to remove unincorporated dNTPs 
which could interfere with subsequent ligation reactions.
b) Alkaline Phosphatase:
Vectors were dephosphorylated (CIP treated) prior to insert ligation using calf intestinal 
alkaline phosphatase (CIAP) (Gibco BRL). lOpig of linearised vector was 
dephosphorylated in the presence of 50mM Tris-HCl pH 8.5 and O.lmM EDTA using 0.1U 
CIAP at 37°C for 30min. followed by a further 30min. after the addition of another 0.1U 
CIAP. The enzyme was inactivated by heating at 75°C for 15min. followed by two 
phenol:chloroform extractions (see 2.2.1.Core techniques). The product was ethanol 
precipitated and reconstituted at 1 OOpg/ml. Parallel reactions in the absence of CIAP were 
run in all cases to allow assessment of dephosphorylation efficiency during ligation 
reactions.
c) Ligase:
Ligation reactions were catalysed by T4 DNA ligase (Gibco BRL) at 12°C overnight in a 
lOpl volume in the presence of 0.25U enzyme, 0.05mM Tris-HCl pH 7.6, lOmM MgCl2, 
ImM ATP, ImM DTT, 25% (w/v) polyethylene glycol-800 and between 10-25pg/ml 
CIAP treated linearised vector at a 1:1 molar ratio with respect to the insert to be ligated. 
Both sticky and blunt end ligations were incubated as described above. Reactions 
containing 2.5:1 and 5:1 ratios of vector to insert and insert to vector were also performed 
as well as the following control reactions:
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1) Native vector + ligase. (To assess transformation efficiency.
Ligase is not required but is included since it will 
decrease transformation efficiency.)
2) Linearised vector 
(non CIP) - ligase.
(To assess efficiency of digestion of vector.)
3) Linearised vector 
(non CIP) + ligase.
(To assess ligation efficiency)
4) Linearised vector (To assess CIP efficiency)
(CIP) + ligase.
DNA fragment isolation
DNA fragments were isolated using a Qiaex gel extraction kit (Qiagen) according to 
manufacturer’s instructions. Gei slices containing the fragment were pre-washed in Tris 
buffer pH 7.0 to lower the sample pH as binding efficiency of DNA to the Qiaex decreases 
rapidly above pH 7.5. The method utilises the property of nucleic acids binding to silicagel 
particles in the presence of high concentrations of chaotropic salts such as Nal, NaC104 and 
GuSCN. Fragments were resolved on both regular TAE agarose gels up to 2% 
concentration and on TBE “Metaphor™” gels (Flowgen) up to 5% concentration. Yields 
were generally around 50% and were calculated by comparison of aliquots of isolated 
fragment with parallel fragment digests of known amounts.
Nucleic acid electrophoresis 
Agarose gels
Routine electrophoresis of both DNA and RNA was performed using 1-2% regular agarose 
gels using ultra pure electrophoresis grade agarose (Gibco BRL). Gels were cast by melting 
the agarose in the presence of Tris acetate EDTA (TAE) buffer with a final concentration 
of 0.04M Tris acetate, 0.001M EDTA and 0.5pg/ml ethidium bromide and run in the same 
buffer. Samples were loaded with 6x TAE gel loading buffer (6x TAE; 30% glycerol 
(Sigma); 0.25% bromophenol blue (BDH chemicals Ltd.); 0.25% xylene cyanole FF 
(Sigma) ). Gels were viewed using a “Fotoprep I” ultraviolet transilluminator (Fotodyne 
Inc.) and photographed using a Polaroid MP4 land camera (Polaroid), a T2201 
transilluminator (Sigma), a Wratten 22A filter (Kodak) and Polaroid 667 (ASA 3000) film.
Metaphor gels
Resolution of small DNA fragments (< lOObp) and separation of fragments differing by as 
little as 10 base pairs (bp) was achieved using “ Metaphor™” agarose gels (Flowgen).
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“Metaphor” is an intermediate melting temperature (<75°C) agarose with twice the 
resolution capacity of the finest sieving agarose products. Metaphor gels have a similar 
resolution capacity to polyacrylamide gels in resolving small fragments (~ 20-1000bp), 
whilst being much less toxic to handle. Gels of between 2-5% were used and were 
prepared and run in Tris borate EDTA buffer (TBE) to give smaller gel pore size and 
higher resolution. Final buffer concentration was 0.09M Tris borate, 0.002M EDTA and 
0.5pg/ml ethidium bromide. Gel loading buffer was the same as for agarose gels.
Microbiological manipulations 
Bacterial media
a) Luria-Bertani medium (LB medium):
1 Litre Tryptone lOg
Yeast extract 5g
NaCl lOg
Dissolve in distilled water and adjust pH to 7.0 using ~ 0.2ml 5N NaOH. Sterilise by 
autoclaving for 20min. at 151b/sq. in.
Bacteria containing plasmids conferring ampicillin or tetracycline resistance were grown in 
LB containing 100pg/ml ampicillin or 50pg/ml tetracycline respectively.
b) SOC medium:
1 Litre Tryptone 20g
Yeast extract 5g
NaCl 0.5g
Dissolve in distilled water, add 10ml of 250mM KC1 and adjust pH to 7.0 using ~ 0.2ml 
5N NaOH. Sterilise by autoclaving for 20min. at 151b/sq. in. Allow to cool to less than 
60°C and add 20ml of filter sterilised 1M glucose solution.
c) M9 minimal medium:
250ml Na2HP04.7H20  1.5g
KH2P 0 4 0.75g
NaCl 0.125g
NH4C1 0.25g
47
Make up to 238ml with distilled water and pH to 7.4 with NaOH. Sterilise by autoclaving 
for 15min. at 151b/sq. in. Cool to ~50°C and add:
1M M gS04 64g
1M CaCl2 15g
20% glucose (filter sterilised) 2.5g
Thiamine (lOmg/ml, filter sterilised) 5.0g
d) LB agar plates:
LB agarose plates were prepared at a concentration of 1.2% by the addition of 12g agar/L 
of LB prior to autoclaving. The mix was allowed to cool to 50°C before pouring (approx. 
30ml/90mm plate) at which time any thermolabile substances such as antibiotics were 
added. Ampicillin (NBL) was added to media and plates at a concentration of 1 OOpg/ml. 
Tetracycline (NBL) was added at a concentration of 50pg/ml. Both medium and plates 
were stored at 4°C and plates were removed from storage 2hrs. before use to prevent 
“sweating” and smearing.
e) M9 agar plates:
M9 agar plates were prepared at a concentration of 1.2% by the addition of 3g agar to the 
M9 media prior to autoclaving. The mix was cooled to 50°C prior to addition of glucose, 
thiamine and additional salts.
Competent cell preparation
Competent cells were prepared from JM101 Escherichia coli bacteria (supE, thi, A(lac- 
proAB), [F \ traD36, proAB, lacI9ZAM15]) (Pharmacia) maintained on M9 thiamine 
agarose plates as single colony cultures. Cultures were replated every 6-8 weeks.
1) Inoculate a single colony into 10ml L broth and incubate overnight at 37°C and 200 
rpm. in an orbital incubator.
2) Inoculate 1ml of the culture into 100ml L broth and incubate under the above 
conditions for ~ 1.5-2hrs. until the optical density (600nm) (OD600) of the culture is
g
between 0.2-0.3. This ensures that the number of viable cells does not exceed 10 
cells/ml.
3) Aseptically transfer the cells into 3x 40ml, sterile, ice cold, polypropylene tubes
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(Becton Dickinson) and incubate on ice for 20min. All subsequent steps should be 
carried out aseptically
4) Recover the cells by centrifugation at 5000rpm. for 5min. at 4°C (JA-20 rotor) and 
remove the media from the pellet
5) Gently reconstitute the pellets in 50ml (total vol.) of ice cold, filter sterilised 
(Flowpore 0.45pm filter (Biomedicals Ltd.))100mM MgCl2 and recover the cells 
again as above.
6) Gently reconstitute the pellets in 50ml (total vol.) of ice cold, filter sterilised 
lOOmM CaCl2 and incubate on ice with occasional gentle agitation for 60min.
7) Recover cells as above and reconstitute in 10ml ice cold filter sterilised lOOmM 
CaCl2 with 15% glycerol.
8) Aliquot into 1.5ml ependorfs, snap freeze in liquid nitrogen and store at -70°C. 
Allow 24hrs. before using for transformations.
T ransformations
Transformations were performed in sterile 40ml polypropylene tubes pre-chilled on ice. 
Between 0.05-25ng of DNA was aliquoted and made up to a final volume of lOOpl with 
Tris EDTA buffer (TE) pH 8.0 (lOmM Tris Cl pH 8.0/lmM EDTA pH 8.0). Competent 
cells were thawed by hand. A lOOpl aliquot was added to the DNA, swirled gently and 
incubated on ice for 3Omin. The competent culture was then heat-shocked at 42°C for 
45sec. and rapidly transferred to ice for a further 2min. The cultures were incubated at 
37°C and lOOrpm. for lhr. in an orbital incubator after the addition of 800pl SOC medium, 
and duplicate 200pl aliquots were plated out onto LB agar plates using a sterile bent glass 
rod. Plates were left at room temperature until the liquid had been absorbed, inverted and 
incubated at 37°C overnight.
Plasmid preparations
a) Minipreps:
Total amounts of plasmid DNA < lOpg were isolated from bacterial cells using the 
Wizard™ minipreps DNA purification system (Promega). This is based on the alkaline 
lysis procedure (Bimboim and Doly 1979) with lysis of bacteria using sodium dodecyl 
sulphate (SDS) and NaOH (SDS denatures bacterial proteins, and NaOH denatures 
chromosomal and plasmid DNA). Neutralisation with potassium acetate causes the 
covalently closed plasmid DNA to reanneal rapidly whilst most chromosomal DNA and 
bacterial proteins precipitate with the SDS and form a complex with the potassium which 
is removed by centrifugation. Plasmid DNA is further purified by passage through a
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proprietary chromatography column before elution with Tris EDTA (TE) buffer. Yields of 
up to 10pg were obtained from 3ml overnight cultures.
b) Maxipreps:
Large scale preparation of plasmid DNA from 200ml overnight cultures followed the 
protocol above using the WizardTM maxiprep DNA purification system with yields of up 
to lmg DNA.
Plasmids were stored as both purified DNA at -20°C and as bacterial culture glycerol 
stocks (800pl culture + 200pl sterile glycerol) at -70°C.
2.2.2.Analysis of transcripts 
RNA Extraction 
Fresh Tissue
RNA was isolated from tissue using RNAzol™ B (Biotech Laboratories, Inc.) following 
the manufacturer’s instructions. The method is a modification of the single step procedure 
of Chomczynski and Sacchi (1987) and utilises the complexing of RNA with guanidinium 
and water molecules in the aqueous phase from which DNA and proteins are excluded. 
Plastic-ware and apparatus were soaked overnight in a sterile 0.1% solution of di-ethyl 
pyrocarbonate (DEPC) in distilled water, autoclaved for 15min. and oven dried prior to 
use.
Tissue samples were frozen in liquid nitrogen after collection. Tissue samples greater than 
O.lg were homogenised in liquid nitrogen with a mortar and pestle followed by a Dounce 
homogeniser in the presence of the required amount of RNAzol (l-2ml/100mg tissue). 
Small tissue samples were triturated through decreasing needle sizes (21 gauge to 27 
gauge) using 1ml RNAzol and a 2ml syringe. One tenth of the total volume of chloroform 
was added to the homogenate and vortexed for 15 seconds before incubation on ice for 15 
minutes. The sample was centrifuged at 4°C for 15min. at 12,000g and the upper clear 
aqueous phase removed and retained. RNA was precipitated using an equal volume of 
isopropanol. Samples with expected yields of over 1 pg were left for 15min. on ice before 
centrifuging at 4°C for 15min. at 12,000g. Samples with lower expected yields were 
precipitated overnight at 4°C. Pellets were washed with 800pl 75% ethanol/DEPC-treated 
sterile distilled water (SDW) and dried under vacuum for 2-3min. The RNA pellet was 
reconstituted in 0.1% DEPC-treated SDW and RNA concentration assessed either by 
absorbence spectrophotometry at 260nm and 280nm UV, gel comparison with aliquots of 
RNA of known concentration or colourimetrically using a DNA Dipstick™ (Invitrogen).
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Fixed Tissue
Tissues fixed using Camoy’s fixative were treated in the same manner as fresh tissue apart 
from liquid nitrogen freezing which was not required.
cDNA Preparation
First strand cDNAs were synthesised from 2pg of total RNA given availability. RNA was 
initially denatured at 65°C for 5min. and quenched on ice. Reactions proceeded in the 
presence of 3pg random primers (Gibco BRL), 0.5mM deoxynucleotides, lOmM 
dithiothrietol and 20 U RNasinR (Promega) ribonuclease inhibitor for 3 Omin. at 37°C and 
60 min. at 42°C using 400U Moloney murine leukaemia virus (M-MLV) reverse 
transcriptase (Gibco BRL) in the manufacturer’s buffer. Reactions were terminated with 
2.5pi 500mM EDTA. The product was ethanol precipitated (see 2.2.1.Core techniques) and 
reconstituted in SDW at 25ng/pl.
Reverse transcription polymerase chain reaction (RT-PCR)
Pip and dm-20 RT-PCR products were amplified using a “Perkin Elmer” DNA thermal 
cycler from 50ng cDNA using a forward primer in exon 2 and a reverse primer in exon 4 
spanning exon 3 (Table 2). In the presence of both pip and dm-20 cDNAs two products of 
506 and 401 base pairs, respectively, were generated (Figure 7). Cyclophilin products were 
generated in parallel with plp/dm-20 products when semi-quantitative information was 
required about the expression of the pip or P0 genes. Cyclophilin is an ubiquitous 
constitutively expressed protein (Danielson et al. 1988) and generation of RT-PCR product 
could therefore be used as an internal control to ensure equal loading of cDNA between 
samples. Cyclophilin product of 300bp was generated using the primers described below 
(Table 2). Major peripheral myelin protein P0 RT-PCR product was generated using the 
primers described below (Table 2) giving a final product of 210bp. Reactions were 
performed in 0.5ml eppendorfs in the presence of 2.5U Taq DNA polymerase (Promega) in 
the manufacturer’s reaction buffer, 0.2mM dNTPs, either 0.3pM each cyclophilin/P0 
primer or 0.3pM PLP forward primer and 0.2pM PLP reverse primer and between 1.5- 
4.5mM MgCl2. Reagents were overlaid with 50 pi mineral oil (Sigma).
Between 2-5ng of plasmid containing the appropriate cDNA insert were used as target for 
positive internal controls; pC4 (PLP), pCl 1 (DM-20), plB15 (Cyclophilin), pP0 (P0).
51
The PCR program consisted of:
1) Initial denaturation 94°C lmin. 30sec.
2) Step cycle (25-39 cycles)
Annealing
Extension
Denaturation
3) Final cycle
Annealing
Extension
4) Soak (storage)
55°C
72°C
94°C
55°C
72°C
4°C
45 sec. 
1 min. 
45 sec.
1 min.
5 min.
PCR products were extracted from the mineral oil either by direct removal of the lower 
aqueous layer or by chloroform extraction (see 2 .2 .1.Core techniques).
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Figure 7. The use of RT-PCR technology to identify pip and dm-20 transcripts. By 
designing PCR primers placed either side of exon 3B, pip and dm-20 products of different 
lengths are generated. Dm-20 product will be shorter by 105bp, thus allowing the two 
products to be resolved during gel electrophoresis.
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2.2.3.Southern blotting (pPLP-3B probe specificity 
confirmation)
Gel preparation
DNA was run on standard 2% agarose gels, to achieve adequate resolution of plp/dm-20 
PCR/RT-PCR products, with appropriate DNA size markers. Gels were photographed 
with a ruler alongside to allow later identification of bands on the transfer membrane. The 
gel was rinsed in distilled water, placed in denaturing solution (0.5M NaOH/1.5M NaCl) in 
a plastic dish and shaken slowly on a platform shaker for 15min. The rinse and 
denaturation were repeated. The gel was then rinsed and shaken twice in neutralisation 
solution (3M NaCl/0.5M Tris pH 7.4) for 30min. to lower the pH to below 9.0, above 
which DNA binding to membranes is poor.
Transfer
DNA was transferred by upward capillary action using a high-salt transfer buffer (20x 
standard sodium citrate (SSC); 3M NaCl/0.3M trisodium citrate) onto “Hybond™-N+” 
nylon membranes (Amersham) cut to the same size as the gel. A solid support was placed 
in a tray containing 20x SSC and wicks made from Whatman 3MM paper (Whatman 
International Ltd.) soaked in buffer were placed over the support trailing into the buffer, 3 
lengthways and 3 breadthways. The gel was placed on top and the surrounding paper 
sealed with “Sealon film” (Fuji) to ensure only vertical capillary transfer. Positioned above 
this were; the transfer membrane which had been previously soaked in SDW followed by 
6x SSC; 3 pieces of 3MM cut to gel size, soaked in 20x SSC; 3 pieces of 3MM cut to gel 
size, unsoaked; paper towels cut to gel size to a height of ~ 4cm; a sheet of glass and a 
weight to hold everything in place. Transfer was carried out overnight ensuring that the 
20x SSC reservoir did not run dry. Efficiency of transfer was assessed by viewing the gel 
and filter using a UV transilluminator. The filter was rinsed in 6x SSC, air dried and the 
DNA immobilised on the filter by UV crosslinking using an XL-100 UV crosslinker 
(Spectronics corporation).
DNA radiolabelling
32Random primed P labelled DNA probes were generated from pPLP-3B plasmid using the 
“High prime” labelling kit (Boehringer Mannheim). Pip-specific insert was liberated from 
the plasmid by an Eco Pl/Hin dill digest, gel isolated and quantified as described above. 
50ng of insert was reconstituted in 11 pi SDW, denatured in a boiling water bath for lOmin. 
and quenched on ice. This was used as template in a 20pl reaction containing 4pl “High 
Prime” solution and 5pi (50pCi) 32P dCTP, 3000 Ci/mMol, aqueous solution. The mixture 
was incubated for lOmin. at 37°C and the reaction stopped by the addition of 2pl 0.2M
32EDTA (pH 8.0). Labelled DNA was separated from unincorporated P-labelled
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nucleotides by elution from “Sephadex Nick” columns (Pharmacia Biotech) according to 
the manufacturer’s instructions. Specific activity of probes was estimated using a mini-
8 9monitor and found to be in agreement with predicted values ( - 1x 10 -1x10 cpm/pg). 
Prehybridisation
Filters were prehybridised in heat sealed plastic bags using O.lml/cm “Rapid-hyb” buffer 
(Amersham). Buffer was pre-heated to 65°C and prehybridisation was carried out in a 
shaking water bath for a minimum of lhr.
Hybridisation
Approximately 2ng/ml of labelled probe was added to the prehybridisation solution after 
separate mixing in a 1ml aliquot to prevent concentrated probe being added directly to the 
membrane. After ensuring even mixing and distribution, hybridisation was allowed to 
proceed with shaking at 65°C overnight.
Washing
Washes to remove non-specifically bound probe were as follows:
1) 2x SSC, 0.1% (w/v) SDS
2) 2x SSC, 0.1% (w/v) SDS
3) 1.0-0.1x SSC, 0.1% (w/v) SDS
4) O.lx SSC, 0.1% (w/v) SDS
3 Omin.
3 Omin.
15min. x2 
15min. x2
room temp. 
65°C 
65°C 
65°C
Reduction in background levels of probe was moitored using a mini-monitor and the 
stringency and length of washes increased as appropriate.
Development
Hybridised filters were allowed to air dry and placed in heat-sealed plastic bags. 
Autoradiography was performed using Cronex 10S X-ray film (DuPont) with Kodak “X- 
Omatic” regular intensifying screens for the appropriate times.
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2.3.IN SITU HYBRIDISATION
2.3.1.Riboprobes 
35S riboprobes
35Both sense and antisense S probes were generated which would recognise pip  and dm-20 
(PLP-1) or only pip transcripts (PLP-3B) using the SP6/T7 Transcription kit (Boehringer 
Mannheim). PLP-1 probes were generated from a 0.8kb cDNA containing mainly coding 
region cloned into pGEM 4 (Promega), (Milner et al. 1985). PLP-3B probes were 
generated from an 81 bp cDNA fragment in exon 3B subcloned into pGEM 3Z (Promega), 
(see 3.1.SUBCLONING OF THE MOUSE pip SPECIFIC SEQUENCE). Plasmids were 
linearised using the appropriate restriction enzyme (see below), confirmed by analytical gel 
analysis, ethanol precipitated and reconstituted at 500pg/ml. All restriction enzymes were 
chosen to generate 5f overhangs as 37 overhangs may cause aberrant transcript generation.
Plasmid Digest Promoter Sense/aSense
pPLP-1 Bam HI T7 a  Sense
pPLP-1 Hin dill SP6 Sense
pPLP-3B Eco RI SP6 a  Sense
pPLP-3B X bal T7 Sense
A 20pl labelling reaction contained the following:
l-2pg linearised DNA, l.Opl each of nucleotides (ATP, GTP, UTP (lOmM in Tris buffer)), 
5.0pl (50pCi) 35S aCTP (specific activity 37TBq/mM; < 1000 Ci/mM; Amersham), 2.0pl 
lOx transcription buffer, l.Op.1 RNAse inhibitor (20 units/pl) and DEPC SDW to 20pl. 
The mixture was incubated at 37°C for 30min. after the addition of l.Opl either T7 or SP6 
RNA polymerase (20 units/pl). An additional l.Opl enzyme was then added and the 
incubation repeated. Template was digested with the addition of 2.0pl RNAse free 
DNAse(10 units/pl) incubated at 37°C for 15min. The product was phenol chloroform 
extracted and a back extraction performed after the addition of a further 22pl DEPC SDW. 
The RNA was precipitated with 7.5M NH4Ac, a 5.0pl aliquot removed prior to 
centrifugation and placed in 5.0ml “Ecoscint” (National Diagnostics) labelled A. RNA 
pellets were reconstituted in lOOpl DEPC SDW and 5.0pl of this, labelled B and 5.0pl of 
the supernatant, labelled C were added separately to 5ml Ecoscint. The riboprobe was 
reprecipitated overnight with 3M NaAc.
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Ecoscint vials were counted on a Beckman LS 1801 scintillation counter.
Vial A represented Total amount of isotope.
Vial B represented Amount of incorporated isotope.
Vial C represented Amount of unincorporated isotope.
Percentage isotope incorporation was calculated as a ratio of B/A. Isotope incorporated 
into RNA was calculated by a standard formula and the riboprobe reconstituted in 0.01M 
dithiothreitol at a concentration of l.Ong/pl/kb. Probe was stored at -20°C and used within 
6-8 weeks.
Digoxigenin riboprobes
Digoxigenin probes were generated using the DIG RNA Labelling kit (SP6/T7)
35(Boehringer Mannheim). Although S-labelled probes provided greater sensitivity, 
digoxigenin-labelled riboprobes offered the advantages of safer handling and greater
o c
stability. Digoxigenin-labelled probes are stable for more than 1 year, whereas S-labelled 
probes must be used within 6-8 weeks. A 20pl labelling reaction contained the following:
1 jug linearised DNA, l.Opl NTPs (lOmM ATP, CTP, GTP, 6.5mM UTP, 3.5mM DIG-11- 
UTP, pH 7.5), 2.0pl lOx transcription buffer, l.Opl RNAse inhibitor (20 units/pl) and 
DEPC SDW to 20pl. The mixture was incubated at 37°C for lhr. after the addition of 
l.Opl either T7 or SP6 RNA polymerase (20 units/pl). An additional l.Opl of enzyme was 
added and the incubation repeated. Template was removed with the addition of 2.0pl 
RNAse free DNAse (10 units/pl) incubated at 37°C for 15min. The reaction was 
terminated with 2.0pi 0.2M EDTA and precipitated with 4M LiCl (see above). RNA 
pellets were reconstituted in lOOpl DEPC SDW + l.Opl RNAse inhibitor and incubated at 
37°C for 3 Omin. before storing at -20°C.
Incorporation of digoxigenin was checked using an alkaline phosphatase conjugated anti- 
digoxigenin antibody and dig-labelled pSPT18-neo (lOOpg/ml) as a positive control. 
Serial 50% dilutions of control and probe were dotted onto Hybond™-N nylon 
hybridisation transfer membrane (Amersham), air dried and immobilised by crosslinking 
(see 2.2.3.Southern blotting (pPLP-3B probe specificity confirmation)). Filters were
incubated in sealed polythene bags (Pifco) at room temperature on a platform shaker with; 
20ml maleate buffer (0.1M maleic acid, 0.15M NaCl, pH 7.5) for lmin.; 20ml blocking 
reagent (1% w/v in maleate buffer; Boehringer Mannheim) for 3Omin.; 10ml anti DIG-AP, 
Fab fragments (2.0pl (0.75U/pl); Boehringer Mannheim, in 10ml TBS buffer (0.1M Tris 
HC1, 0.15M NaCl, pH 7.5)) for 30min.; 2x 20ml TBS buffer for 15min. and 10ml substrate 
(45pl 4-nitroblue tetra-zolium chloride(NBT); lOOmg/ml; (Boehringer Mannheim), + 35pl 
5-bromo-4-chloro-3-indoyl-phosphate (X-phosphate, BCIP); 50mg/ml; (Boehringer 
Mannheim) + 10ml substrate buffer (0.1M Tris HC1, 0.1M NaCl, 0.05M MgCl2, pH 9.5)).
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Incubation with the substrate was without shaking and blue reaction product was generally 
visible after l-5min. after which time filters were rinsed in DW and air dried.
2.3.2.ISH Protocol
The basic procedure was as described by Cox et a l (1984) and modified by Wilkinson et 
al. (1987). Pre-treatment involves several steps which increase the accessibility of the 
target (mRNA) to the probe whilst maintaining morphological preservation of the tissue. 
Proteinase K treatment removes protein bound to the target whilst acetylation (Hayashi 
1978) decreases non-specific binding due to electrostatic interactions between probe and 
basic proteins. Hybridisation of riboprobe to the target is performed under low stringency 
conditions favouring hybrid formation and washing removes unbound probe giving 
acceptable background. An RNase step is included to remove single stranded RNA.
Apparatus/Tissue preparation
To minimise RNase activity, all glassware and slides were soaked in 6.0% sulphuric acid, 
6.0% potassium dichromate overnight; rinsed for 2-4hr. in tap water; rinsed in distilled 
water; immersed in 0.01% DEPC SDW overnight, and oven-dried at 60°C and baked at 
180°C for 4hr. loosely wrapped in foil. Eppendorfs and pipette tips were DEPC-treated as 
described previously(see 2.2.2. Analysis of transcripts).
Coverslips used to cover sections during hybridisation were siliconised to decrease probe 
binding. They were soaked in 1M HC1 for 30min.; washed in distilled water 3 times; air 
dried; immersed in Repelcot™ (BDH) for 20min.; rinsed in distilled water and baked at 
130°C for 90min.
3-aminopropyltriethoxy-silane (APES) (Sigma) coated slides were prepared as follows. 
Slides were washed as above, soaked in Decon 90 (Decon Lab. Ltd.) (5% solution) 
overnight, washed well and oven dried wrapped in foil. In a fume hood slides were soaked 
in, 0.25% APES in methylated spirit for 2min. and 0.01% DEPC SDW for 2min. prior to 
oven drying wrapped in foil. Slides were stored at room temperature.
Chrome alum/gelatin coated slides were prepared as follows. A 1% (w/v) gelatin, 
0.1%(w/v) chrome alum, 0.01% DEPC solution was made by dissolving the gelatin in 
boiling DW, cooling, adding the chrome alum, filtering through 3MM paper and adding 
the DEPC. Slides were coated in three separate solutions for 2min. each, oven dried 
wrapped in foil and stored at room temperature.
In situ hybridisation was performed on cultured cells grown on poly-L-lysine coated 
coverslips (see2.6 .TISSUE CULTURE), 6pm tissue sections from BNF perfused tissue 
(see 2.1.1.Fixation) on APES coated slides or 15pm tissue sections from unfixed cryo- 
preserved tissue (see 2.1.1.Fixation) on gelatin coated slides. Tissue culture coverslips
59
were fixed onto RNase free slides using Loctite glassbond (Loctite UK.) prior to 
processing.
Pre-treatment
Slides were passed through the following solutions:
1) Xylene lOmin. (paraffin-embedded sections only)
2) Absolute alcohol 5min. (paraffin-embedded sections only)
3) Methylated spirit 5min. (paraffin-embedded sections only)
4) 0.85% saline 5min.
5) Phosphate buffered saline (PBS) 5min.
6) 4% paraformaldehyde (in PBS) 20min.
7) PBS x2 5min.
(PBS- 137mM NaCl/2.8mM KCl/1.5mM KH2PO4/8111M Na2HP04)
Sections were then covered with a 0.002% solution of proteinase K in 0 05M Tris-HCl (pH 
7.6); 0.005M EDTA for 7.5min., washed in PBS for 5min. and the proteinase K inactivated 
by fixation in 4% paraformaldehyde for 5min. Slides were placed in 0.1 M triethanolamine 
+ 625pi acetic anhydride in a fume hood with magnetic stirrer for lOmin. with a further 
625pi acetic anhydride added after 5min. Finally slides were passed through:
1) PBS 5min.
2) 0.85% saline 5min.
3) Methylated spirit 5min.
4) Absolute alcohol (x2) 5min.
Slides were then air dried for lhr.
(Proteinase K treatment was omitted with cryo-sections and tissue culture coverslips.)
Hybridisation
Total volume of probe required was calculated depending on number and size of sections 
(brain sections ~ 6pl; spinal cord sections ~ 3 pi) and dilution factor of the probe. 
Generally PLP-1 was used at 1:10 and PLP-3B at 1:2-5. Dilutions were made in 
hybridisation buffer:
50% formamide 
10% dextran sulphate 
lx  Denhardt’s 
20mM Tris-HCl (pH 8.0)
0.3MNaCl
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5mM EDTA
lOmM NaH2P 04 (pH 8.0)
0.5mg/ml yeast tRNA
Hybridisation buffer was stored at -20°C and 1% 1M dithiothrietol (DTT) diluted with 
DEPC SDW was added to the final probe/buffer mixture. Probe was denatured at 80°C for 
2min., quenched on ice and aliquoted onto the sections which were covered with 
siliconised coverslips (see above). Slides were placed horizontally in a slide holding box 
containing tissue soaked in 50% formamide/5x SSC. The box was sealed with tape, placed 
inside 3 vacuum sealed bags and immersed in a 50°C waterbath for overnight 
hybridisation.
Washing
Post-hybridisation treatment consisted of:
1) Washes:
a) Wash 1 5x SSC/0.01M DTT 50°C 30min.
b) Wash 2 2x SSC in 50% formamide/ 65°C 20min.
0. 1M DDT
c) Wash 3 0.5M NaCl/0.005M EDTA/ 37°C lOmin. (x3)
0.01M Tris-HCl (pH 7.5)
d) RNAse A 0.02mg/ml in Wash 3 37°C 30min.
e) Wash 3 37°C 15min.
f) Wash 2 65°C 20min.
g) Wash 4 2x SSC Room T° 15min.
h) Wash 5 O.lxSSC Room T° 15min.
2) Dehydration:
D 1 75ml ethanol, 162.5ml water, 12.5ml 6M ammonium acetate 30sec.
D 2 150ml ethanol, 87.5ml water, 12.5ml 6M ammonium acetate 30sec.
D 3 200ml ethanol, 37.5ml water, 12.5ml 6M ammonium acetate 30sec.
D 4  237.5ml ethanol, 12.5ml 6M ammonium acetate 30sec.
Slides were finally dehydrated through absolute alcohol for 2min. (x2) and air dried. 
Autoradiography
Slides were exposed against Cronex (DuPont) medical screen film inside a radiographic 
cassette at room temperature overnight. Intensity of developed image determined 
subsequent exposure times. Slides were dipped in a solution of Ilford K5 emulsion in a 1:1
ratio with distilled water containing 1.0% glycerol, at 42°C. Slides were air dried for 4- 
6hr. and stored at 4°C in light tight boxes containing a sachet of silica gel for the required 
exposure time. Exposure times were generally between 1-7 days.
Digoxigenin (modifications)
35Digoxigenin in situ protocol was identical to S protocol up to washing with the omission 
of DTT from the hybridisation buffer.
Washes:
1) Wash 1 2x SSC 50°C 2.5hr.
2) Wash 2 2x SSC in 50% formamide 50°C 1.5hr.
3) Wash 3 O.lxSSC room temp 30min.
4) Wash 4 . Tris pH7.5 room temp 15min.
At room temperature, slides were then blocked with Tris pH7.5/10% foetal calf serum for
15min., incubated with anti DIG-AP (1:500) (see 2.3.1.Riboprobes) for lhr., washed in 
Tris pH7.5 for 30min. and incubated with the substrate (see 2.3.1.Riboprobes) overnight.
Slides were wet mounted with 90% glycerol in PBS.
Tissue culture (modifications)
After fixation in 4% paraformaldehyde (pre-treatment step 6) tissue culture coverslips were 
treated as for tissue sections, with the omission of the Proteinase K treatment. If coverslips 
had been immunostained previously, hybridisation time was reduced to 3.5hr. instead of 
overnight to reduce degradation of the fluorescent signal. Washes not at room temperature 
were also reduced by half apart from the RNase treatment.
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2.4.IMMUNOCYTOCHEMISTRY
2.4.1.Tissue sections
Peroxidase anti-peroxidase
Paraffin embedded tissue
Sections were initially hydrated:
1) Xylene 2min.
2) Absolute alcohol 2min.
3) Methylated spirit 2min.
4) Water 2min.
5) Iodine lmin.
6) Water 2min.
7) 5% sodium thiosulphate lmin.
8) Water 2min.
Endogenous peroxidase activity was blocked by immersing the slides in 3% hydrogen 
peroxide in absolute alcohol for 30min., then washed in running water for 30min. Non­
specific binding sites were blocked with 10% normal goat serum in PBS for 2hr. and the 
sections blotted dry. Sections were incubated at 4°C overnight with the primary antibody 
diluted in 1% normal goat serum in PBS.
Sections were warmed to room temperature, washed in 6 changes of PBS over 30min., and 
the secondary antibody (link) diluted in 1% normal goat serum in PBS added for lhr. 
Sections were washed with 6 changes of PBS over 20min., and covered with the PAP 
complex diluted in 1% normal goat serum in PBS for 30min. Sections were washed with 6 
changes of PBS over 20min., placed in 0.2M phosphate buffer (~ 80% Na2H P04, ~ 20% 
KH2P 0 4 added to achieve pH 7.4) for lmin. and transferred for 20min. to a filtered 
solution of 50mg 3,4,3,,4’,-tetraminobiphenyl hydrochloride (DAB) in 50ml distilled water 
made up to 100ml with 0.2M phosphate buffer. 330pl 30% aqueous hydrogen peroxide 
was added to the DAB solution and the colour allowed to develop over 3-5min. Sections 
were washed in 0.2M phosphate buffer for 2min. and running water for 5min.
Resin embedded tissue
Resin was removed from the sections prior to hydrogen peroxide treatment by submerging 
the slides in sodium ethoxide solution (50% ripened sodium ethoxide solution in absolute 
alcohol). Removal was checked microscopically after 30min. and the sections washed 6 
times in absolute alcohol and submerged in running water for 30min. Hydrogen peroxide
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(3%) was made up in absolute alcohol for the resin-embedded slides. After endogenous 
peroxidase blocking, slides were treated as above.
Primary antibodies, their associated links and PAP complexes with dilutions and sources 
are detailed in Table 3
Immunofluorescence
Cryosections
Cryosections (15pm) were stained by single or double immunofluorescence. To 
demonstrate myelin proteins (PLP/DM-20, PLP, MBP) or neurofilaments (NF) the fixation 
and permeabilisation technique of Gow et al. ( 1994a) was used:
Sections were thawed and covered with Tris buffered saline (TBS) pH7.5 (25mM Tris 
pH7.5, 136mM NaCl, 2.6mM KC1) for lOmin. Sections were fixed in 4% 
paraformaldehyde in PBS for 30min. and washed in PBS for 20min. (x2). Sections were 
permeabilised with 0.1% saponin (Sigma) in PBS for 30min. in a humidity chamber and 
excess solution removed with a tissue. Blocking buffer was applied for at least 30min. 
again in a humidity chamber. Blocking buffer consisted of:
2% bovine serum albumin (BSA/Fraction V ) (BDH)
0.1% porcine skin gelatin/type A (Sigma)
2% normal goat serum (NGS) (Scottish antibody production unit)
0.02% biotin (Sigma) (omit if using biotinylated secondary antibody)
0.1% saponin (Sigma)
Excess solution was removed with a tissue and the primary antibody applied overnight at 
4°C in a humidity chamber. Antibody was diluted in the same blocking buffer but with 
0.02% saponin. Sections were washed with PBS for 20min. (x3) and the secondary 
antibody, diluted as above, applied for 30min. at room temp. Sections were washed in PBS 
for 5min. (x2), water for 5min., and mounted in Citifluor antifade mountant (UKC Chem 
Lab).
To demonstrate the surface protein marker 04, sections were fixed in 2% 
paraformaldehyde in PBS for 5min., washed and the primary antibody applied for lhr. at 
room temperature..
2.4.2.Tissue culture
Immunofluorescence
Dissociated cell cultures were stained by single or double immunofluorescence. All 
primary and secondary antibodies were diluted with buffered staining solution (4% donor
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calf serum, 0.05% azide in HEPES made up in Hank’s buffered salt solution, Ca2+, Mg2+ 
free (HBSS)). All incubations were carried out in closed staining trays.
For surface markers, coverslips were incubated with ~ 20jli1 of the primary antibody for 
20min at room temp, washed 3 times in staining solution before the addition of ~ 20ml of 
the secondary antibody for 20min. followed by a further 3 washes. The procedure was 
repeated for double surface immunostaining.
For immunostaining with cytoplasmic markers after a surface marker, the surface stained 
cells were washed twice in buffered DMEM and fixed with 2% paraformaldehyde in 
DMEM for 30min. at room temperature. From that point the Gow’s method was used as 
described above. Coverslips were mounted in Citifluor antifade mountant (UKC Chem 
Lab).
Immunostained coverslips for ISH or H thymidine studies were fixed as appropriate and 
attached to slides as described previously (see 2.3.2.ISH Protocol). After ISH processing 
slides were dipped and developed as previously described (see 2.3.2.ISH Protocol) prior to 
sealing in Citifluor media under an additional coverslip.
All primary and secondary antibodies, with dilutions and sources are detailed in Table 4.
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2.5.MORPHOMETRY
2.5.1.Glial cell quantification
All cell counting was performed on lpm  resin embedded sections, stained with methylene 
blue/azure II. Cells in selected areas (see below) were counted using a 6.3X eyepiece lens, 
a 100X oil immersion lens and a 100 square graticule (Graticules Ltd.). A minimum of 
600 squares were counted for each area. Total cell counts included precursor cells, 
oligodendrocytes, astrocytes and microglia. Endothelial cells were not counted. Cells 
were only counted when an intact nucleus could be seen. Longitudinal sections taken at 
right angles to the counting sections allowed estimation of maximum and mean glial 
nuclear length. The length of 50 cells in the appropriate field were counted. Where 
multiple sections were needed, serial sections were cut at a separation greater than the 
maximum glial cell length. Areas of sections were calculated from Polaroid light 
microscopy images with appropriate calibration standards using Sigma Scan™/Image 
image measurement software (Jandel Scientific Software) and a Summa Sketch III graphics 
tablet (Summagraphics). Corrected total glial cell counts and glial cell densities were 
calculated using Abercrombie’s formula as discussed by Sturrock (1983). Three animals 
were counted for each area and data was plotted using Graphpad Prism software (Graphpad 
Software Inc.).
Area counted Section
b) Optic nerve
a) Spinal cord ventral columns Transverse/proximal cervical intumescence 
Transverse/mid thoracic cord 
Transverse/proximal lumbar intumescence 
Transverse/mid optic nerve
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2.6.TISSUE CULTURE
2.6.1.Tissue preparation 
Spinal cords
The method used is that described by Fanarraga et al. (1993). Spinal cords were dissected 
from embryos into HBSS medium and nerve roots, ganglia and meninges completely 
removed. Tissue was minced with a No. 10 scalpel blade, transferred to a sterile centrifuge 
tube with ~ 900pl collagenase solution and incubated at 37°C for 30-45min.
The tube was centrifuged at 1000 rpm. for 3min. at room temperature and the supernatant 
removed. 1ml. of 0.05% trypsin/0.02% EDTA solution was added to the pellet and 
incubated at 37°C for 30min followed by 1ml SD solution for 2min. to stop enzymatic 
activity and prevent cell clumping. The suspension was centrifuged at 1000 rpm. for 3min. 
at room temperature, the supernatant removed and the cells mechanically dissociated by 
trituration in warm HBSS through decreasing gauge needles (21G, 23G, 25G, and 27G). 
The suspension was centrifuged at lOOOrpm. for lOmin. at room temperature and the pellet 
reconstituted in ~ 200pl 50% HBSS/50% Bottenstein and Sato medium (Bottenstein and 
Sato 1979) + 0.4% foetal calf serum (FCS). Cell density was calculated using a Levy 
counting chamber with a Neubauer ruling and cell numbers adjusted to 3-4,000,000/ml 
with the same medium. Cells were plated at 60-80,000 (~ 20pl) per 13mm poly-L-lysine 
coated coverslip placed inside Linbro 24 well plates (Flow Laboratories) and incubated at 
37°C/5% C 02 until cells attached (10-30min.). Cultures were fed with 600pl Bottenstein 
Sato 0.4% FCS and maintained at 37°C/5% C 02 for up to 48hr. All solutions were 
prewarmed to 37°C prior to use.
Spinal roots and ganglia
Spinal roots and ganglia dissected from the spinal cords were cultured as described above. 
Olfactory bulbs
Olfactory bulbs were dissected from PI mice into L I5 medium and the meninges removed. 
Cultures were performed as described above with the following exceptions. Collagenase 
solution was diluted 1:1 with L I5 and incubated for lhr and trypsin/EDTA treatment was 
omitted. Cultures were resuspended and fed with Dulbecco’s modified Eagle medium 
(DMEM)/10% FCS rather than SATO medium.
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2.6.2.Thymidine incorporation
In some studies, 3pCi H thymidine (Amersham) per 0.5ml. medium was added to 
embryonic day 12 (E l2) cultures for lhr. immediately after plating. Fresh medium was 
then added for survival times of 1, 24 or 48hr. after radiolabelling.
2.6.3.Solutions
1) Hanks’ balanced salt solution (HBSS):
2+ 2+Ca , Mg free solution (Sigma) to prevent enzyme inactivation.
2) Collagenase:
50mg/ml stock solution/~200 units/mg collagenase (Couper biomedical) in 
HBSS. 200pl aliquots stored at -20°C and diluted 1:3 with HBSS
3) Trypsin/EDTA:
0.1% trypsin (Flow laboratories) solution in HBSS, 0.04% EDTA (Flow 
laboratories) in HBSS. 0.5ml. aliquots stored at -20°C mixed 1:1 for use.
4) SD solution:
0.52mg/ml soybean trypsin inhibitor (SD) (Sigma)
0.04mg/ml bovine pancreas DNAse (Sigma)
3mg/ml factor V bovine serum albumin (Sigma)
Made up in L15/HBSS, 1ml. aliquots stored at -20°C.
5) Bottenstein Sato media:
lg/1 glucose
2mM glutamine (Sigma)
lOpg/ml insulin (bovine/27.3 U/mg) (Sigma)
100pg/ml transferrin (human) (Sigma)
0.0286% BSA-pathocyte (ICN)
0.2pM progesterone (Sigma)
O.lmM putrescine (Sigma)
0.45pM thyroxine (Sigma)
0.224pM selenite (Sigma)
0.5pM tri-iodo-thyronine (Sigma)
Made up in DMEM, 30ml aliquots stored at -20°C.
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Poly-L lysine coverslips
Coverslips were coated with poly-L-lysine to encourage cell adhesion (Mazia et al. 1975) 
and were prepared as follows:
1) Wash in 70% alcohol
2) Rinse in distilled water
3) Soak in 1M nitric acid overnight
4) Rinse in distilled water
5) Rinse in absolute alcohol
6) Separate individually and air dry on filter paper
7) Autoclave (20min. 151b/sq. in)
8) Immerse in poly-L-lysine (lOOpg/ml in SDW) (Sigma) for 30min.
9) Rinse in SDW x2
10) Air dry
Coverslips were stored at room temperature prior to poly-L-lysine treatment, or at -20°C 
after treatment. After autoclaving, all procedures were performed in a tissue culture hood.
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CHAPTER 3. RESULTS
3.1.SUBCLONING OF THE MOUSE pip SPECIFIC 
SEQUENCE 
3.1.1.Background
At the level of immunodetection or ISH performed on tissue sections or cells, only PLP 
protein or transcripts can be individually identified by the use of antibodies or probes 
directed against the exon 3B region of the protein or transcript. Since DM-20 differs from 
PLP only by the deletion of the 35 amino acids (105 base pairs) coded by exon 3B it is not 
possible to generate DM-20 specific antibodies or probes. The presence of DM-20 may be 
inferred by differential methods if a difference is seen using an antibody/probe recognising 
PLP and DM-20 or a PLP specific antibody/probe. This approach must be treated with 
some caution as other factors such as different avidity or affinity of antisera or differing 
availability of the target antigens could also affect differential staining during 
immunocytochemistry. Likewise during ISH there may be variation in activity and 
hybridisation kinetics of specific and non-specific probes.
Identification of dm-20 transcripts on northern blots has been performed using a probe that 
is complementary to the exon 3A/4 junctional region. Although both the exon 3A and 
exon 4 sequences are present in pip RNA, it is only in dm-20 RNA that they are 
contiguous. This method relies on using stringent hybridisation and washing conditions 
which will favour hybridisation to dm-20 transcripts (Ikenaka et al. 1988; LeVine et al 
1990). A similar strategy has been employed for immunostaining by generating antibodies 
to a variety of junctional peptides bridging the exon 3A/4 boundary. As yet this approach 
has proved unsuccessful in vivo (N. Groome, unpublished).
An anti-C-terminal antiserum raised against residues 271-276 reacting with both PLP and 
DM-20 and a PLP specific antiserum raised against amino acids 117-129 were available for 
use and have been described elsewhere (Fanarraga et al. 1993). A plasmid containing pip 
sequence for the generation of riboprobes hybridising to both pip and dm-20 transcripts 
(PLP-1) (Griffiths et al. 1989) was also available, however it was judged advantageous to 
produce a pip specific riboprobe vector for use in differential ISH studies as described 
above.
3.1.2.Experimental strategy
A 2.2kb Bam HI restriction fragment containing the complete coding sequence plus some 
5/ and 3/ untranslated region (UTR) was obtained from the low copy number, 
Okayama/Berg fragment plasmid pC4 (Nave et al. 1986). The fragment was gel isolated 
from a 1% standard agarose gel using a Qiaex extraction kit (see 2.2.1.Core techniques). 
The fragment was ligated into the high copy number vector pBluescript II (Stratagene) 
following Bam HI digestion and CIP treatment of the plasmid (see 2.2.1.Core techniques). 
Transformation of JM101 competent cells and plasmid mini/maxi-preps were performed as
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described in methods (see 2.2.1.Core techniques) and insertion confirmed by liberation of 
the fragment following Bam HI digestion. This plasmid was termed pBluescript-PLP.
A Sau 961/Bfa I, 81 bp fragment from exon 3B was isolated from pBluescript PLP and 
subcloned into pGEM 3z (Promega) according to the following strategy:
1) 40pg pBluescript-PLP was digested with Bfa I and a 413 bp Bfa I fragment containing 
the desired sequence was gel isolated from a 2% TBE Metaphor gel and Qiaex extraction 
kit (Figure 8).
2) 2.5pg Bfa I fragment was digested with Sau 961 to liberate the desired sequence, and 
with Hae II to digest a fragment of similar size to maximise resolution. (Figure 9). The 
sequence was isolated from a 5% TBE Metaphor gel as above.
The fragment was Klenow treated to produce flush ends and blunt ligated into the pGEM 
3z plasmid vector following Sma I digestion and CIP treatment of the plasmid (see
2.2.1.Core techniques). The plasmid was termed pPLP-3B. Transformation of competent 
JM101 cells and plasmid mini/maxi-preps were performed as described in 2.2.1.Core 
techniques, and presence of insert was confirmed by release of fragment and presence of an 
insert specific Bsr BI restriction site on diagnostic digests (Figure 10, Figure 11).
Fragment orientation was deduced from Eco RI/Hin dllVBsr BI, Eco R1/Bsr BI and Hin 
dill/Bsr BI restriction digests exploiting the asymmetric position of the Bsr BI site in the 
fragment (Figure 12, Figure 13). Both digests indicated -> 5f orientation. Generation of 
sense probes would therefore be possible using the SP6 promoter after linearising the 
plasmid with Eco RI and antisense probes using the T7 promoter following Xba I 
digestion.
Operational specificity of the pPLP-3B probe was confirmed by Southern blotting of PCR 
product generated from pip specific (pC4) and dm-20 specific (pCl 1) plasmids and from a
3215 day old wild type brain cDNA library (Figure 14). Generation of P random labelled 
probe using the “High Prime” DNA labelling kit (Boehringer Mannheim), blotting and 
hybridisation were as previously described (see 2.2.3.Southern blotting (pPLP-3B probe 
specificity confirmation)). The autoradiograph was exposed for 5 hours and additional 
film was overexposed for 24 hours to confirm absence of significant hybridisation to dm- 
20 RT-PCR product.
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1 2  3 4
(b)
Figure 8. a) Bfa I digest of pBluescript-PLP. Lane 1 100 bp calibration ladder; Lane 2 
pBluescript-PLPASyd I digest; Lane 3 pBluescript III Bfa I digest; Lane 4 123 bp calibration 
ladder. The 413 bp Bfa I fragment containing the insert is arrowed, b) Qiaex isolated Bfa I 
fragment (lanes 1 and 2), Lane 3 X Hin dill marker; Lanes 4-7 fragment quantification 
standards comprising pBluescript-PLP/Z?yh I digests of known amounts.
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pBluescript-PLP
Bfa
Bf a  I S S
V
SS Bfa
1 II II 1 1 1i si
Sau  961
1 1 1 /15 / 24 1 81 I 841 209 (fragment sizes)
| Hae II
V
38/46
Subclone into pGEM 3z
(a)
(b)
Figure 9. a) Schematic diagram of subcloning strategy for pip specific probe. S= Sau 961 
restriction sites, b) Sau 961/Hae II digestion of initial Bfa I fragment; Lane 1 Bfa I 
fragment; Lane 2 Sau 961/Hae II digest; Lane 3 X/Bst E li marker; Lane 4 100 bp calibration 
ladder. Final 81 bp fragment to be isolated is arrowed.
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srBI 2260
T7
Amp r
Smal
pPLP-3B
2824 bp B s r B I — |lac Z
—  B s r B I
SmalsrBI 218
on
SP6
srBI 459
Bsr BI restriction profile
pGEM 3z pPLP-3B (insert 5 -3 ) pPLP-3B (insert 3 -5 )
241/701/1801 144/241/638/1801 165/241/617/1801
Figure 10. pPLP-3B plasmid map showing Bsr BI restriction sites. Position of insert in 
the multiple cloning site (MCS) is shown as a shaded area. Diagnostic Bsr BI restriction 
profile is shown below. Differing fragment sizes are shown in bold.
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Figure 11. pPLP-3B/Rsr BI digest; Lane 1 undigested pPLP-3B, Lane 2 pPLP-3B/£co 
RI/Ps/ I digest showing liberated insert (arrow), Lane 3 pPLP-3B/Rsr BI digest, Lane 4 
pGEM 3zJBsr BI digest, Lane 5 undigested pGEM 3z, Lane 6 pGEM 3z/Eco RI digest, 
Lane 7 100 bp calibration ladder, Lane 8 AJBst Eli marker.
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Eco RI/Hin d i l l /Bsr BI restriction profile
pPLP-3B (insert 5 -3 ) pPLP-3B (insert 3-5 )
68/69/76/241/569/1801 48/76/89/241/569/1801
Eco RI/Bsr BI restriction profile
pPLP-3B (insert 5 -3 ) pPLP-3B (insert 3 -5 )
69/144/241/569/1801 48/165/241/569/1801
Hin d i l l /Bsr BI restriction profile
pPLP-3B (insert 5 -3 ) pPLP-3B (insert 3 -5)
68/76/241 /638/1801 76/89/241/617/1801
Figure 12. pPLP-3B plasmid map showing Bsr BI, Eco RI and Hin dill restriction sites. 
Diagnostic Bsr BI/Eco Rl/Hin dill restriction profiles to determine insert orientation are 
shown below. Differing fragment sizes are shown in bold.
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(b)
Figure 13. pPLP-3B insert orientation digests, a) Eco RI/Hin dill/Bsr BI digest; Lane 1 
undigested pPLP-3B, Lane 2 pPLP-3B/isco Rl/Hin dllVBsr BI digest, Lane 3 100 bp 
calibration ladder, Lane 4 pPLP-3B/Rsr BI digest, b) Eco R l/for BI and Hin dill/Bsr BI 
digests; Lane 1 undigested pPLP-3B, Lane 2 pPLP-3B Eco RI/Rsr BI digest, Lane 3 pPLP- 
3B Hin dlll/Rsr BI digest, Lane 4 100 bp calibration ladder.
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(a)
1 2 3
(b)
32Figure 14. pPLP-3B P Southern blot (5 hour exposure), a) Gel prior to blotting; Lane 1 
pC4 (pip) PCR product, Lane 2 p C ll (dm-20) PCR product, Lane 3 15 day mouse brain 
RT-PCR product, pip product (P), dm-20 product (D). b) Southern blot autoradiograph; 
PLP-3B labelled probe is hybridised with pC4 (pip) PCR product (P) and with the upper 
pip band of the 15 day brain RT-PCR product. No significant hybridisation to either pCl 1 
(dm-20) product (D), or the lower dm-20 band of the 15 day brain product is seen.
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3.2./Y/J GENE EXPRESSION STUDIES 
3.2.1 .Plp/dm-20 transcript ratio studies 
Introduction and aims
In general terms, the level of total pip transcripts defined by dot or northern blotting 
appears to parallel myelination within a particular region (Gardinier et a l 1986; LeVine et 
al 1990; Naismith et a l 1985; Sorg et a l 1987). It has also been shown using RT-PCR 
that dm-20 is the only isoform expressed in the embryonic rodent brain and that pip 
becomes the dominant transcript during post-natal life (Ikenaka et a l 1992; Timsit et a l 
1992a). All these studies however have used bulk tissue samples, at the best limiting tissue 
to gross areas such as the cerebrum or hindbrain. As discussed in the introduction the 
myelination state of specific tracts within these gross areas will be highly varied thus 
making it difficult to make comments in relation to myelination status other than in general 
terms. The change in plp/dm-20 transcript ratio is interesting, given the probable different 
roles of the two subsequent isoproteins, and in order to study the precise relationship 
between transcript ratio and state of myelination and gliogenesis, more discreet areas with 
a more uniform state of myelination should be chosen.
Initial studies were performed on bulk mouse spinal cord and brain samples to give an 
appreciation of times of onset of expression and general trends in transcript ratios. Specific 
areas of the CNS were then chosen which were known to have different times of onset of 
myelination. The ventral columns of the spinal cord is the first area of the CNS to 
myelinate beginning around birth (Bjartmar et a l 1994) and could further be divided into 
cervical, thoracic and lumbar regions since myelination proceeds temporally in a rostral to 
caudal direction in the spinal cord (Schwab and Schnell 1989; Tilney 1933). The optic 
nerve begins myelinating approximately 6-7 days later and this was chosen as an example 
of a later myelinating area. In an attempt to eliminate some of the heterogeneity in 
myelination present even within the optic nerve as a whole (Skoff et a l 1980), the study 
was limited to the mid third portion of the nerve. The main aim of the study was to 
determine whether changes in plp/dm-20 transcript ratios were associated with age of the 
animal or “age” of myelination. We hypothesised that changes in the ratio would be 
associated with myelination status and would therefore occur at different chronological 
times in areas with different times of onset of myelination. As well as demonstration of 
myelin sheaths by light microscopy and at the earliest time points by electron microscopy, 
other markers of myelination such as plp/dm-20 expression in oligodendrocytes on ISH, 
appearance of PLP/DM-20 protein as demonstrated by immunocytochemistry and changes 
in glial cell densities were also studied.
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PCR calibration
RT-PCR is an invaluable technique for the analysis of gene expression using 
mRNA/cDNA hybrids as template for PCR amplification. This is particularly useful when 
analysing low abundance mRNAs such as plp/dm-20 transcripts in the embryo, or when 
limiting amounts of material are available such as spinal cord ventral columns or mid third 
optic nerves.
Such a powerful technique is however not without its problems. The exponential nature of 
PCR amplification means that initially small artefacts may generate significant false 
positive results. Contamination of reactions with target DNA either in the form of 
previously amplified material, or positive control template is a significant operational 
problem. Contamination can be minimised by the use of dedicated laboratory equipment, 
filter pipette tips and ultraviolet irradiation of equipment and reagents (excluding primers 
and target). Set up and analysis of PCR reactions should be performed in separate, 
dedicated areas and all PCR runs should include negative controls consisting of all reagents 
minus target.
In addition to looking at plp/dm-20 transcript ratios, relative transcriptional activity over a 
series of ages was studied in whole spinal cord and mid third optic nerve. Conventional 
methods of studying spatio-temporal expression of genes such as northern blotting and 
transcript mapping have the disadvantage of requiring relatively large amounts of mRNA 
as starting material. Semi-quantitative RT-PCR allows for the indirect analysis of much 
smaller amounts of mRNA and is therefore particularly useful when looking at expression 
of genes such as pip, when mRNA is present in low abundance. Semi-quantitative RT- 
PCR as a means of measuring transcriptional activity has its disadvantages; it is an indirect 
measurement of transcriptional activity (through the intermediate step of an mRNA/cDNA 
hybrid), unlike northern blotting or transcript mapping; secondly, the possibility of 
generating false positive results is higher as is the possibility of underestimating 
transcriptional activity due to exhaustion of the system or the plateau effect. Reactions will 
plateau when amplification is no longer exponential. This will occur relatively sooner for 
samples with higher target concentrations leading to an underestimation of transcript 
levels. The same problem may occur within a sample when looking at the relative ratio of 
two isoforms such as pip and dm-20 and is most likely to be a problem where 
transcriptional activity is very high. As with direct methods of measuring transcriptional 
activity, it is necessary to ensure processing of equivalent amounts of the tissues being 
compared during RT-PCR analysis. This is achieved by the amplification of an internal 
control target in parallel with the target being studied. Ideally this control target will be 
derived from a constitutively expressed gene such as cyclophilin.
Semi-quantitative RT-PCR was considered to be the only practical way of studying 
plp/dm-20 transcript ratios and activity during embryonic and early post natal life due to 
the low abundance of transcripts. The limitations of the system as described above mean
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that data generated should be interpreted in terms of general trends as opposed to finite 
values.
Transcript ratio
Before analysing data it was essential to confirm that under the specific range of PCR 
conditions to be employed, the ratio of plp/dm-20 RT-PCR product was a true reflection of 
the initial plp/dm-20 transcript ratio. Several factors could potentially lead to anomalous 
results; differences in efficiency of primer annealing, presence of exonuclease activity, 
susceptibility to template reannealing and time to reach plateau (the time at which 
amplification is no longer exponential) could all potentially result in altered product ratios. 
Two plasmids, pC4 and pCl 1 containing pip and dm-20 specific cDNAs respectively, were 
quantified spectrophotometrically and linearised with Sal I. The relative concentrations 
were further confirmed by standard agarose gel analysis (Figure 15). Varying ratios of the 
linearised plasmids (4:1,1:1,1:4) were used as target in PCR reactions between 10 and 40 
cycles. Product ratio was analysed using standard agarose gels (Figure 16). A 4:1 target 
ratio was also used with variation in magnesium concentration (1.5mM-4.5mM) at a 
constant 25 cycles to check for product ratio variation with magnesium concentration 
(Figure 15).
The following conclusions were drawn:
Under the standard PCR conditions used (see 2.2.2.Analysis of transcripts):
1) Fidelity of plp/dm-20 product ratio to plp/dm-20 plasmid input ratio appeared to be high 
even up to 40 cycles, although slight drift with apparent favouring of dm-20 product was 
occasionally seen at the highest cycle numbers.
2) Fidelity of plp/dm-20 product ratio to plp/dm-20 plasmid input ratio appeared to be high 
with variations in magnesium concentration at cycle numbers less than 40.
It was therefore decided to employ a cycle number of less than 40, and that when high 
cycle numbers were used (for sensitivity purposes), the ratios would be confirmed at lower 
cycle numbers.
RT-PCR product
Recent investigations have demonstrated the likelihood of a DM-20-like family of proteins 
(Kitagawa et al. 1993; Yan et al. 1993). It was therefore considered necessary to ensure 
that the PCR product generated was from genuine plp/dm-20 transcripts. Evidence to 
support this was threefold:
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1) Products generated were of the correct size (plp-506/dm-20-40l) as predicted from pip 
sequence data (Figure 7).
2) Computer-assisted analysis of primers and known mouse dm-20-like sequences 
(M6a/M6b) demonstrated insufficient sequence identity for the generation of stable hybrids 
at the PCR annealing temperatures used. Even excepting this fact, products generated 
would not have been of a similar length to those predicted for plp/dm-20.
3) Pip and dm-20 RT-PCR products were gel isolated and diagnostic digests performed 
using 6 restriction enzymes known to have one or more recognition sequences within the 
predicted fragment. Despite the presence of partial digestion with 3 of the 12 enzymes, all 
restriction profiles were in agreement with those from predicted sequence data. (Figure 
17, Figure 18).
The presence of high molecular weight RT-PCR bands when using pip primers has been 
reported (Ikenaka et al. 1992; Timsit et a l 1992a) and was also noted in the present studies 
(e.g. Figure 22). Whether these products represent RT-PCR artefacts or novel transcripts is 
yet to be resolved, however their presence was noted when pC4 plasmid was used as 
template which would suggest that RT-PCR artefact is the more likely explanation.
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(b)
Figure 15. PCR calibration of input/output plp/dm-20 ratio, a) Quantification of plasmid 
target: Upper bands; Lanes 1-3 and 5-6 pCll/Stf/ I 12.25ng, 18.75ng, 25ng, 31.25ng, 
37.5ng; Lane 4 pC4/Sal I 25ng. Lower bands; Lanes 1-3 and 5-6 pCl MSal I 50ng, 75ng, 
lOOng, 125ng, 150ng; Lane 4 pC4/Sal I lOOng. b) Magnesium assay confirming fidelity of 
plp/dm-20 product ratio; Lanes 1-3 pC4/pCll target ratio 4:1, Mg concentrations 1.5mM, 
3.0mM, 4.5mM. Pip product (P), dm-20 product (D).
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(a)
H
(b)
(c)
Figure 16. PCR calibration of input/output plp/dm-20 ratio (cont.). Pip and dm-20 PCR 
product from 10, 15, 20, 25, 30 and 40 cycle reactions, a) 10 and 15 cycles, b) 20 and 25 
cycles, c) 30 and 40 cycles. Lanes 1-3 4:1, 1:1, 1:4 pC4/pCll target ratios; Lane 4 123 bp 
calibration ladder; Lanes 5-7 4:1, 1:1, 1:4 pC4/pCll target ratios. Fidelity of input to 
output ratios is maintained over the cycle range. Pip product (P), dm-20 product (D).
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w
1 2 3 4 5 6 7 8 9 1011 12 13
Predicted plp/dm-20 RT-PCR product restriction profdes
Restriction enzyme pip dm-20
BglU 181/324 181/220
Dde I 74/148/283 74/148/179
Hhal 16/57/171/261 16/57/156/171
Figure 17. Restriction analysis of plp/dm-20 RT-PCR products. Lanes 1,9 undigested pip 
product, Lanes 5,13 undigested dm-20 product, Lanes 3,7,11 lOObp DNA calibration 
ladder, Lane 2 plp/Bgl II digest, Lane 4 dm-20/Bgl II digest Lane 6 plp/Dde I digest, Lane 
8 dm-20/Dde I digest, Lane 10 plp/Hha I digest, Lane 12 dm-20/Hha I digest. Predicted 
restriction profiles are shown below.
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1 2 3 4 5 %7 8 9 1011 12 13
I !
Predicted plp/dm-20 RT-PCR product restriction profdes
Restriction enzyme pip dm-20
Sau 961 1/24/78/84/133/185 1/78/84/105/133
Bsr BI 212/293 401 (undigested)
Bfa I 51/133/321 51/350
Figure 18. Restriction analysis of plp/dm-20 RT-PCR products (cont.). Lanes 1,9 
undigested pip product, Lanes 5,13 undigested dm-20 product, Lanes 3,7,11 lOObp DNA 
calibration ladder. Lane 2 plp/San 961 digest, Lane 4 dm-20/Sau 961 digest Lane 6 pip/Bsr 
BI digest, Lane 8 dm-20/Bsr BI digest, Lane 10 pip/Bfa I digest, Lane 12 dm-20/Bfa I 
digest. Predicted restriction profiles are shown below.
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Materials and methods
Studies were performed on C3H/HeH x 101H mice at the following ages; embryonic day 
12 (E12), 14, 16, 18, and post-natal day 1 (PI), 5, 10, 15, 20 and 25. Intermediate ages 
were studied if considered necessary. The stage of embryonic development was timed 
from the appearance of cervical plugs after timed matings and also from crown/rump 
measurements in older embryos and somite counts of younger embryos. Mice were time 
mated for 3 hours each morning and animals with plugs were recorded as E0. Post-natal 
animals were recorded as post-natal day 1 (PI) on the day of birth.
Bulk brain and spinal cord samples for RT-PCR analysis (E12-P20) were dissected free of 
meninges, nerve roots and ganglia and processed as described in methods (see
2.2.2.Analysis of transcripts). To allow more accurate dissection, spinal cord ventral 
columns (E18-P20) were collected from 2 thin slices of Camoy’s-fixed material taken from 
proximal cervical intumescence, mid thoracic cord and proximal lumbar intumescence. 
Mid third optic nerve (P1-P20) was collected from both fresh and Camoy’s-fixed material. 
All samples collected from fixed tissue were subsequently processed as for fresh material. 
Semi-quantitative analysis of transcripts was performed on whole spinal cord and fresh mid 
third optic nerve using cyclophilin primers as an internal control. Densitometric analysis 
of the ethidium bromide stained signals was determined from Polaroid negative images 
using a Chromoscan 3 densitometer (Joyce Lobel). Pip and dm-20 values were corrected 
for variation in gel loading. Standardised incremental aliquots of one cyclophilin RT-PCR 
product were assayed against test samples to determine if readings were within the linear 
range of the densitometer.
35ISH studies were performed on paraffin sections of post-natal mice with S and 
digoxigenin-labelled riboprobes recognising pip and dm-20 transcripts (PLP-1) (see 2.3.IN 
SITU HYBRIDISATION). Some sections were counterstained with haematoxylin, and 35S 
sections were viewed in both bright and darkfield illumination. Glial cell quantification 
was performed as described in methods on 1pm resin embedded sections (see 2.5.1.Glial 
cell quantification). The peroxidase anti-peroxidase method was used to demonstrate 
PLP/DM-20 protein (C-terminal antiserum) and MBP in post-natal mice on 1pm resin 
embedded sections (see2.4.IMMUNOCYTOCHEMISTRY).
Results
RT-PCR
1) Bulk brain/spinal cord:
Both pip  and dm-20 product were detected at all ages studied from E12-P20 in the spinal 
cord and E13-P20 in the brain using 39 cycles (Figure 19). In both brain and spinal cord 
three distinct phases could be identified in terms of plp/dm-20 product ratio, however the
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temporal progression varied between the two samples. In the spinal cord, dm-20 was the 
predominant product from E l2 to El 8 with a shift to an approximate equimolar 
relationship between E l8 and PI. From PI onward pip was the predominant isoform. In 
the brain equimolar amounts of product were not present until P5 with pip  becoming 
predominant from P10 onward.
Semi-quantitative analysis of spinal cord product demonstrated marked up-regulation of 
the pip  gene around PI at about the same time that pip was becoming the predominant 
transcript (Figure 20). Both pip and dm-20 transcripts appear to be up-regulated with pip 
transcript levels increasing to a much greater degree. Plp/dm-20 product ratio as assessed 
by densitometric analysis increased from approximately 0.5 at E l2 to 3.5 at P20 (Figure 
20).
2) Spinal cord ventral columns:
Product ratios for Camoy’s-fixed spinal cord ventral columns generally paralleled those 
seen in the bulk spinal cord samples. At E l8 dm-20 was the predominant product but from 
PI onward, pip predominated (Figure 21). No obvious difference could be seen in plp/dm- 
20 ratios between cervical, thoracic and lumbar areas at the same age (Figure 21).
3a) Mid third optic nerves:
Analysis of mid third optic nerves was performed on two sample types; Camoy’s-fixed 
material, to allow direct comparison with the ventral spinal columns, and unfixed material. 
Quality of RNA extracted from unfixed tissue was considerably better than that from fixed 
tissue as assessed by standard agarose gel analysis. Since the small amounts of transcript 
available precluded spectrophotometric analysis, this better quality allowed more accurate 
gel quantification and subsequent semi-quantitative RT-PCR analysis. Analysis of unfixed 
tissue also served to check for the possibility of alterations in transcript ratio due to 
Camoy’s fixation.
The profile of plp/dm-20 product ratios was the same for both fixed and non-fixed samples 
and varied in several respects from that seen in the spinal cord at the same age (Figure 22): 
RT-PCR products were demonstrated at all ages studied, however the change from dm-20 
to pip predominance occurred between P5 and P7, approximately 6-7 days later than the 
spinal cord. Marked up-regulation of the gene was seen at the same time as the change in 
product ratio (Figure 23). At ages where dm-20 predominated (PI and P5) levels of pip 
product were very low (undetectable for fresh samples) even when compared to E12 spinal 
cord samples. Consequently, the change from dm-20 to pip dominance was more abrupt in 
the mid third optic nerve than in the spinal cord (Figure 22). Plp/dm-20 product ratio as 
assessed by densitometric analysis increased from 0 (totally dm-20) at PI to 2.5 at P I5 
(Figure 23).
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3b) Whole optic nerves:
RT-PCR analysis of whole optic nerves from a separate study revealed a difference in 
plp/dm-20 ratio compared to mid third optic nerve samples at PI and P5. Although dm-20 
was still the major isoform present, the level of pip product was considerably greater than 
for mid optic nerves and was approaching equivalence (Figure 24).
Immunocytochemistry
Results of immunostaining with PLP-CT or MBP antibodies were essentially identical for 
all areas studied in the postnatal mouse at PI, 5, 10, 15, and 20, with both antibodies 
staining the myelin sheaths.
a) spinal cords:
At PI (Figure 25, Figure 26) at the level of the proximal cervical intumescence, a few 
myelin sheaths were present and immunostained for PLP/DM-20 and MBP in the ventral 
columns and cuneate tract of the dorsal column. An occasional sheath was also seen in the 
lateral column. No immunostained sheaths were present in the gracile or corticospinal 
tracts of the dorsal column. At the level of the mid thoracic cord, a few sheaths stained in 
the ventral and lateral columns, but staining of sheaths was absent from the dorsal columns. 
At the level of the proximal lumbar intumescence the few positive staining sheaths were 
restricted to the ventral columns.
Increasing numbers of PLP positive sheaths were seen at older ages (Figure 27). By P5, 
numerous positive staining sheaths were present at all cord levels. Cervical and thoracic 
cords were very similar, still with fewer positive sheaths in the gracile and corticospinal 
tracts. There were generally fewer positive sheaths in all areas of the lumbar cord. By P10, 
similar staining is seen in cervical, thoracic and lumbar areas. Gracile and corticospinal 
tracts are still less intensely stained. The distribution of positive staining sheaths is fairly 
homogenous throughout all the white matter tracts at all cord levels by P20.
b) Mid optic nerves:
No positive staining sheaths were present at PI or P5 (Figure 28). At P10 numerous 
sheaths immunostaining for both PLP/DM-20 and MBP were present and the number of 
these increased at P I5 and P20 (Figure 28).
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ISH
a) spinal cords:
At PI, numerous strongly positive cells were present predominantly in the ventral and 
ventro-lateral white matter with occasional cells present in the dorsal columns (Figure 30). 
The number of positive cells and signal intensity per cell decreased slightly passing in a 
rostral to caudal direction. This gradient was still visible at P5 (Figure 29), although there 
was now considerably more signal, especially in the dorsal columns, and occasional 
expressing cells were present in the grey matter. From P10 to P20 both number of cells 
and strength of expression increased with little difference between cord levels by P10. By 
P20 numerous positive cells were present in the grey matter, however the majority of 
plp/dm-20 positive cells were found in the white matter tracts (Figure 30).
b) Mid optic nerves:
No positive cells were detected in either PI or P5 mid optic nerves. By P10 numerous 
positive cells were present (Figure 31), and numbers of positive cells and intensity of 
signal increased up to P20 (Figure 31). On longitudinal optic nerve sections one or two 
positive cells were present in the optic chiasm by P2 (Figure 32). By P5 several positive 
cells were present along the length of the nerve, but were concentrated towards the 
chiasmal end (Figure 32) and by P7 numerous positive cells were fairly evenly distributed 
along the nerve, apart from the optic nerve head which was always devoid of positive cells 
(Figure 32).
Glial cell counts
Three data points were collected for each area measured. Whilst this may limit statistical 
analysis of results, general trends in glial cell density with age or area may be commented 
upon.
The developmental profiles of glial cell densities at cervical, thoracic and lumbar levels of 
the spinal cord were essentially very similar. Values were at a maximum at PI or P5 with 
the general trend of decreasing values from PI onwards. No obvious peak in glial cell 
density was apparent after PI (Figure 33, Figure 34, Figure 35). Although variation in 
glial cell densities of mid optic nerves was relatively large, especially at the earlier time 
points, the trend appears different from that seen in the spinal cord. A peak in cell density 
is seen at P5 with values decreasing at later time points (Figure 34, Figure 35).
When comparing glial cell densities at different levels of the spinal cord at the same age, 
no obvious rostro-caudal trend in values was apparent. (Figure 36, Figure 37, Figure 38).
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Discussion
The predominance of the dm-20 isoform of the pip gene during embryogenesis, which was 
apparent in the RT-PCR data for bulk spinal cords, brains and spinal cord ventral columns 
in this study, is in good agreement with the previously published data (Ikenaka et al. 1992; 
Timsit et al. 1992a). The presence of pip product in the present study, although it was 
always present as the minor isoform during embryogenesis, is at variance with these 
reports, in which the selective expression of dm-20 alone is particularly noted. This 
difference could be due to one of three reasons; the product generated in the present study 
is due to RT-PCR contamination; the product is not authentic pip product, or the sensitivity 
of the present study is greater than previous studies thus revealing levels of pip  product 
previously below the level of detection. Steps taken to eliminate RT-PCR contamination 
have been described above, and all negative control reactions, in the absence of target 
generated no PCR product. Generation of the predicted product lengths and 
comprehensive restriction enzyme analysis of the RT-PCR products, as described in the 
results above, show that both the pip and dm-20 products are generated from authentic 
plp/dm-20 transcripts. Ikenaka’s study (1992) utilised a PCR amplification of 45 cycles
32followed by Southern blotting and probing with P labelled oligonucleotide probes. One 
would expect this approach to be more sensitive than the 39 cycle RT-PCR employed in 
the present study, however pip product was detected only at P2 in brain after prolonged 
exposure and not at all in post-natal sciatic nerve. Using the current protocol pip  product is 
easily demonstrable in these two tissues after a RT-PCR of only 30 cycles, and pip  product 
has been demonstrated by RT-PCR in previous studies of post-natal sciatic nerve (Pham- 
Dinh et al. 1991). Additionally, PLP specific protein has been demonstrated in post-natal 
sciatic nerve by several groups (Agrawal and Agrawal 1991; Griffiths et al. 1995a; Tetzloff 
and Bizzozero 1993), from which one can infer that the transcript must also be present. It 
therefore seems likely that if the protocol employed by Ikenaka is unable to detect pip 
transcripts in post-natal sciatic nerve it will also be unable to detect it in embryonic brain, 
when the amounts present are considerably lower. The protocol of Timsit et. al. (1992) 
used a standard 33 cycle RT-PCR reaction and also failed to demonstrate pip  product in 
embryonic brain. Sensitivity and efficiency of RT-PCR reactions may vary considerably 
depending on numerous variables such as target concentration and quality, magnesium 
concentration, cycle profile and design of primers. Both of the previous studies utilised 
primers in exons 1 and 7 which generated pip product of over 800bp. The present study 
used primers in exons 2 and 4 generating a much smaller product of around 500bp. As well 
as the possibility of decreased overall sensitivity, it must also be noted that neither of the 
previous studies demonstrated the fidelity of plp/dm-20 input to output ratios with their 
particular RT-PCR protocols, as has been described for the current protocol. It is possible 
that the particular RT-PCR conditions used favoured amplification of the dm-20 product, 
thus selectively decreasing sensitivity of detection of the pip transcripts. The
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demonstration of ^ -sp ec ific  transcripts and PLP-specific protein in embryonic spinal cord 
sections by ISH and immunostaining during the present study, is further evidence of the 
authenticity of this pip specific RT-PCR product (see 3.2.2.Embryonic expression studies).
Plp/dm-20 product ratios for spinal cord ventral columns were similar to those seen in bulk 
spinal cords down to the earliest age studied, El 8, at which time a moderate predominance 
of dm-20 was seen. The use of Camoy’s fixed tissue does not appear to have affected the 
RT-PCR efficiency adversely even though the quality of RNA extracted from the fixed 
tissue was poorer than that from fresh tissue; standard agarose gel analysis revealed 
degradation of RNA from fixed tissue, evident as smearing and loss of the 28S and 18S 
ribosomal RNA bands. Due to the relatively small size of the product being generated 
during the RT-PCR reaction, moderate degradation of the target RNA is not a major 
problem. When looking at plp/dm-20 ratios, the assumption is made that any degradation 
and resultant decrease in product will affect pip and dm-20 transcripts equally. This 
assumption appears to be validated by the similar plp/dm-20 ratios obtained when using 
Camoy’s-fixed and fresh tissue from mid-third optic nerves.
It was evident from both the immunostaining and ISH studies that the ventral columns of 
the spinal cord were the first areas to acquire myelin sheaths and exhibit positive plp/dm-20 
ISH signal. This is in good agreement with previous studies (see 
1.6.MYELINOGENESIS). No difference however was seen in Has plp/dm-20 ratios when 
comparing whole spinal cord and ventral column RT-PCR products. Likewise the well 
documented rostral to caudal gradient of myelination (see 1.6.MYELINOGENESIS) which 
was demonstrated at PI and even at P5 quite clearly by the ISH and immunostaining, was 
not reflected in a similar gradient of ventral column plp/dm-20 ratios at these levels. If the 
initial hypothesis that changes in plp/dm-20 ratios should mirror changes in myelination 
status, one would have expected to see a greater pip predominance in the ventral column 
samples relative to the whole cord and in the cervical ventral column samples relative to 
thoracic or lumbar, since these areas are relatively more advanced in terms of myelination. 
Either the hypothesis is incorrect or the difference in myelination between the comparative 
areas is not great enough to demonstrate a significant difference in plp/dm-20 ratios. 
Although myelination in the cord is highly heterogeneous, gross differences between 
cervical and lumbar cord or between general areas at the same level appear to resolve over 
a period of approximately 1 to 2 days, and certainly less than 5 days. To distinguish 
between these two possibilities it is necessary to compare areas with a much greater 
difference in time of onset of myelination, such as the ventral columns and the mid third 
optic nerve where a difference of at least 6 days is seen.
As stated above, similar results were obtained with Camoy’s-fixed and fresh mid third 
optic nerves. Dominance of dm-20 product, almost to the exclusion of pip, was seen post- 
natally up to P5, with a change to pip  predominance at the next time point studied (P10 for 
Camoy’s-fixed and P7 for fresh tissue). This change over in ratio correlates well with the
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appearance of PLP/DM-20+ sheaths on immunostaining and plp/dm-20 ISH signal on mid­
optic nerve transverse sections, both being found only at P10, the next time point studied 
after P5. It therefore seems apparent that change in plp/dm-20 ratio from dm-20 to pip  
predominance is correlated with the appearance of myelin sheaths in a particular 
myelinating area. Correlation of plp/dm-20 ratio changes with appearance of positive ISH 
signal is not as obvious. Even though a significant increase in plp/dm-20-positive cells is 
seen in the spinal cord at PI as myelin sheaths are appearing, positive cells are present well 
before this time. Expression of the pip gene in these cells (see 3.2.2.Embryonic expression 
studies), may well not be directly related to myelin sheath formation itself. Although no 
ISH signal was seen on P5 transverse mid optic nerve sections, signal was present in 
several cells on P5 longitudinal nerve sections. These positive cells probably represent 
immature oligodendrocytes similar to those found in the embryonic cord, rather than 
actively myelinating cells since myelin sheaths have not been demonstrated at this age. 
Analysis of increased numbers of mid optic nerve sections would probably have revealed 
occasional ISH-positive cells. Product ratio in whole optic nerve samples at PI and P5 
were still dm-20 predominant, however there was considerably more pip product. This 
may well reflect the heterogeneous nature of myelination described in the optic nerve 
suggesting more advanced myelination in either the proximal or distal-third of the nerve, or 
both. Analysis of product ratio in all three portions of the nerve would allow clarification 
of this point. A more heterogeneous population of myelinating cells in the whole optic 
nerve compared to the mid third optic nerve would also explain the more gradual change 
from dm-20 to pip predominance seen in these samples, similar to that seen in the spinal 
cord. Colello et al. (1995) describe a gradient of pip expressing cells from the chiasmal to 
retinal end of the rat optic nerve between P2 and P7 which is similar to that seen in the 
present work. The gradient of myelination at P7, however, was in the opposite direction. 
The gradient of pip expression would correlate well with the more gradual change in 
plp/dm-20 ratio seen in the whole optic nerves, and it would be interesting to see if a 
gradient of pip dominance also existed similar to that seen for myelination in the study of 
Colello etal.{1995).
Increases in glial cell density have been shown to occur in the CNS just prior to the onset 
of myelination in a specific area (Bensted et a l 1957; Matthews and Duncan 1971; 
Samorajski and Friede 1968; Schonbach et al. 1968), although the exact profile seems to 
vary from area to area (Matthews and Duncan 1971; Schonbach et al. 1968). The profile 
and glial cell densities seen in the spinal cord are in good agreement with previous work 
(Fanarraga 1993; Matthews and Duncan 1971). The presumed peak in glial cell density is 
likely to occur prior to or around birth in the ventral columns as myelination has already 
begun at P I . The later peak in cell density seen in the optic nerve is also in agreement with 
previous studies (Vaughn 1969), and seems to be correlated with the later appearance of 
myelin and the later change in plp/dm-20 product ratio in this area. The similarity seen
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between glial cell density at different cord levels at the same age is also reflected in the 
plp/dm-20 product ratios. It seems that changes in glial cell density and plp/dm-20 
transcript ratios are less precise temporal markers than the appearance of stainable myelin 
sheaths since it is only with the latter that a rostral to caudal gradient is seen.
The third parameter which appears to be correlated with appearance of myelin and change 
in transcript ratio at around PI in the spinal cord and P7 in the optic nerve is a marked up- 
regulation of the pip gene. The up-regulation seen in the spinal cord is in good agreement 
with the appearance of plp/dm-20 signal on northern blots of mouse brain RNA at P2-P3 
found in two previous studies (Gardinier et a l 1986; Sorg et al. 1987). The lack of signal 
earlier than P2 on northern analysis is presumably due to a combination of the slightly later 
myelination of the brain as a whole, relative to the spinal cord, and the lower sensitivity of 
this technique compared to RT-PCR. A study using rat cerebra or hindbrain, demonstrated 
northern signal increasing from PO in the hindbrain and P4 in the cerebra (LeVine et al 
1990). The hindbrain myelinates earlier than the cerebra in accordance with the general 
caudal to rostral gradient in the brain and is similar in time of onset to the spinal cord. 
Approximately ten-fold increases in total transcripts were seen in spinal cords between El 8 
and P20 and in mid optic nerves between P5 and P I5. It must be emphasised again 
however that the semi-quantitative RT-PCR data is not being presented to define absolute 
values of up-regulation or total transcription rates, but more as an indication of time points 
where marked changes in both plp/dm-20 product ratio and pip gene expression are seen. 
Absolute values of transcripts as discussed previously are probably higher than is apparent 
and more stringent controls would be necessary before statements could be made regarding 
any such figures. Such stringent controls were not considered necessary in the present 
context.
Analysis of plp/dm-20 RT-PCR product ratios for whole brain samples also reveals a more 
gradual, and later appearance of pip predominance compared to whole spinal cord. The 
later onset of pip predominance would be expected, given the later myelination of the brain 
relative to the spinal cord (Langworthy 1928; Langworthy 1933; Windle et a l 1934; 
Zgorzalewicz et a l 1974). It has been demonstrated that trigeminal ganglia express dm-20 
very strongly in the embryonic and post-natal mouse, as is the case with spinal ganglia 
(Timsit et a l 1992a; Timsit et a l 1995). However, it is not possible to remove this source 
of dm-20 transcripts from bulk brain samples as it is for spinal ganglia from spinal cord 
samples, and this may help to maintain dm-20 dominance in bulk brain samples. Dm-20 
transcripts from cranial ganglia plus the greater heterogeneity present in the myelinating 
brain would also account for the more gradual transition to pip predominance seen in the 
bulk brain samples.
In summary, the change in plp/dm-20 transcript ratio from dm-20 to pip  predominance 
during development of the mouse CNS appears to be correlated with the onset of
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myelination and not with chronological age of the developing CNS as a whole. Onset of 
myelination was assessed by appearance of myelin sheaths and associated changes in glial 
cell densities, and expression of the pip gene. The change in transcript ratio is 
accompanied by a marked up-regulation of the pip gene with an increase in both pip  and 
dm-20 transcripts. The precise mechanisms controlling this up-regulation and change in 
transcript ratio are poorly understood and will be discussed more fully in the final 
discussion.
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Figure 19. RT-PCR product from whole mouse spinal cord and brain, a) spinal cord; pip 
product (p) and dm-20 product (d) are seen at all ages from E12-P20. Cyclophilin product
(c) used as an internal control is shown below. The change in predominance from dm-20 
during embryogenesis to pip in post-natal life is illustrated, b) brain; predominance of pip 
lags temporally behind the spinal cord and is not seen until after P5
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Mouse spinal cord: semi-quantitative RT-PCR
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Figure 20. Spinal cord semi-quantitative RT-PCR analysis, a) Densitometric analysis of 
RT-PCR products illustrates marked up-regulation of the pip gene coinciding with the 
change to pip predominance around P I . b) Increasing pip predominance in post-natal life is 
seen as plp/dm-20 product ratios greater than l rising to 3.5 by P20. Gestation length is 
approximately 20 days in the strain of mice studied and approximate time of birth is marked 
on the graphs (*).
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Figure 21. RT-PCR product from spinal cord ventral columns, a) cervical; b) thoracic; c) 
lumbar. No significant differences can be seen between samples of the same age at 
different spinal cord levels. Pip product (P), dm-20 product (D).
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Figure 22. RT-PCR products from mid third optic nerves, a) Fresh tissue; dm-20 product 
(d) predominates until P7 when pip (p) is the major isoform present. Cyclophilin product
(c), used as an internal control is shown below, b) Carnoy’s fixed tissue; developmental 
profile is the same as for fresh tissue. Pip product is almost totally absent before P7 at 
times when dm-20 predominates. A larger product which is probably a PCR artefact is 
present at the older ages (arrow).
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Mouse mid-optic nerve: semi-quantitative RT-PCR
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Figure 23. Mid third optic nerve semi-quantitative RT-PCR analysis, a) Densitometric 
analysis of RT-PCR product illustrates marked up-regulation of the pip gene coinciding 
with a change to pip predominance around P7. b) Plp/dm-20 ratios greater than 1 are seen 
later in the mid third optic nerve (P7) than in the spinal cord (PI).
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Figure 24. Whole optic nerve RT-PCR product. Levels of pip product (P) are 
considerably higher at PI and P5 in whole optic nerves compared to mid third optic nerves. 
Cyclophilin product (C) used as an internal control is shown for PI (whole ON), P5 (whole 
ON) and PIO (mid third ON).
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(b) (c)
Figure 25. PLP/DM-20 immunostaining of PI spinal cords (ventral columns), a) Cervical 
cord, b) thoracic cord, c) lumbar cord. At this early stage of myelination the rostral to 
caudal gradient (cervical to lumbar) of myelination is apparent with many more PLP 
staining sheaths (arrows) in the cervical cord compared to the lumbar cord. The ventral 
columns are the first area of the spinal cord to acquire myelin sheaths.
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Figure 26. PLP/DM-20 immunostaining of PI spinal cords (dorsal columns), a) Cervical 
cord, b) thoracic cord, c) lumbar cord. PLP positive staining sheaths are present only in 
the cervical cord and only in the cuneate tract (c). The later myelinating gracile tract (g) 
and corticospinal tract (ct) have yet to acquire myelin at any level. The rostral to caudal 
gradient is again evident, as is the earlier myelination of different tracts at the same age and 
spinal cord level.
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Figure 27. PLP/DM-20 immunostaining of P5, P10 and P20 cervical spinal cords (dorsal 
columns), a) P5, b) P10, c) P20. (cuneate tract=c, gracile tract=g, corticospinal tract=ct). 
Increasing numbers of PLP positive sheaths are seen at older ages and the rostral to caudal 
gradient is no longer obvious. However, the later myelination of the gracile and 
corticospinal tracts is still evident. By P20 the degree of myelination is more homogenous 
in all tracts.
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Figure 28. PLP/DM-20 immunostaining of P5, P10 and P20 mid optic nerves. ( a) P5, b) 
P10, c) P20. Positive staining sheaths are found in increasing numbers from P10 onwards.
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35Figure 29. Post-natal mouse spinal cords; plp/dm-20 ISH ( S-PLP-1). a) P5 cervical, b) 
P5 thoracic cord, c) P5 lumbar cord. The rostral to caudal gradient of myelination in the 
spinal cord can still be seen at P5 with fewer positive cells present in lumbar cord sections 
relative to cervical cord.
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Figure 30. Post-natal mouse spinal cords;plp/dm-20 ISH (PLP-1). a) PI cervical cord, b)
35P10 cervical cord, c) P20 cervical cord. S labelled riboprobes are shown except on the 
P20 section where a digoxigenin labelled riboprobe has been used. From PI to P20, 
plp/dm-20 expressing cells are found with increasing frequency throughout the white 
matter. By P20 numerous positive cells are also found within the grey matter.
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Figure 31. Post-natal mouse mid optic nerve; plp/dm-20 ISH (PLP-1). a) P5 mid optic
35nerve, b) P10 mid optic nerve, c) P20 mid optic nerve. S PLP-1 riboprobes are shown 
except on the P20 section where a digoxigenin PLP-1 riboprobe has been used. Plp/dm-20 
expressing cells are absent from P5 sections, but are present by P10 and increase in number 
between P10 and P20.
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35Figure 32. Post-natal mouse longitudinal optic nerve plp/dm-20 ISH ( S-PLP-l). a) P2 
optic nerve, b) P5 optic nerve, c) P7 optic nerve. Plp/dm-20 expressing cells are first 
apparent in the optic chiasm (ch) of the P2 nerve. By P5 positive cells are found 
sporadically along the whole nerve and by P7, numerous strongly expressing cells are 
present. The absence of positive cells from the optic nerve head at the retinal end of the 
optic nerve (r) is illustrated.
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Figure 33. Glial cell density, cervical and thoracic cord ventral columns, a) cervical cord,
b) thoracic cord. All data points are plotted on the left hand graphs and mean values on the
right.
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Figure 34. Glial cell density, lumbar cord ventral columns and mid optic nerve, a) lumbar
cord, b) mid optic nerve. All data points are plotted on the left hand graphs and mean
values on the right.
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Figure 35. Glial cell density, spinal cord all levels and mid optic nerve. Glial cell density at 
all levels of the spinal cord exhibits a decreasing trend from PI onwards. Mid optic nerve 
glial cell density appears to peak around P5 with a decreasing trend from P5 onwards. This 
later peak of glial cell density is consistent with the later onset of myelination and up- 
regulation of the pip gene seen in the optic nerve compared to the spinal cord.
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Figure 36. Glial cell densities, spinal cord rostral to caudal gradient, a) PI, b) P5, c) P10.
All data points are plotted on the left-hand graphs and mean values on the right.
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Figure 37. Glial cell density, spinal cord rostral to caudal gradient (cont.). a) P I5, b) P20. 
All data points are plotted on the left hand graphs and mean values on the right.
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Figure 38. Glial cell density, spinal cord rostral to caudal gradient (summary). No 
significant or consistent trends are apparent when comparing mean glial cell density from 
rostral (cervical) to caudal (lumbar) levels of the spinal cord. The decrease in mean glial 
cell density with age is also apparent at cervical, thoracic and lumbar levels.
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3.2.2.Embryonic expression studies
Introduction and aims
Induced, high levels of expression of the pip gene is conventionally associated with mature 
post-mitotic oligodendrocytes and the production and maintenance of myelin sheaths. 
Demonstration of dm-20 transcripts in rodent brain by mid gestation (Ikenaka et al. 1992; 
Timsit et a l 1992a) well before the onset of myelination was therefore both surprising and 
intriguing in terms of a possible alternative non-structural role for DM-20 protein. 
Subsequent ISH studies have localised plp/dm-20 expressing cells in the brain and spinal 
cord of mice (Timsit et al. 1995) and rats (Yu et a l 1994) during this developmental 
period.
In the rat spinal cord, transcripts were localised to a column of cells either side of mid-line 
just above the floor plate at E l2, whereas in the mouse the positive cells were slightly more 
dorsal and identified at E14.5. In the rat expression appeared to be transient at E12 and 
was only detected again at E l8 in ventral white matter. In contrast in the mouse, positive 
cells progressively colonised the white matter areas of the cord throughout late 
embryogenesis. This variation may be related to the two species but additionally the two 
reports ascribed the positive cells to different cell types. In the mouse they were predicted 
to be oligodendrocyte precursors (Timsit et a l 1995) while a possible neuronal basis was 
considered in the rat (Yu et a l 1994). This latter suggestion was based on a more ventral 
localisation of the plp/dm-20 transcripts relative to those for platelet-derived growth factor 
a  receptor (PDGF-aR) and 2’,3’-cyclic nucleotide 3’-phosphodiesterase (CNP), presumed 
markers for the early oligodendrocyte lineage. The cells expressing the pip  gene have not 
therefore been unequivocally linked to a cell lineage, nor has a gene product been 
demonstrated. The purpose of the study on embryonic expression of the pip gene in the 
mouse was 1) to clarify discrepancies in previous publications regarding the initial 
localisation of cells expressing plp/dm-20 transcripts; 2) to determine if there is detectable 
product; 3) to define whether these cells can be categorically linked to the 0-2A lineage.
Materials and methods
Studies were performed on mice aged E l2 to PI with stage of development timed as 
described previously (see 3.2.1.Plp/dm-20 transcript ratio studies). ISH to localise plp/dm-
3520 expressing cells was performed with S-labelled riboprobes recognising pip  and dm-20 
transcripts (PLP-1) or only pip transcripts (PLP-3B). ISH was performed on cervical, 
thoracic and lumbar spinal cord on both paraffin sections and cryosections (see 2.3.2.ISH 
Protocol). Animals E14 or older were transcardially perfused and younger animals 
immersion fixed using BNF prior to paraffin processing. Complete spinal columns or 
whole embryos were snap frozen unfixed in OCT for cryostat sections (see 2.1.TISSUE 
FIXATION AND PROCESSING). Some sections were counterstained with haematoxylin
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and examined in bright and darkfield illumination, with or without coloured filters. To 
visualise the signal relative to normal architecture the bright and darkfield images were 
either double exposed or digitised and merged using appropriate software.
Cervical and thoracic spinal cord cryosections (15pm) were immunostained by single or 
double immunofluorescence. To demonstrate myelin proteins or neurofilaments, Gow’s 
technique was used (see 2.4.1.Tissue sections). To stain for 04, sections were fixed for 5 
min. in 2% paraformaldehyde followed by primary antibody for 1 hour at room 
temperature.
In order to increase the probability of detecting PLP-CT+ cells and to allow their 
characterisation, dissociated cell cultures were prepared from El 2-El 6 spinal cords, spinal 
ganglia and roots (see 2.6.1 .Tissue preparation). Cells were cultured for 2 hours to give an 
indication of their in vivo status prior to either double immunostaining for myelin proteins 
and markers for various cell lineages or combined immunostaining/ISH. Some cultures 
were maintained for 24 or 48 hours so that development of the PLP expressing cells could 
be studied. Immunostaining for surface markers, myelin proteins and neurofilaments, 
combined immunostaining/ISH and H thymidine incorporation studies were performed as 
described in methods (see 2.4.2.Tissue culture and 2.6.2.Thymidine incorporation).
H thymidine incorporation was also studied in E l4 spinal cord cryosections following 
intra-peritoneal injection of 5pCi H thymidine/gram body weight into a time mated 
pregnant mouse 2 hours prior to killing and embedding of the embryos. Cryosections were 
counterstained with haematoxylin and processed for autoradiography as described in 
methods (see 2.3.2.ISH Protocol). H Thymidine incorporation was used as a mitotic 
marker to determine whether cells immunostaining with the PLP-CT antibody were 
capable of mitosis and to visualise the position of dividing cells in the E14 spinal cord.
Results
ISH
Plp/dm-20 transcripts were detected initially in the El 3 cervical cord of one embryo in one 
cell per transverse section located in the ventricular layer approximately 2/3 down the 
dorsal/ventral length of the central canal and one or two cells outwith the canal. The 
position in the dorso-ventral axis was immediately ventral to the sulcus limitans of the 
neural canal. By E l4 (Figure 39) approximately two to three positive cells per section 
were usual in the cervical cord of all embryos in an identical position to El 3 while thoracic 
segments contained one cell and none were present in lumbar sections. In serial 15pm 
sections approximately every third section of cervical and thoracic cord contained positive 
cells. By E l6 several additional positive cells were located immediately lateral to the floor 
plate and reaching to the surface of the marginal layer (Figure 39). Very occasional 
expressing cells were present in the medial aspects of the mantle layer. At El 8 positive
120
cells were identified around the pial surface of the ventral and lateral marginal layer, in the 
dorsal columns and occasionally through the mantle layer (Figure 40). The positive cells 
immediately ventral to the canal (the site of initial embryonic expression) were now much 
less prominent. By PI numerous expressing cells were present throughout the white matter 
and less frequently in grey matter (Figure 40).
RT-PCR data presented above (see 3.2.1 .Plp/dm-20 transcript ratio studies) strongly 
suggested that the dm-20 isoform was predominantly responsible for the signal detected by 
ISH. The non-specific PLP-1 probe recognises both pip  and dm-20 transcripts and it is not 
possible to label dm-20 transcripts specifically in tissue sections. Their presence however 
can be inferred by differential labelling with a pip-specific probe. A pip  specific probe 
(PLP-3B, see 3.1. SUB CLONING OF THE MOUSE pip SPECIFIC SEQUENCE) was 
therefore used to label alternate tissue sections. No signal was detected with the PLP-3B 
probe at any level until E l6 when occasional cells were present adjacent to the central 
canal and floor plate. The pattern of expression subsequently followed that identified with 
the PLP-1 probe but with fewer positive cells until the postnatal period.
Satellite cells in ganglia and cells in nerve roots and peripheral spinal nerves hybridised 
strongly with the PLP-1 probe at all ages (Figure 39) but not with the PLP-3B probe.
Immunocytochemistry
Reactivity to the PLP-CT antibody was not detected at E l3 but was present at E14 in the 
cervical segments in one, or occasionally two, cells per transverse section located in an 
identical position to that described for ISH (Figure 41). Subsequently the developmental 
pattern of cells reacting to the PLP-CT antibody mirrored that found in the hybridisation 
studies (Figure 41, Figure 42). The developmental pattern was identical at cervical, 
thoracic and lumbar regions with approximately a 1 day sequential difference moving 
caudally between the 3 regions. Between E l4 and E l6 the PLP-CT antibody stained the 
lumen of the central canal and, more faintly, the area of the floor plate (Figure 41). This 
pattern was not seen with other polyclonal antibodies such as the PLP-specific antibody, 
nor with normal rabbit serum, and was abolished by pre-incubation with the specific C- 
terminal peptide.
No protein was detected with the PLP-specific antibody before E l7 when positive cells 
were located around the floor plate; subsequent staining mirrored that with the PLP-CT 
antibody. Co-labelling studies showed that MBP was not detectable in the PLP-CT+ cells 
until E l6.5/17.
Satellite cells in ganglia and cells in nerve roots and peripheral spinal nerves stained 
strongly with the PLP-CT antibody at E l3 and older, but not with the PLP-specific
121
antibody. Spinal roots and ganglia failed to stain with 04  at E l3 and E l4 but were 
positive at E l8.
Dissociated cell culture
Initially E l4 and older embryonic cultures were studied. As would be expected from 
immunostaining of cryostat sections PLP-CT+ cells were found, in increasing numbers, at 
all ages from E l4 onwards. The majority of these cells co-stained with A2B5, 04  or 
RmAb and in older embryos (E16+), MBP, suggesting that they were from the 0-2A 
lineage. Cultures also contained numerous neurones labelling with A2B5 and SMI-31 
(neurofilament) antibodies.
At E l2, numerous small A2B5+ cells were present; 04+ cells were obvious though less 
frequent; very occasional RmAb+ cells were seen but 08+ cells were not detected. Cells 
immunostaining with the PLP-CT antibody (Figure 43) or hybridising with the PLP-1 
probe (Figure 44) were detected at a frequency of approximately 1 to 3 per coverslip (60- 
80,000 cells/coverslip) at El 2 and 10 to 20 positive cells at El 3. Small clumps of positive 
cells were also seen. Cells staining with PLP-CT or hybridising with the PLP-1 probe 
labelled with A2B5 or 04 and occasionally RmAb. Not all cells staining for A2B5 or 04  
or RmAb co-labelled for PLP-CT or hybridised with the PLP-1 probe, and at 2 hours, and 
to a lesser degree at 24 and 48 hours after culture of E l2 cords, cells were identified 
labelling with the PLP-CT antibody or PLP-1 probe, but negative for A2B5, 04  or RmAb. 
After 24 hours in culture, multiprocess oligodendrocytes labelling with 04  and RmAb 
were detected, which became more numerous by 48 hours. Some of these cells co-labelled 
with PLP-CT antibody (Figure 43). No cells from E12 spinal cords immunostained with 
MBP or PLP-specific antibodies up to 48 hours in culture. Although numerous PLP-CT+ 
cells were present in dissociated cultures of spinal roots and ganglia, no PLP-CT+/04+ or 
PLP-CT+/RmAb+ cells were seen.
3
H thymidine incorporation
Pulse labelled, dissociated cells were immunostained with PLP-CT and a recognised 0-2A 
lineage marker, either 1, 24 or 48 hours after removal of thymidine. In E12 dissociated 
spinal cord cultures one hour after labelling, PLP-CT+ cells were present which had 
incorporated thymidine, many of which were co-labelled with A2B5 (Figure 45). One 
RmAb+ cell was seen but no 04+ cells. After up to 48 hours in culture, multiprocess PLP- 
CT+/04+ and PLP-CT+/RmAb+ cells were identified, which had incorporated thymidine 
during the 1 hour pulse (Figure 45).
Numerous cells which had incorporated thymidine in the E14 embryos could be seen 
throughout the body structures. Within the developing spinal cord positive cells were seen 
much less frequently. Several positive cells per section were present, mostly in the outer 
mantle area, predominantly ventrally. Occasional positive cells were seen in the marginal
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zone. In all sections studied a few positive cells were present in the ventral ventricular area 
corresponding to the location of the PLP-1 +/PLP-CT+ cells seen in ISH and 
immunostaining studies (Figure 46).
Discussion
The above results demonstrate that the pip gene is expressed in a very discrete region of the 
ventricular layer of the embryonic spinal cord, located immediately ventral to the future 
central canal, at El 3 and probably at E l2. Between E14 and birth, cells expressing the pip 
gene appear to progress ventrally via the borders of the floor plate to reach the pial surface 
between E l6 and E l8. At E l8 similar cells are also found in the lateral and to a lesser 
extent, dorsal columns. Full length protein product is present in these cells, the majority of 
which can be identified as belonging to the 0-2A lineage.
Presence of pip transcripts in the mouse embryo (as discussed in 3.2.1. Plp/dm-20 transcript 
ratio studies) has been demonstrated previously, and indeed it has been suggested that dm- 
20 is exclusively expressed in the embryo (Ikenaka et al. 1992; Timsit et al. 1992a). The 
validity of the RT-PCR findings is strengthened by the demonstration of /?/p-specific 
transcripts by ISH at E16 and PLP-specific immunostaining at E17 and E18. It is clear 
however from the above results that at all embryonic ages dm-20 is the predominant 
message. Dm-20 transcripts have been demonstrated previously in the mouse or rat spinal 
cord (Timsit et al. 1995; Yu et al. 1994) but this is the first demonstration of the presence 
of protein. As the PLP-CT antibody is directed against the C-terminal portion of the 
protein it would indicate that a full length, and therefore functional product is present. 
Demonstration of product implies that the presence of transcripts is not likely to be due to 
non-regulated transcription and that the presence of DM-20 in the embryonic spinal cord is 
likely to have real functional significance.
The apparent orderly spread of PLP-CT+ cells and eventual co-expression of the myelin 
proteins MBP and PLP strongly suggest that they are derived from the 0-2A lineage. 
Freshly dissociated cells from E12 spinal cords and older which are positive for dm-20 
transcripts and protein co-stain with known markers of the 0-2A lineage:
1) A2B5, a marker for some 0-2A progenitors in the mouse (Raff et al. 1983). A2B5 does 
label other cell types such as neurones and type 2 astrocytes (Einsenbarth et al. 1979; 
Schnitzer and Schachner 1982), however no evidence was found that DM-20+ cells co­
stained with the neuronal marker SMI-31 (neurofilaments) and E12 spinal cords did not 
stain for the astrocytic marker GFAP.
2) 0 4  and RmAb, markers of the proligodendroblast and immature oligodendrocyte 
respectively. Perinatal and postnatal Schwann cells also bind 04  and RmAb. In rat, 
Schwann cells acquire 04  staining at E l6/17 and Gal C (also recognised by RmAb) at 
E l8/19 (Jessen and Mirsky 1991; Mirsky et al. 1990), but neither was detected at E l4 
(Jessen et al. 1994). Although all efforts were made to prevent contamination of spinal
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cord cultures with PNS material it was necessary to exclude this possible contamination as 
a source of the PLP-CT+/04+ or PLP-CT+/RmAb+ cells. This was done on the basis that 
04  staining of ganglia and spinal roots was present on cryostats only at E l 7 and older, and 
that no PLP-CT+/04+ or PLP-CT+/RmAb+ cells were present in E l2/13 spinal root and 
ganglia dissociated cultures prepared using material removed during the establishment of 
the spinal cord cultures of the same age.
After 24 to 48 hours in culture, cells with typical oligodendrocyte morphology and positive 
for Gal C, some of which co-stained for PLP-CT, were detectable.
Some of the cells expressing dm-20 transcripts or staining for PLP-CT could not be co­
stained with A2B5, 04 or RmAb, nor with SMI-31. These may represent; 1) earlier 
precursor cells, known to exist (Gonye et al. 1994; Hardy and Reynolds 1991; Nakafuku 
and Nakamura 1995), for which there are as yet no defining markers; 2) 0-2A  cells which 
are staining for DM-20 but are unlabelled by A2B5 or 04  due to the discontinuity between 
loss of A2B5 and gain of 04  in the mouse. In the rat the earlier A2B5 marker is 
overlapped by 04  which is then followed by RmAb. This overlap does not occur in the 
mouse thus giving rise to some cells unlabelled by either A2B5 or 0 4  (Fanaragga et al. 
1995). It is possible that some of the positive cells may represent early neuronal precursors 
not expressing neurofilaments, but neither the present results nor those of other groups 
using neuronal markers such as TuJl (Timsit et al. 1995) would support this.
Mouse E l2 spinal cord cultures at 2 to 48 hours, contained 04+ and RmAb+ cells which 
did not co-express PLP-CT. These cells may represent; 1) sub-populations of 0-2A 
lineage cells exhibiting differences in the timing and level of dm-20 expression relative to 
cell differentiation, perhaps regulated by their immediate environment; 2) biphasic 
expression in individual cells. Early 0-2A progenitors may express dm-20 with a partial 
down-regulation of the gene in the intermediate proligodendroblast stage accounting for 
the O4+/DM-20- cells, to be followed by a further period of dm-20/plp expression as the 
GalC+ oligodendrocyte matures. The absence of a biphasic expression profile in the RT- 
PCR data reflects the fact that the generation and differentiation of all 0-2A lineage cells is 
not synchronous so that bulk samples from whole spinal cords will contain increasing 
numbers of cells at various stages of development.
It is known that 0-2A progenitors are motile in vitro (Small et al. 1987), and probably in 
vivo although precursor cells may also contribute to the dispersion of the lineage (Gonye et 
al. 1994). Progenitors and proligodendroblasts are known to be proliferative and divide in 
response to various mitogens (Gard and Pfeiffer 1990; Hardy and Reynolds 1991; Barres 
and Raff 1994). On the other hand, oligodendrocytes expressing myelin proteins are 
classically non-motile (Small et al. 1987), post-mitotic cells (Gard and Pfeiffer 1990; 
Hardy and Reynolds 1991). If the PLP-CT+ cells present in the embryonic cord are 0-2A 
progenitors, we would therefore expect them to be both motile and capable of cell division. 
The studies suggest indirectly that the PLP-CT+ cells are likely to be motile. This is based
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on the sequentially progressive distribution of labelled cells in tissue sections, suggestive 
of migration. The thymidine incorporation in dissociated cultures show that PLP-CT+ 
cells undergo mitosis and subsequently develop into oligodendrocytes. The presence of 
thymidine-labelled cells in the same location as PLP-CT+ and PLP-1+ cells in the E l4 
embryo sections is consistent with the in vitro thymidine labelling, however it is not 
possible to ascribe these cells to a particular lineage based on thymidine labelling alone. 
The majority of radiolabelled cells in the E l4 cord cryosections probably represent glial 
precursors as most neurogenesis in the spinal cord is essentially complete by E14 in the 
mouse (Nomes and Carry 1978; Sims and Vaughn 1979). The majority of glial 
proliferation, however, has still to occur (Gilmore 1971). The above data challenge 
previous perceptions relating to myelin gene expression during oligodendrocyte 
development indicating the DM-20 isoform is present in progenitors, much earlier than 
previously recognised, and not just in the more mature, post-mitotic oligodendrocyte.
The results also support the proposition that oligodendrocytes originate in a discrete region 
of the ventral spinal cord (Noll and Miller 1993; Timsit et a l 1995; Warf et al. 1991; Yu et 
al 1994). The location of DM-20+ cells in this study is in agreement with the findings of 
Timsit et a l (1995) in the mouse rather than those of Yu et al. (1994) in the rat. It may be 
that DM-20 labels different cell types in the rat or that the same cell types originate in 
slightly different locations. The transient nature of pip  gene expression seen in the rat 
relative to the mouse is harder to explain. In the rat, other markers such as CNP and 
PDGFa receptor have been used to define 0-2A progenitors in the embryonic spinal cord 
(Pringle and Richardson 1993; Y u ^  al 1994). The pattern of expression seen with these 
markers is somewhat different from that seen with DM-20 in the mouse. Positive cells 
tend to be more numerous and more widely distributed throughout the grey and white 
matter. If the CNP+, PDGFaR+ cells are all 0-2A progenitors it is possible that not all 
these cells express dm-20, or that they do so in a more transient manner, possibly 
influenced more by local environment. Cells present in white matter areas may express 
dm-20 whilst those migrating through grey matter areas may lack expression although still 
exhibiting other 0-2A markers such as CNP and PDGFaR. Changes in antigenic profile in 
precursor cells whilst migrating through grey matter areas have been reported previously in 
studies on oligodendrocyte differentiation in rat brain (LeVine and Goldman 1988). Rapid 
changes in both morphology and loss of ability to bind anti-GD3 antibody were seen when 
cells entered the grey matter. Presumably, local environment must play an important role 
in determining cell morphology and expression of markers such as GD3 and possibly, 
therefore, PLP/DM-20. It is also possible that not all CNP+, PDGFaR+ cells are destined 
to become oligodendrocytes or that oligodendrocytes may be derived from more than one 
distinct lineage. PDGFaR expression is seen at earlier times in the rat spinal cord, 
probably in developing intemeurones (Pringle and Richardson 1993). CNP appears to mark 
two populations of cells, strongly staining cells with a distribution similar to that seen with
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dm-20, and diffusely staining cells with a more widespread distribution (Yu et al. 1994). 
The appearance ofplp/dm-20+ cells in the dorsal columns at El 8 raises questions about the 
possible migration pathways of the oligodendrocyte precursor cells. It is possible that 
precursors may migrate ventrally and then laterally to colonise the ventral and ventro­
lateral columns or, alternatively, cells may “ take the shortest route” migrating in a radial 
manner. This would be consistent with previous studies which have demonstrated that 
immature spinal cord oligodendrocyte precursors in the developing white matter have a 
striking radial orientation (Choi et a l 1983; Hirano and Goldman 1988). Migration of 
cells to the dorsal columns, however, would logically occur in a dorsal direction, a theory 
supported by studies of oligodendrocyte precursors in embryonic chicken spinal cord (Ono 
et al. 1995). No plp/dm-20+ “migrating” cells are seen in the intermediate grey matter 
between E14 and appearance of plp/dm-20+ cells in the dorsal columns at E l8. It is 
possible that expression in oligodendrocyte precursors and oligodendrocytes once they 
have reached the white matter areas is controlled by different factors than those influencing 
early expression in the germinal areas of the ventricular zone during earlier embryogenesis. 
* There is currently much speculation regarding the factors involved in inducing specific 
cells in the ventricular zone to develop into particular lineages and express associated 
genes. Expression or activation of transcription factors, DNA-binding proteins which 
exercise control over transcription of genes is likely to be of critical importance. Genes 
encoding these proteins are involved in rostro-caudal positioning (Hox genes), 
dorso/ventral positioning (Pax genes) and also may be involved in the determination of cell 
fate (for review see Lemke (1993)). It has recently been demonstrated that expression of 
the pip gene itself is sufficient for, and directly associated with, secretion of a factor which 
influences oligodendrocyte development (Nakao et al. 1995). Culture supernatants from 
pip expressing cell lines were shown to increase oligodendrocyte numbers when added to 
primary glial cell cultures from embryonic brain. Whether plp/dm-20 expression is one of 
the initial committing steps towards the oligodendrocyte lineage, and what the factors 
initiating this early pip expression are, remain as yet, unanswered questions. The 
notochord and floor plate are known to exert a strong influence on the development of the 
embryonic cord (Yamada et al. 1991) and substances produced by the floor plate, such as 
retinoids (Noll and Miller 1994), PDGF-A (Orr-Urtreger and Lonai 1992) and products of 
the hedgehog gene family (Marti et al. 1995), are possible influencing factors. Indeed it 
has recently been shown in the chick embryo that floor plate or notochord explants can 
influence oligodendrocyte differentiation in vitro (Trousse et al. 1995). The close
* Using isotopic/isochronic grafts of chick and quail neural tube, Cameron-Curry and Le Douarin (1995) 
have demonstrated that oligodendrocytes are also generated from dorsal neural tube and that extensive 
ventrodorsal and dorsoventral migrations of oligodendroblasts occurs.
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association of pip expressing cells with the floor plate, as observed in the present study 
would also raise the question as to whether the floor plate may exert a chemotactant 
influence on these cells.
It may be possible to further confirm that the oligodendrocyte lineage is the source of early 
embryonic expression of the pip gene by a combination of either ISH or immunostaining of 
thick vibratome tissue sections with PLP/DM-20 markers followed by EM examination of 
ultra-structural morphology of labelled cells. Such an approach has been used by Ono et 
al (1995) to study early 04+ cells in chicken spinal cord, another proposed marker of the 
oligodendrocyte lineage. These authors demonstrated 04+ cells were present in the 
ventricular zone, in a similar position to dm-20+ cells seen in the rat, and that they had 
many characteristics associated with ventricular cells. Indeed the 04+ cells were 
essentially identical to their surrounding neighbours. It may therefore be necessary to look 
at cells which are further along the differentiation pathway, around E l6 in the mouse, 
before typical morphology associated with the oligodendrocyte lineage or possibly other 
lineages becomes apparent. The major problem with this approach is the assumption that 
one can infer developmental changes by examining a series of static images. The cells 
expressing plp/dm-20 at E l6 or older ages may not be the same cells as those seen at E l4 
adjacent to the central canal, nor may they be derived from these cells. This is especially 
pertinent given the apparent transient nature of expression seen in these cells in the rat (Yu 
et a l 1994). The limitation of only being able to view a specific cell at one particular time 
point is the root of this problem. Demonstrating that expression of the pip  gene is biphasic 
is difficult using different cells at single time points, but may be accomplished by double 
immunostaining for PLP/DM-20 and a series of sequential 0-2A markers such as GD3, 
A2B5, 04, RmAb. This will still be difficult given the very small number of expressing 
cells in the embryonic cord. Optic nerve cultures contain considerably more DM-20+ 
progenitors, and their use may overcome this problem. Similar problems of studying 
single time points arise when trying to follow migration and expression of these early 
PLP/DM-20+ cells. Ideally, it would be desirable to be able to label and view positive 
cells both in vivo and in vitro, possibly in cord explant cultures, using a non-invasive 
technique. This would allow assessment of expression in the same cell over a defined 
period. One approach to this would be the generation of transgenic mice expressing PLP 
fusion proteins consisting of PLP plus a marker protein such as Lac-Z or Green fluorescent 
protein (GFP) (Chalfie et al 1994; Prasher et a l 1992). A PLP/Lac-Z transgenic mouse 
with apparently normal temporal and spatial expression of the PLP-fusion protein has been 
reported (Wight et a l 1993). GFP exhibits inherent fluorescence under UV illumination 
and appears to exert no toxic effects in eukaryotic systems. A PLP/GFP transgenic mouse 
similar to the PLP/Lac-Z mouse, with normal expression and targeting, would allow non- 
invasive monitoring of pip expression in the embryo in real time. This may prove a useful 
tool in unravelling some of these remaining questions.
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(a)
(b)
Figure 39. Embryonic spinal cord ISH (PLP-1 probe recognising pip and dm-20). 
Hybridisation signal has been photographed in darkfield using either a red filter and then 
double exposed with the brightfield image or with a green filter, digitised and merged with 
the brightfield image using software, a) E14 Positive cells are present in a discrete region 
of the ventricular zone (arrows), spinal ganglia (g) and nerve roots (n). b) E l6 Positive 
cells are now seen adjacent to the floor plate.
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(b)
Figure 40. Embryonic spinal cord ISH (PLP-1) (cont.). a) E l8 Positive cells are now 
more widespread in the ventral marginal zone with occasional positive cells in the dorsal 
columns (arrow), b) PI Numerous strongly positive cells are now present throughout the 
white matter with occasional positive cells present in the grey matter.
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Figure 41. Embryonic spinal cord immunostaining. PLP-CT antibody (green), 
neurofilament antibody (SMI-31), detecting axons (red), a) E l4 One or two positive cells 
are present adjacent to the central canal (c). The luminal surface of the canal and the floor 
plate area (appearing as yellow) are also stained with PLP-CT. b) E l6 Cells are present 
below the central canal and around the floor plate (f). The yellow appearance of some cells 
is due to superimposition of cells and axons , not co-localisation. Nuclei are stained with 
DAPI (blue).
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(b)
Figure 42. Embryonic spinal cord immunostaining PLP-CT antibody (cont.). a) E l6 floor 
plate region (f) in more detail; positive cells can be seen in close association with the 
lateral borders of the floor plate, b) By PI intense staining is now present throughout the 
white matter (central canal = c ).
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(c)
Figure 43. E12 spinal cord dissociated cell culture, a) 2 hours, b) 24 hours, c) 48 hours in 
culture. Cells can be seen co-immunostaining with PLP-CT (PC) and 0 4  or RmAb (RM), 
markers of the 0-2A  lineage. With time in culture, the development of a multipolar 
morphology typical of developing oligodendrocytes is evident.
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(b)
(e)
Figure 44. E l3 spinal cord dissociated culture, combined ISH/immunostaining. Cells 
were cultured for 2 hours before immunostaining with a) A2B5, b) RmAb, and then 
hybridised for c) PLP-1. Co-localisation of hybridisation signal (arrow) with markers of 
the 0-2A  lineage is demonstrated.
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Figure 45. Thymidine incorporation, E l2 dissociated spinal cord culture. Two hour total
3  3
culture time after 1 hour H thymidine labelling; a) A2B5, b) PLP-CT, c) H thymidine. 
Co-immunostaining with the 0 -2 A lineage marker A2B5 and PLP-CT demonstrates a 
clump of A2B5+/PLP-CT+ cells at 2 hours, one of which has incorporated radiolabel 
(arrow).
3Figure 46. E l4 embryo spinal cord, in situ H thymidine labelling. Numerous labelled 
cells are present throughout the body of the embryo with fewer labelled cells in the spinal 
cord. Within the cord, positive cells can be seen in the ventral ventricular area (arrows).
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3.2.3.PNS studies
Introduction and aims
The expression of the pip gene in the peripheral nervous system has been well documented 
for several years (Ono et al. 1990; Puckett et al. 1987; Stahl et al. 1990). It is known that 
in the normal animal PLP/DM-20 protein is not incorporated into the myelin sheath (Ono 
et a l 1990; Puckett et al 1987) and that DM-20 is the predominant isoform (Pham-Dinh et 
al 1991). Unlike myelin proteins which are incorporated into PNS myelin (P0, PMP-22, 
MBP), it has been shown that plp/dm-20 expression does not parallel the myelination 
process, as it does in the CNS (Gupta et a l 1991; Stahl et a l 1990), although a modest 
increase concomitant with increasing numbers of Schwann cells may be seen (Kamholz et 
a l 1992). However, there is little information relating to possible changes in plp/dm-20 
ratios during this developmental period. It has also been demonstrated that the effect of 
nerve section or crush injury on pip gene expression is minimal compared to the dramatic 
down-regulation seen with other PNS myelin proteins such as P0 or PMP-22 (Gupta et al 
1991; Kamholz et a l 1992). Again, little information is available regarding the possible 
effects on plp/dm-20 transcript ratios following axotomy or crush injury of peripheral 
nerve. It was therefore decided to use RT-PCR to study the relative developmental pattern 
of expression of the pip and dm-20 isoforms in the PNS and also to determine whether 
transection of peripheral nerve would have any effect on plp/dm-20 transcript ratio.
Materials and methods
Developmental studies were performed using sciatic nerves from PI, 5, 10, 15, and 20 
C3H/HeH X 101H mice. Cervical sympathetic trunks (CST) and cranial cervical ganglia 
(CCG) and sciatic nerve were collected from adult Sprague-Dawley rats. Rats were used 
as a source of CST material due to the limiting amounts of tissue obtainable from mice. 
Transection studies were performed on distal segments of transected sciatic nerve from 
adult mice 1 and 3 weeks post-transection. Six transected and six contralateral non­
transected sciatic nerves from age matched littermates were processed for RT-PCR as 
previously described using cyclophilin as an internal control, and P0 as a positive control 
for down-regulation (see 2.2.2. Analysis of transcripts). As a comparative study, plp/dm-20 
transcript ratio was studied in transected and non-transected adult rat optic nerves 3 weeks 
post-transection. Both sciatic and optic nerve transections were performed under 
halothane/oxygen general anaesthesia using an induction chamber and mask. Access to the 
sciatic nerve was via a lateral approach separating the vastus and biceps muscles. Access 
to the optic nerve was achieved via an incision over the dorso-lateral aspect of the bony 
orbit and blunt dissection between the eyeball and the bony orbit. Skin wounds were 
closed with Michel clips (International market supply).
136
Results
Developmental profile
Both pip and dm-20 products were identified in the sciatic nerve at all ages studied. Dm-20 
was always the predominant product and there was no observable alteration in product ratio 
over the period from PI to P20 (Figure 47). Both products were also present in rat CST, 
CCG and sciatic nerve. When CST and sciatic nerve were compared, the relative 
abundance of the dm-20 product was greater in the CST with the pip isoform being a minor 
signal in both (Figure 47).
Sciatic nerve transection
Three weeks after transection of mouse sciatic nerve, semi-quantitative RT-PCR analysis 
of distal nerve segments identified a marked decrease in P0 mRNA in the transected nerve 
compared to the contralateral non-transected nerve (Figure 48). Using plp/dm-20 primers a 
similar product ratio to the one seen in the mouse developmental profile was observed in 
the non-transected nerve with marked predominance of dm-20 product. No significant 
change in amount of dm-20 product was seen in the transected nerve, however pip  product 
was significantly less in the transected nerve (Figure 48). This would suggest that there 
was selective down-regulation of the pip isoform. The experiment was repeated with 
analysis of transcripts 1 week post-transection with results similar to those of the 3 week 
post-transection study (Figure 48).
Effects of transection of the rat optic nerve is similar to that seen in mouse sciatic nerve 
with dm-20 product levels remaining unchanged, and pip levels decreasing (Figure 49). 
Pip however is the major isoform present at all times as would be expected in the CNS.
Discussion
Upon transection of a peripheral nerve, down-regulation of myelin genes coding for 
proteins incorporated into the PNS myelin sheath such, as P0j PMP-22 and MBP, is well 
documented (De Leon et al 1991; Gupta et a l 1991; Kamholz et a l 1992; LeBlanc et a l 
1987; Snipes et a l 1992; Trapp et a l 1988). It has been suggested that maintenance of 
Schwann cell expression of these genes is highly dependent on axonal contact, and 
regulation occurs primarily at the level of transcription. Similar studies into plp/dm-20 
expression following either transection or crush injury of sciatic nerve demonstrated that 
down regulation may be relatively small, possibly as little as 30% as compared to >90% 
for P0 (Gupta et a l 1991) following transection. These findings together with the apparent 
uncoupling of the pip gene from the co-ordinate expression seen in other PNS myelin 
genes, has lead to the conclusion that unlike the major myelin proteins in the PNS, pip 
gene expression is not under strict axonal control.
No apparent developmental change in plp/dm-20 ratio was seen in this study, unlike the
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CNS where the dramatic plp/dm-20 ratio change appears to be a feature of co-ordinate gene 
expression during myelination (see 3.2.1.Plp/dm-20 transcript ratio studies). This would 
imply that not only is total transcriptional activity not correlated with myelination in the 
PNS, as has been demonstrated previously (Gupta et al. 1991; Stahl et al. 1990), but also 
that regulation of transcript ratios appears to be unaffected by the onset of myelination. 
Myelination of mouse sciatic nerve commences around birth (Fraher 1972; Winter et al. 
1982) and probably slightly before. The current study did not look at embryonic sciatic 
nerves. However given the constancy in ratio seen during the earliest post-natal period, it 
is unlikely that any gross changes will be seen in late embryonic nerves. This may imply 
that either the pip gene does not have a critical role in PNS myelination, as might be 
supported by the lack of abnormalities in the PNS of pip mutant animals, or any role that it 
does play does not require predominance of the pip isoform. Abnormalities in the PNS of 
pip mutant animals may exist, but may be subtle and require demonstration at EM level. It 
is also possible that the markedly reduced lifespan of these severely affected mutants is too 
short for structural changes to develop. A further consideration is that the function of DM- 
20 may be duplicated by other molecules unaffected by mutations of the pip  gene so that 
no phenotypic effect is evident, a theory supported by the surprisingly normal phenotype 
reported in pip transgenic “knockout” mice (Boison and Stoffel 1994) (K.Nave 
unpublished). It is interesting to note that levels of dm-20 product were found to be higher 
in CST relative to sciatic nerve. The CST contains predominantly unmyelinated fibres 
compared to the mixed population found in the sciatic nerve and this increased dm-20 
product level possibly reflects a high abundance of dm-20 transcripts in non-myelin- 
forming Schwann cells.
It has been suggested that the difference between pip gene expression in the PNS and the 
co-ordinate expression seen during myelination in the CNS may be due differences in the 
trans-acting factors involved in the regulation of transcription in the Schwann cell and 
oligodendrocyte (Kamholz et al. 1992). Consistent with this notion is the fact that most 
transcripts in the PNS are initiated from the more proximal of two start sites, possibly 
responsible for maintenance expression, while in the CNS the distal site is used, which 
may be responsible for inducible transcription as is seen during CNS myelination. 
Interestingly, it appears that steady state transcription in the CNS may also involve 
transcription from this proximal start site (Scherer et al. 1992). A recent study has shown 
that the two PLP isoproteins are targeted to different locations in the Schwann cell 
cytoplasm, with the less abundant PLP being found only in the perinuclear cytoplasm of 
myelin forming Schwann cells, and DM-20 being found predominantly at the paranodes, 
Schmidt-Lantermann incisures and in non-myelin-forming Schwann cells (Griffiths et al. 
1995a). This may imply that the two proteins have different functions in the PNS (as is 
postulated in the CNS). Given this apparent uncoupling of targeting of the two isoforms it 
is interesting that regulation of the two isoforms at the transcript level also appears to be
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under differing controls. Although levels of pip transcripts in the PNS are low, PLP 
specific product has been demonstrated (Griffiths et al. 1995a) and the down-regulation 
seen upon nerve transection would imply that expression of pip  is influenced by axonal 
factors. Whether this results from loss of positive regulatory influences, activity of silencer 
elements known to exist (Bemdt et a l 1992; Cambi and Kamholz 1994; Nave and Lemke 
1991) or variation in transcript splicing remains to be seen. Dm-20 transcript levels on the 
other hand do not seem to be affected by nerve transection either in the PNS or CNS. As 
dm-20 is by far the predominant isoform in the PNS, this may explain why only minimal 
down-regulation of total transcripts is seen on northern and dot blots after nerve 
transection/crush, as the two isoforms cannot be distinguished using these techniques. 
Down-regulation of myelin genes in the CNS following optic nerve transection is not as 
severe as that seen in the PNS but can be up to 50% by 10 days post transection (Kidd et 
al. 1990; McPhilemy et al. 1990; Scherer et al. 1992). The down-regulation seen with the 
RT-PCR after 3 weeks is in good agreement with these studies and interestingly, as in the 
PNS, appears to show that loss of axonal influences are responsible for down-regulation of 
pip transcripts, but have little effect on dm-20 transcript levels. Optic nerve transections 
were performed on rats due to size limitations and familiarity with the procedure in this 
species. An interesting observation in the PNS was that although overall levels of 
transcript were little altered, it was not possible to demonstrate immunostaining in the 
distal segment of the 3 week transected nerves using the PLP-CT antibody. However, 
PLP/DM-20 protein was present in the Schwann cell cytoplasm of the degenerating nerve 1 
week post-transection. This would imply additional post-transcriptional control of 
PLP/DM-20 protein levels, or at least of DM-20 protein, in the PNS since no such decrease 
in transcript is demonstrated by RT-PCR. Lack of staining of PLP specific protein is 
presumably attributable to the transcriptional down-regulation similar to that seen with 
other major PNS myelin proteins such as P0 and MBP. Post-transcriptional control of 
PLP/DM-20 has been demonstrated in vitro by Kamholz et al. (1992). Loss of 
immunostaining for P0 and PLP/DM-20 in primary rat Schwann cell cultures was 
demonstrated over a 1 week period, after which time, addition of high concentrations of 
dibutryl 2’, 3’ cyclic AMP produced a marked increase in P0 and PLP/DM-20 
immunoreactive cells. However, whereas steady state levels of P0 mRNA increased after 
addition of cyclic AMP, levels of pip message remained the same, suggesting post- 
transcriptional regulation of PLP/DM-20.
Based on previous studies suggesting a dual role for the pip gene, the specific targeting of 
the two isoforms in the Schwann cell and the relative abundance of DM-20, it seems likely 
that DM-20 may well have a non-structural role to play in Schwann cells. The evidence 
that regulation of transcript levels of the two pip isoforms may be under the influence of 
different factors adds weight to this theory. Additional corroboration of the RT-PCR data 
will be needed, preferably by a direct method such as transcript mapping along with
139
western analysis of protein levels in the intact and transected nerves, although limiting 
amounts of tissue may well pose considerable problems. Differences between Schwann 
cells and oligodendrocytes in transcript regulation and targeting of the final protein is 
intriguing and poorly understood. Studies using transgenic mice carrying extra copies of 
the pip  gene (Readhead et a l 1994) or mice expressing pip or dm-20 cDNA transgenes 
(Nadon et al. 1994) on various mutant and wild type backgrounds (Anderson and Griffiths 
unpublished data) have demonstrated incorporation of PLP protein into the myelin sheath 
in some but not all cases. If the control of pip and dm-20 is indeed influenced by different 
factors and the two proteins perform different functions, effects of one or both of the 
transcripts in these transgenic animals may provide further insight into this largely 
unresolved area of study.
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(a)
(b)
Figure 47. PNS plp/dm-20 RT-PCR products, a) Developmental profile: Lane 1 adult rat 
CCG, Lanes 2-6 mouse sciatic nerves aged PI, 5, 10, 15, 20 respectively, Lane 7 lOObp 
DNA calibration ladder, Lane 8 pC4 (pip) control. Predominance of dm-20 product (D) at 
all ages is demonstrated. Pip product (P). There is no apparent change in plp/dm-20 
product ratio between PI and P20, during which time peak myelination in the sciatic nerve 
is occurring, b) Adult rat CST: Lane 1 adult rat brain, Lane 2 adult rat CST, Lane 3-5 adult 
rat sciatic nerve, decreasing product loading, Lane 6 pC4 (pip) control, Lane 7 pCl 1 (dm- 
20) control, Lane 8 lOObp DNA calibration ladder. The difference between plp/dm-20 
ratio in the pip predominant CNS and dm-20 predominant PNS is illustrated. Dm-20 
accounts for virtually all the signal in the CST which contains almost exclusively non­
myelin-forming Schwann cells. A relatively greater pip signal is present in the sciatic 
nerve which contains a higher proportion of myelin-forming Schwann cells.
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Figure 48. Adult mouse sciatic nerve transections, semi-quantitative RT-PCR. a) 3 weeks 
post-transection: Lane 1 transected nerve (plp/dm-20), Lane 2 intact nerve (plp/dm-20) 
Lane 3 transected nerve (Pq), Lane 4 intact nerve (P0), Lane 5 transected nerve (cycl), Lane 
6 intact nerve (cycl), Lane 7 pC4 (pip) control, Lane 8 pP0 (Pq) control, Lane 9 p 1B 15 
(cycl) control, b) 1 week post-transection: Lane 1 transected nerve (Po), Lane 2 intact 
nerve (Pq), Lane 3 transected nerve (cycl), Lane 4 intact nerve (cycl), Lane 5 pC4 (pip) 
control, Lane 6 pP0 (P0) control, Lane 7 plB15 (cycl) control, Lanes 8,10,12 transected 
nerve (plp/dm-20) (PCR Mg conc. 1.5/3.0/4.5mM), Lanes 9,11,13 intact nerve (plp/dm-20) 
(PCR Mg conc. 1.5/3.0/4.5mM), Lane 14 pC4 (pip)control. Marked down-regulation of P0 
is seen in transected sciatic nerves. Levels of dm-20 product (D) appear relatively 
unaltered whereas pip product (P) is considerably reduced.
Figure 49. Adult rat optic nerve transection, semi-quantitative RT-PCR. Lanes 1,3 
transected nerve (plp/dm-20) (PCR Mg conc. 3.0/4.5mM), Lanes 2,4 intact nerve (plp/dm- 
20) (PCR Mg conc. 3.0/4.5mM), Lane 5 transected nerve (cycl), Lane 6 intact nerve (cycl), 
Lane 7 pC4 (pip) control, Lane 8 plB  15 (cycl) control. 3 weeks post-transection, levels of 
pip product (P) are decreased in the transected nerve whereas dm-20 product levels (D) 
remain unchanged.
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3.2.4.01factory bulb studies
Introduction and aims
During the study of the pip gene in the post-natal mouse, the presence of ISH signal and 
PLP/DM-20 immunostaining was noted in the olfactory nerve layer (ONL) of the olfactory 
bulb (OB). Presence of plp/dm-20 transcripts has been noted previously in the OB in the 
post-natal mouse as early as PI using ISH and P9 using northern analysis (Kanfer et al. 
1989; Shiota et al. 1989) but no specific location could be determined for the source of the 
expressing cells. Subsequent to our initial observations, PLP/LacZ fusion protein has been 
demonstrated in the olfactory bulb at E l4.5 in transgenic mice (Wight et al. 1993) and 
plp/dm-20 transcripts by ISH in the mouse olfactory blastema by E12.5 (Timsit et al. 
1995). It was assumed that ISH signal present in embryonic olfactory bulbs was due to 
dm-20 expression. No information was available regarding precise localisation of pip 
expressing cells, their developmental profile or relative amounts of pip  and dm-20 
transcript and product. To gain a better understanding of the expression of the pip  gene in 
the mouse OB a more detailed ISH and immunocytochemical study of this area was 
undertaken. Pip gene expression was studied from late embryogenesis (E l4) through to 
adult mice (P40).
Materials and methods
Olfactory bulbs, attached to brain to facilitate orientation, were collected from C3H/HeH X 
101H mice aged between E l4 and P40. Tissue for immunocytochemistry was removed 
unfixed for freezing. Samples were embedded in OCT compound and snap frozen as 
previously described (see 2.1.2.Processing). Frozen tissue was also used for ISH and 
additional samples were fixed in BNF for paraffin-wax embedding.
ISH was performed using the PLP-1 probe recognising both pip and dm-20 transcripts and 
the PLP-3B probe recognising pip transcripts specifically. Sections were counterstained 
with haematoxylin and viewed under brightfield, darkfield and combined brightfield and 
darkfield illumination; Immunostaining was performed with the PLP-CT antibody 
recognising both PLP and DM-20 and a PLP specific antibody, using Gow’s technique, as 
previously described (see 2.4.1.Tissue sections). Sections were also stained using the 
DAPI technique to highlight cell nuclei.
In order to confirm the cell lineage responsible for pip gene expression, dissociated cell 
cultures were prepared from mouse PI olfactory.bulbs. Cultures were grown for 2 hours to 
give an indication of their in vivo status prior to immunostaining with PLP-CT and a 
number of other cell lineage markers. These included 04, 01, GFAP, S-100, SMI-31, 
NF2H3 and TuJl. Purified P7 rat ONECs were obtained by fluorescence-activated cell 
sorting (FACS) as described by Barnett et al. (1993) and were kindly provided by Dr. S.C.
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Barnett. These cells were also immunostained using the PLP-CT antibody.
Results
ISH
Using the PLP-1 probe, recognising both pip and dm-20 transcripts, signal was detected in 
the ONL of the OB at all ages studied (Figure 51, Figure 52, Figure 53). Little variation in 
signal intensity was seen throughout this period. Signal was apparent as a diffuse circular 
region lying at the outer surface of the OB adjacent to the glomerular layer on coronal 
sections (Figure 50, Figure 51). The area of positive cells tended to be thickest medially, 
especially with more rostral sections. From P10 onwards positive cells were present in the 
deeper layers of the bulb with a more distinct signal typical of /?/p-expressing 
oligodendrocytes in the CNS (Figure 50, Figure 52). These cells were initially located in 
the granule cell layer with a few strongly positive cells present in the sub-ventricular zone 
in more caudal sections, and extending peripherally into the external plexiform and 
glomerular layers at older ages (Figure 50). Strongly positive cells were not found 
amongst the diffusely hybridising cells in the ONL.
No similar diffuse signal was seen in the ONL using the pip-specific PLP-3B probe at any 
of the ages, even when exposure times were increased 50% relative to the PLP-1 probe 
(Figure 54). From P10 onwards the presence of cells positive for the PLP-3B probe in the 
deeper layers of the bulb mirrored that found with the PLP-1 probe (Figure 54).
Immunocytochemistry
Using the PLP-CT antibody recognising both PLP and DM-20 proteins, faint and 
somewhat patchy immunoreactivity was detected in the ONL at E l4. By E l6 the intensity 
had increased and a complete peripheral band corresponding to the ONL was now visible 
(Figure 55). Immunostaining remained strong until after P10; by P25 the intensity was 
reduced and was considerably less intense by P40 (Figure 56). At P5 and P7 no 
immunoreactivity was detected in deeper layers of the bulb. By P10 reactivity was present 
in the granule cell layer. Initially staining was patchy and incomplete, localised to the 
more lateral aspect of the bulb, but then spread at older ages to the whole granule layer 
encircling the sub-ventricular zone and formed a dense layer of reactivity in the mitral cell 
layer immediately peripheral to the granule cell layer. Radial spokes of staining projected 
from the outer granule cell layer to the glomerular layer (Figure 56). Concurrent with the 
increase in extent and intensity of staining in the deeper layers of the OB, the reaction in 
the ONL became less intense.
No immunoreactivity was seen in the ONL using the PLP-specific antibody at any of the
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ages studied. From P10 onwards reactivity was similar to that found with the PLP-CT 
antibody.
Dissociated cell culture
Purified P7 rat ONECs were FACS sorted as 04+/GC- cells. The cells were further 
characterised using the PLP-CT antibody within 24hr. of sorting. The vast majority of 
these cells (approximately 94%) were PLP-CT+ (Figure 57). Approximately 4% of cells 
were 04+/PLP-CT- and approximately 2% were PLP-CT+/04-.
Dissociated mouse PI olfactory bulb cultures were immunostained with PLP-CT and a 
number of other markers. Approximately 10-15% of cells in the cultures were PLP-CT+. 
Numerous A2B5+ cells and several GC+ and GFAP+ cells were present but no co­
localisation with PLP-CT antibody was present. Approximately 75% of PLP-CT+ cells 
also immunostained with antibodies against 04  and S-100 (Figure 58). No cells 
immunostained with a PLP-specific antibody. Very few cells immunostained with the 
neuronal anti-neurofilament antibodies SMI-31 and NF2H3, however numerous cells were 
strongly stained using the TuJl neurone specific (3 tubulin III antibody. No co-localisation 
with the PLP-CT antibody was present with any of these neuronal markers.
Discussion
The detection of pip transcripts in the post-natal mouse olfactory bulb using ISH or 
northern blotting is not in itself surprising. Myelinated axons are known to originate from 
secondary olfactory pathway neurones in the mitral cell layer and travel along the length of 
the OB, predominantly in the granule cell layer, eventually forming the olfactory tract. 
These myelinated axons passing through the granule cell layer are not the axons of the 
granule cells themselves as these are one of the few anaxonic neurones in the CNS (Price 
and Powell 1970). Ensheathment of these axons will be accomplished by 
oligodendrocytes, and it is these cells which will give rise to the distinct signal and strong 
immunostaining seen in the deeper layers of the OB following ISH and immunostaining 
with plp/dm-20 probes and antibodies. The absence of detectable transcripts or protein 
before P10 would imply that myelination is commencing at around this time in the mouse 
OB. This is confirmed by the observations of Jacobson (1963) and Tilney (1933) who 
described the presence of “stainable” myelin in the olfactory tract of the rat at 10 and 14 
days respectively. The presence of both pip and dm-20 transcripts and protein in these 
cells is the same as would be found in any actively myelinating oligodendrocyte in the 
CNS. Occasional strongly expressing cells which were present in the external plexiform 
and glomerular layers are likely to be oligodendrocytes responsible for myelination of the 
dendrites and cell bodies of mitral, tufted and periglomerular cells (Valverde and Lopez- 
Mascaraque 1991).
The presence of plp/dm-20 transcripts and protein in the ONL is considerably more
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interesting for several reasons. Although occasional myelinated fibres may course with the 
olfactory nerve on its way to the OB, the olfactory nerve itself is unmyelinated as is the 
ONL (De Lorenzo 1957; Gasser 1956). Pip expression is first seen in the deeper layers of 
the bulb around the time of myelination (P10). Expression is present in the ONL, however, 
during embryogenesis, by E14 in the present study. Timsit et al. (1995) demonstrated pip  
ISH signal in the olfactory blastema and olfactory tracts at E12.5 and in the olfactory 
epithelium at E l4.5. Clearly the expression of the pip gene in the ONL is unlikely to be 
associated with myelination directly as signal is present in an area where no myelin sheaths 
are formed, and is present during embryogenesis, probably 10-15 days before myelin is 
present in any part of the olfactory bulb. Although ISH and immunostaining are not easily 
quantifiable, there does appear to be a discrepancy between the apparent maintenance of a 
strong ISH signal at least until P30, whereas immunostaining becomes noticeably weaker 
by P25. The reason for this is unknown and may represent a change in the availability of 
the antigen at older ages or a true decrease in the amount of protein present. If the latter is 
the case it may indicate that control of product levels is occurring, at least in part, at a post- 
transcriptional level. Although it is not possible to detect dm-20 transcripts and protein 
directly on tissue sections, the positive signal and staining in the ONL at all ages using 
non-specific plp/dm-20 probe and antibody and the lack of signal and staining using plp- 
specific probe and antibody, would strongly suggest that dm-20 is the sole or major 
isoform expressed in the ONL at all ages. Appearance of pip-specific signal at P10 in the 
deeper layers of the bulb, around the time of myelination, suggest that the earlier lack of 
signal is genuine, or due to levels of pip-specific transcript and protein below the levels of 
detection, rather than failure of the techniques. The diffuse signal seen in the ONL is 
reminiscent of that seen in non-myelin-forming Schwann cells in the PNS, indeed there are 
many similarities between expression of the pip gene in the PNS and the ONL. The pattern 
of expression in the ONL, in areas and at times when no myelin is present, strongly 
suggests a non-structural role for the pip gene in this situation and, as in the PNS, this is 
associated with a predominance and possibly in the case of the ONL, exclusivity of the 
DM-20 isoform. Although the olfactory bulb as a whole lies within the meninges of the 
CNS it is somewhat misleading to view the ONL as CNS tissue as it originated from the 
olfactory placode and migrated to cover the developing OB during embryogenesis. As 
such, it is not of neural tube origin, nor for that matter of neural crest origin (the origin of 
PNS tissue) and the glial cell which originates from this source, the olfactory nerve 
ensheathing cell (ONEC) should be regarded as a novel glial cell-type.
Of the two glial cells which have been described in the ONL, the astrocyte and the ONEC 
(Doucette 1984; Doucette 1989), it is most probable that the cells expressing the pip gene 
were the latter. Evidence supporting the ONECs being the source of pip expressing cells in 
the olfactory bulb is as follows; 1) During embryogenesis and at post-natal ages less than 
10 days, PLP immunostaining and ISH signal is restricted to the ONL. Although
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expression of the pip gene in ONECs has not been reported in detail previously, it has not 
been demonstrated convincingly that PLP or its message are present in astrocytes. ONECs 
exhibit some characteristics of Schwann cells (Doucette 1990; Norgren et al. 1992) a cell 
type known to express the pip gene, and it has been demonstrated that ONECs can 
elaborate myelin sheaths in vitro and express another myelin protein, MBP (Devon and 
Doucette 1992). It therefore seems likely that the ONEC rather than the astrocyte is the 
cell responsible for pip gene expression in the ONL. 2) Almost all 04+/GC- cell sorted 
ONECs from P7 rats, which have been shown previously not to be astrocytic or 
oligodendroglial in phenotype (Barnett et a l 1993), immunostained for PLP/DM-20. 3) 
Dissociated cell cultures from PI mouse olfactory bulbs demonstrated PLP-CT+ cells, the 
majority of which co-stained with markers such as 04  and S-100 which are characteristic 
of ONECs (Barnett et a l 1993) (S.Bamett personal communication). Although 0 4  and to 
a lesser extent S-100 staining is also found in cells of the oligodendrocyte lineage, no co­
localisation of PLP-CT+ cells with other oligodendrocyte lineage markers such as A2B5 or 
GC was present. It is possible that some of the PLP-CT+ cells in these cultures may 
belong to other cell lineages, possibly of neuronal origin. However, no co-localisation of 
PLP-CT+ cells with neuronal markers NF2H3, SMI-31 (anti-neurofilaments), TuJl (anti-(3 
tubulin III) or A2B5 was present
Much evidence now points to a non-structural role for the DM-20 isoprotein in both the 
CNS and PNS, but progress in elucidating this role has been slow. Techniques to generate 
purified ONEC cultures have been described (Barnett et al 1993), and immortalised 
ONEC cell lines have been generated (S.Bamett personal communication). The study of 
pip gene expression in this glial cell type may provide the background, free of the 
confusing factors of myelin and the PLP isoprotein, against which a specific function of 
DM-20 may be elucidated.
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Figure 50. Olfactory bulb plp/dm-20 ISH (PLP-1 probe). Coronal section of 15 day 
mouse olfactory bulb (OB): a) brightfield illumination, b) combined bright/darkfield 
illumination. The laminar structure of the OB is clearly seen (o-olfactory nerve layer, gl- 
glomerular layer, e-extemal plexiform layer, m-mitral cell layer, g-granule cell layer, s- 
sub-ventricular zone). Strongly positive cells, most probably oligodendrocytes, are seen in 
the granule cell layer in a). Darkfield illumination, b) additionally reveals more diffuse 
staining in the olfactory nerve layer and occasional positive cells in the external plexiform 
layer.
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Figure 51. Post-natal olfactory bulb ISH, plp/dm-20 developmental profile, a) PI 
(dark/brightfield), b) P5 (darkfield). Diffuse signal is evident in the olfactory nerve layer 
under darkfield illumination at both ages (arrow). No signal is seen in the deeper layers of 
the bulb. The PLP-1 probe hybridises both pip and dm-20 transcripts, however signal in 
the olfactory nerve layer can be demonstrated to be exclusively dm-20 and is likely to be 
present in the olfactory nerve ensheathing cells.
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Figure 52. Post-natal olfactory bulb ISH, plp/dm-20 developmental profile, a) P10 
(darkfield), b) P I5 (dark/brightfield), c) P30 (darkfield). Strong diffuse signal is found 
consistently in the olfactory nerve layer at all ages. Strong, focal staining in the deeper 
layers (arrow) is apparent from P10 onwards, and coincides with the onset of myelination 
of axons in the deeper layers of the bulb. This focal staining is similar to that seen in 
oligodendrocytes in other areas of the CNS.
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Figure 53. Embryonic olfactory bulb, ISH plp/dm-20. a) El 6 bright and darkfield images, 
b) E l8 bright and darkfield images. Signal in the olfactory nerve layer is as strong in the 
embryonic as the post-natal olfactory bulb. No signal is present in the deeper layers of the 
bulb.
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Figure 54. Olfactory bulb ISH,/?//?-specific probe (PLP-3B). a) P I5, b) P30; Although 
focal signal is present in the deeper layers of the bulb, no diffuse signal is evident in the 
olfactory nerve layer. This implies that signal in the olfactory nerve layer is 
predominantly, or possibly exclusively, dm-20.
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Figure 55. Olfactory bulb immunostaining, PLP/DM-20 (PLP-CT). a) E l6, b) P5. 
Strong immunostaining in the olfactory nerve layer (o) with an antibody recognising PLP 
and DM-20 can be seen at E l6 and P5. This staining represents the DM-20 isoprotein as 
no similar signal is seen using a PLP-specific antibody.
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Figure 56. Olfactory bulb immunostaining, PLP/DM-20 (PLP-CT). a) P7, b) P40. 
Strong immunostaining is still present in the whole of the olfactory nerve layer at P7; 
staining is still not present in the deeper layers at this age. By P40 staining in the olfactory 
nerve layer is considerably weaker whilst intense staining is present in the deeper layers 
(gl-glomerular layer, e-external plexiform layer, m-mitral cell layer). Staining at this age is 
very similar using a PLP-specific antibody, with the exception of absence of any reactivity 
in the olfactory nerve layer.
Figure 57. Rat P7 04+/GC- cell sorted ONECs immunostained with PLP-CT antibody, 
a) 0 4  immunostaining, b) PLP-CT immunostaining. Almost all 04+ sorted cells co-stain 
with the PLP-CT antibody.
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Figure 58. Mouse PI dissociated olfactory bulb cultures (2 hours). Cells can be seen co- 
immunostaining for PLP-CT (PC) and a) the cell surface marker 04 or b) the cytoplasmic 
marker S-100. Both of these markers are characteristic of the olfactory nerve ensheathing 
cell.
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3.3.GENERAL DISCUSSION
It is now over forty years since myelin proteolipid protein was first reported (Folch and 
Lees 1951). It is a sobering thought that despite the considerable advances in research 
technology during this period, and the numerous groups working in the area, we still do not 
actually know the true function of one or possibly both of the isoforms of the pip  gene. 
Particularly in the case of DM-20, it is very difficult to interpret the large amount of 
experimental data now available without the baseline of a known function.
At the commencement of the present studies, the amount of information regarding the 
more widespread effects of the pip gene in the nervous system was relatively small. 
Studies of the j p sh mutant (Schneider et al. 1992) had added considerable weight to the 
theory of dual roles for the two isoproteins of the pip gene although few examples of the 
non-myelinating role of DM-20 were documented. The ventral origin of oligodendrocytes 
in the spinal cord had been demonstrated using in vitro techniques (Warf et a l 1991), 
however, associated markers for these early precursor cells had still to be demonstrated. 
Expression of the pip gene was considered to be essentially a post-natal event in rodents 
with expression limited spatially to the oligodendrocyte and to a lesser extent the Schwann 
cell where expression appeared to be deregulated. The results presented in the current 
studies have added to the considerable body of information generated over the intervening 
period, and unsurprisingly in this highly complex area, generated new areas of interest. 
The use of RT-PCR technology has allowed the indirect analysis of the two isoforms of the 
pip gene and confirmed the marked up-regulation and transcript ratio changes which occur 
at the onset of myelination in the CNS. The lack of such changes in the PNS was not 
surprising, given the apparent uncoupling of pip gene expression from myelination in this 
tissue. However, the apparent separate regulatory control of the two isoforms apparent in 
the nerve transection studies has raised some intriguing questions. Studies on pip  gene 
expression during embryogenesis have clearly demonstrated the presence of dm-20 
transcripts and protein and linked the expressing cells to the oligodendrocyte lineage. 
Whilst reinforcing previous evidence for the ventral origin of oligodendrocyte precursors in 
the developing spinal cord, this work also challenges some of the previous perceptions 
related to myelin gene expression in the developing oligodendrocyte, in particular, the idea 
of pip expression being restricted to the mature myelinating oligodendrocyte. The 
somewhat serendipitous finding of almost exclusive expression of the dm-20 isoform in the 
olfactory nerve ensheathing cells of the olfactory bulb is an additional example of 
expression of the pip gene, in particular the dm-20 isoform, in a “non-myelin 
environment”. This provides additional evidence of a non-myelin role for DM-20 and 
indicates a possible area for future study to define this aspect.
Structural abnormalities of the compact myelin sheath in the absence of normal PLP, 
together with the physical localisation of the protein, give a strong indication that PLP and 
possibly DM-20 probably function as structural proteins. Evidence from the rumpshaker
158
mutation in mouse, its recently reported homologue in man, and the discovery of the DM 
family of proteins argue strongly in favour of a non-myelin role for DM-20. Several 
aspects of the presented work add further evidence to support this theory. Expression of 
dm-20 at times and in tissues where an obvious link with myelination is absent is 
suggestive of a non-myelin role for this isoform. The present study clearly demonstrates 
the predominant expression of dm-20 during embryogenesis of the spinal cord. Dm-20 
transcripts have been reported previously (Ikenaka et a l 1992; Timsit et a l 1992a), but this 
is the first time that product has been demonstrated. The presence of a protein product 
increases the likelihood that DM-20 does have a functional role and is not just a vestigial 
protein with non-regulated transcription occurring incidentally in cells prior to the up- 
regulation of the pip isoform during myelination. Nevertheless, it is possible that DM-20 
may be a redundant protein; certainly, apart from the structural abnormalities in the myelin 
sheath, the otherwise normal appearance of pip knockout mice would support this (Boison 
and Stoffel 1994). It is also possible that DM-20 function is compensated for in these mice 
by another protein. Such compensation may not be induced in the pip mutant animals due 
to the continued presence of PLP/DM-20 protein, albeit abnormal. If DM-20 is vestigial or 
easily replaceable, why then do we see such lethal phenotypes in pip  mutant animals, and 
such a high degree of conservation of the pip gene? Selection may be acting solely on the 
PLP isoform. If the appropriation of the pip specific sequence and the associated structural 
function was a late evolutionary development, the presence of compensatory mechanisms 
for loss of PLP function would seem less likely thus increasing selection pressure. 
Alternatively, selection may not be acting to maintain the function of an essential protein at 
all, but to prevent the appearance of deleterious proteins which would naturally be absent 
from knockout mice. In the case of a Pelizaeus-Merzbacher patient with a deletion of the 
pip  gene, the clinical phenotype is similar to patients with point mutations of the gene 
(Juurlink and Hertz 1991). This would argue against a toxic protein theory since no protein 
can be present, and would argue for an important role for the products of the gene, 
seemingly contradicting the evidence from the knockout mice.
The present work has demonstrated DM-20 protein in the embryonic cord and identified 
the majority of expressing cells as precursors of the oligodendrocyte lineage, cells destined 
to express strongly the pip gene once myelination has commenced. The presence of DM- 
20 protein in the olfactory nerve ensheathing cells of the olfactory nerve layer not only 
demonstrates DM-20 in an environment devoid of myelin, but also in a cell type which is 
not destined to produce myelin at all in vivo. In this respect this is similar to the presence 
of DM-20 in non-myelin-forming Schwann cells in the PNS (Griffiths et a l 1995a). 
Without actually elucidating a function for DM-20, demonstrating the presence of 
functional protein in these non-myelin environments and cell types is some of the strongest 
circumstantial evidence available indicating a function for the DM-20 isoprotein 
unconnected with myelination.
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Factors affecting regulation of the pip gene may give an insight into its functional 
significance. Results from semi-quantitative RT-PCR analysis of spinal cord and mid­
optic nerve indicate that the dramatic up-regulation and change in plp/dm-20 transcript 
ratio, from dm-20 to pip predominance, correlates well with the onset of myelination. 
Although a rise in dm-20 transcripts is seen, the majority of the increased total transcript 
level, and therefore the reason for the change in plp/dm-20 transcript ratio, is attributable to 
increase of the pip isoform. The moderate rise in dm-20 transcripts may well be due to 
increased transcriptional activity in general rather than a specific, targeted up-regulation of 
this isoform. This would imply that the function of PLP is more closely linked to 
myelination than that of DM-20. The mechanisms controlling the relative amounts of pip 
and dm-20 transcripts and protein are unknown and may be dependent on several factors 
acting at different levels of gene expression. Differences in these regulatory mechanisms 
when comparing pip and dm-20, add further weight to the argument separating the end 
functions of the two isoproteins. Regulation of the pip gene, certainly in actively 
myelinating cells in the CNS, appears to occur mainly at the level of transcription, and 
probably at the level of rate of transcript initiation. The majority of transcripts in the PNS, 
where dm-20 is predominant, are initiated from the more proximal (position -130) of the 
two major transcript initiation sites. In the actively myelinating CNS most transcripts are 
initiated from a more distal site (position -160), whereas in the mature CNS after peak 
transcription has occurred proximally initiated transcripts predominate as in the PNS 
(Kamholz et al. 1992; Scherer et al. 1992). It has been suggested that the proximal site 
(PNS and mature CNS) may be used during maintenance expression and is not inducible, 
while the distal site is responsible for the rapid, inducible increase of pip message during 
myelination. Induction may be due to transiently expressed factors or to utilisation of the 
distal site once the proximal site is “saturated”. This certainly could explain differences in 
total transcript levels, however, it is less clear how alternative splicing may be affected. 
One could hypothesise that subsequent splicing of the primary transcript may be influenced 
by differing sequences present in the initiation region. This seems unlikely given that both 
PNS and mature CNS transcripts are predominantly initiated from the same site, yet have 
plp/dm-20 ratios which are dm-20 predominant and pip  predominant respectively. 
Generation of PCR primers complementary to the two transcript initiation sites, with a 
common primer downstream of exon 3 would allow semi-quantitative analysis of the 
relationship between choice of transcript initiation site and subsequent levels of pip and 
dm-20 transcripts. This could be further applied to nerve transection studies to determine if 
a relationship exists between choice of initiation site and selective down-regulation of the 
pip  isoform.
Post-transcriptional regulation is the most likely mechanism for controlling relative levels 
of plp/dm-20 transcripts. There is no strong evidence to suggest that stability of the 
different transcripts plays a significant role, however this is a possibility. Assuming that
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both mRNA species are equally stable in vivo, the variations in transcript ratio must be due 
to selective utilisation of one or other of the alternate 57 splice sites in exon 3, selection of 
the distal site resulting in the generation of dm-20 transcripts. There is no obvious 
difference in homology of the alternate 51 splice sites compared to the consensus sequence:
% conserved 70 60 80 100 100 95 70
Consensus A/C A G 4- g t a/g a
PLP A A G 4- g t g a
DM-20 A C G l G T  A A
Favouring of one splice site due to greater homology to the consensus sequence therefore 
seems unlikely. Additionally, this could not explain the predominance of different 
transcripts in different tissues. It is more likely that other factors confer differential 
specificity. Assembly of the spliceosome onto the nascent pre-mRNA is mediated by 
RNA/RNA interactions between small nuclear RNAs (snRNAs), in particular the U1 
snRNA, and the pre-mRNA. Numerous proteins are also involved, some of which are 
complexed to the snRNAs (forming small nuclear RNA protein complexes (snRNPs)). 
Other proteins, such as the SR protein family, which are required for constitutive splicing, 
have also been implicated in the function of specifying alternate splice site selection with 
specific SR proteins allowing for the preferential use of different 51 splice sites within the 
same precursor (Zahler and Roth 1995). Whether or not control of dm-20 and pip  
transcript levels at this or other levels is truly integrated, or under separate controls, 
remains to be resolved. Based on the evidence of the sciatic and optic nerve transections it 
certainly appears that axonally related factors play a role in determining pip transcript level 
but have little or no effect on dm-20. Whether this difference is expressed as a function of 
transcriptional control, decreased pip transcript stability or an alteration in the splice site 
selection procedure is as yet unclear. It appears that predominance of the pip isoform is 
limited to the myelinating oligodendrocyte, as demonstrated in the post-natal spinal cord 
and optic nerve. In all other situations, such as oligodendrocyte precursors , ONECs, 
Schwann cells, cardiac myocytes and peri-neuronal satellite cells, the dm-20 isoform 
predominates. Selection of the distal 57 splice site appears, therefore, to be common to all 
these different cell types and may well be the constitutive pathway for pip pre-mRNA 
splice site selection. This would be consistent if the appearance of PLP protein was a later 
evolutionary event requiring additional regulatory mechanisms.
At the present time it is very difficult to rationalise the large, and occasionally conflicting, 
amounts of data regarding expression of the pip gene. In vitro manipulation of pip 
genotype in several lines of mice has produced a spectrum of phenotypes, and whilst
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demonstrating the ability to disrupt pip gene expression, it has not necessarily increased 
our understanding of pip expression. The control and effects of the pip gene are obviously 
highly complex and it is very likely that many, as yet unidentified players are involved in 
its co-ordinated expression. Identification and study of these factors may well provide the 
wider backdrop necessary to interpret the data already available. Several techniques have 
been reported which will allow identification of genes which are either linked with a 
specific target gene or protein, such as PLP, or which allow the identification of genes 
which are differentially expressed due to developmental or extracellular stimuli. The use 
of commercial in vivo yeast hybrid reporter systems may allow the identification of either 
proteins binding to pip c/s-regulatory elements which may be involved in transcriptional 
regulation of the pip gene, or proteins interacting directly with PLP/DM-20 proteins 
themselves. Problems may be encountered if looking for genes encoding proteins which 
bind to pip c/s-elements since these regulatory regions of the pip gene have yet to be fully 
characterised. Identification of genes encoding proteins interacting directly with PLP/DM- 
20 is potentially less problematic and may prove very interesting.
Identification of differentially expressed genes may be investigated by the differential 
display of mRNA using RT-PCR. This is a much less labour intensive approach than 
previously used subtractive hybridisation techniques. A combination of degenerate 
primers and small arbitrary primers gives a profile of RT-PCR products which will 
represent the numerous mRNAs present in the sample. Comparison of profiles from 
different samples, at different developmental stages for example, allows identification of 
bands which are specific or increased/decreased in intensity in one of the samples. Cloning 
and sequencing of these bands then gives direct access to genes which are either up or 
down-regulated during this developmental period. If we are interested in identifying genes 
which are closely linked with expression of the pip gene, comparison of samples taken 
from time points either side of the dramatic up-regulation and change in transcript ratio 
seen around PI in the spinal cord would be a good starting point. There will probably be 
many other genes unrelated to pip coincidentally undergoing up/down-regulation at this 
time. Isolation and sequencing of numerous candidate products is potentially very time 
consuming, especially if many of the candidates are of such a coincidental nature. One 
possible way of eliminating some of these products would be to compare two sets of 
samples at the same time, which are at the same developmental stage with respect to the 
gene of interest, but at a different age chronologically. The demonstration that mid optic 
nerves undergo the same up-regulation and change in transcript ratio as the spinal cord, but 
delayed by approximately 6 days, provides such a comparison. Interest could then be 
concentrated on changes in differential products which are consistent across both the spinal 
cord and optic nerve samples.
The dramatic ratio changes seen in both spinal cord and optic nerve serve to highlight 
important time points in relation to myelination and expression of the pip  gene. Study of
162
the wider spectrum of gene expression at these time points may well provide the additional 
information to allow us to understand this important, but as yet elusive gene.
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Abbreviations
APES 3-aminopropyltriethoxy-silane
ATP Adenosine-triphosphate
BNF Buffered neutral formaldehyde
bp Base pairs
BSA Bovine serum albumin
°C Degrees centigrade
CaCl2 Calcium chloride
cAMP Cyclic adenosine monophosphate
CCG Cranial cervical ganglia
cDNA Complementary DNA
CIAP Calf intestinal alkaline phosphatase
CMT-1A Charcot-Marie-Tooth disease type 1A
CNP 2’,3’-cyclic nucleotide 3’-phosphodiesterase
CNS Central nervous system
cpm Counts per minute
CST Cervical sympathetic trunk
CTP Cytidine-triphosphate
DAB 3,-diaminobenzidine tetrachloride
DAPI 4’ ,6-diamidino-2-phenylindole
dCTP 2 ’ -Deoxy-cytidine-5 ’ -triphosphate
DDSA Dodecanyl succinic anhydride
DEPC Di-ethyl pyrocarbonate
DIG Digoxigenin
DMEM Dulbecco’s modified Eagle medium
DMP 2,4,6-tri-dimethylaminomethyl-phenol
DNA Deoxyribonucleic acid
dNTP Deoxynucleoside-triphosphate
DS Dejerine-Sottas hypertrophic neuropathy
DTT Dithiothrietol
DW Distilled water
E Embryonic day
EDTA (Ethylenedinitrilo)tetraacetic acid
EM Electron microscopy
ER Endoplasmic reticulum
FACS Fluorescence-activated cell sorting
FCS Foetal calf serum
FITC Fluorescein isothiocyanate
g Gram
GalC Galactocerebroside
GFAP Glial fibrillary acidic protein
GTP Guanosine-5 ’ -triphosphate
GuSCN Guanidine thiocyanate
H andE Haematoxylin and eosin
HBSS Hanks’ balanced salt solution
HC1 Hydrochloric acid
HEPES (N-[2-hydroxyethyl]piperazine-N’-[2-ethane-sulphonic acid])
hr Hour
lie Isoleucine
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ISH In situ hybridisation
j P  w
Jimpy
. msd 
JP „ Jimpy myelin synthesis deficient. rsn
JP Jimpy rumpshaker
kb Kilobase
kD KiloDalton
k 2h p o 4 Potassium hydrogen phosphate
L Litre
lb Pound
LB Luria Bertani
LiCl Lithium chloride
M Molar
MAG Myelin associated glycoprotein
Mb Megabase
MBP Myelin basic protein
md- rat Myelin deficient rat
mg Milligram
MgCl2 Magnesium chloride
MgS04 Magnesium sulphate
min Minute
ml Millilitre
mM Millimolar
MMLV Moloney murine leukaemia virus
MOBP Myelin-associated oligodendrocyte basic protein
MOG Myelin oligodendrocyte glycoprotein
MOSP Myelin oligodendrocyte-specific protein
mRNA Messenger ribonucleic acid
NaAc Sodium acetate
NaCl Sodium chloride
NaC104 Sodium chlorate
NaH2P 0 4 Sodium hydrogen phosphate
Nal Sodium iodide
NaOH Sodium hydroxide
NBT Nitroblue tetra-zolium chloride
N-CAM Neural cell adhesion molecule
NF Neurofilaments
ng Nanogram
NGF Nerve growth factor
NGS Normal goat serum
NH4Ac Ammonium acetate
n h 4ci Ammonium chloride
0-2A 01igodendrocyte-type2 astrocyte
OB Olfactory bulb
OD Optical density
Omgp Oligodendrocyte-myelin glycoprotein
ONEC Olfactory nerve ensheathing cell
ONL Olfactory nerve layer
P Post-natal day
Po Protein zero
PAP Peroxidase anti-peroxidase
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PDGFa Platelet-derived growth factor alpha
PDGFaR Platelet-derived growth factor alpha receptor
PLP Proteolipid protein
PLP-CT Proteolipid protein-carboxy terminal
PMD Pelizaeus-Merzbacher disease
PMP-22 Peripheral myelin protein-22
PNS Peripheral nervous system
POA Proligodendroblast antigen
p t Paralytic tremor
Ran-2 Rat neural antigen 2
RER Rough endoplasmic reticulum
RmAb Ranscht monoclonal antibody
RNA Ribonucleic acid
rpm Revolutions per minute
RT-PCR Reverse transcriptase-polymerase chain reaction
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis
SDW' Sterile distilled water
sec Second
s/z-pup Shaking pup
SnRNA Small nuclear RNA
SnRNP Small nuclear RNA protein complex
SPG2 Spastic paraplegia type 2A
sq. in. Square inch
SSC Standard sodium citrate
SUL Sulphatide
TAE Tris acetate EDTA
TBE Tris borate EDTA
TE Tris EDTA
Thr Threonine
tRNA Transfer ribonucleic acid
TxR Texas red
U Units
pCi Microcurie
Microgram
pi Microlitre
pm Micrometre
UTP Uridine-5 ’ -triphosphate
UV Ultra-violet
vim Vimentin
w/v Weight in volume
X-phos 5-bromo-4-chloro-3-indoyl-phosphate
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